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MULTI-LEVEL REGULATION OF ENDOTHELIAL ARGININOSUCCINATE 
SYNTHASE: SIGNIFICANCE FOR NITRIC OXIDE PRODUCTION 
 
Karen Davidowitz Corbin, MS, RD 
 
ABSTRACT 
 
The citrulline-nitric oxide (NO) cycle, comprised of the enzymes 
argininosuccinate synthase (AS), argininosuccinate lyase (AL) and endothelial nitric 
oxide synthase (eNOS), is responsible for the regulated production of endothelial NO. 
Although most studies have focused on eNOS to uncover important regulatory 
mechanisms, we and others have determined that AS is an essential and regulated step in 
endothelial NO production. AS is rate limiting for endothelial NO production and is the 
primary source of arginine, the substrate for eNOS-mediated NO production, despite 
saturating intracellular levels of arginine and available arginine transport systems. AS is 
essential for endothelial cell viability and its expression is regulated coordinately with 
eNOS by TNFα and thiazolidenediones with concomitant effects on NO production. 
Given the importance of AS for endothelial health, we explored three independent 
regulatory mechanisms. In Chapter One, the functional consequences of altered AS 
expression due to overexpression, insulin, VEGF and ceramide were studied. We 
xii 
demonstrated that overexpression of AS leads to enhanced NO production and that 
insulin, VEGF and ceramide coordinately regulate the expression of AS and eNOS. In 
Chapter Two, the first post-translational modifications of AS in the endothelium were 
characterized. We determined that AS is an endogenous phosphoprotein in the 
endothelium, described several levels of biological significance of AS phosphorylation, 
identified 7 sites of AS phosphorylation and began to uncover the direct impact of 
phosphorylation on AS function. Finally, in Chapter Three, endothelial AS subcellular 
localization was defined and important protein interactions were identified including 
caveolin-1 and HSP90. The work presented in this dissertation demonstrates that multiple 
mechanisms regulate the function of AS, often coordinately with eNOS, and have a direct 
impact on nitric oxide production. Our findings suggest that the global understanding of 
the citrulline-NO cycle as a metabolic unit will unravel new paradigms that will re-define 
our understanding of the regulation of vascular function by NO. 
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INTRODUCTION 
 
Nitric Oxide: Historical Perspectives and Biochemistry 
 
Nitric Oxide (abbreviation: NO; chemical formula: N═O·) is a readily diffusing 
gas that can be poisonous in the environment yet powerful in biology [1, 2]. Due to its 
unpaired electron, NO is a free radical, making it highly reactive. The “Molecule of the 
Year” in 1992 [3, 4], the discoveries made about NO and heart function earned Robert F. 
Furchgott, Louis J. Ignarro and Ferid Murad the Nobel Prize in 1998 (NobelPrize.org). In 
1980, endothelium-dependent vessel relaxation was first described [5] and in 1987, it was 
determined that the endothelium derived relaxing factor (EDRF) was in fact NO [6, 7]. 
 
NO moves easily in and out of cells so it cannot be stored inside producing cells 
like other endogenous messengers. In the presence of oxygen, it has a half life of just a 
few seconds, but its longevity in the body is not known [1, 2]. There are several nitrogen-
derived compounds that exert distinct biological functions including NO+ (nitrosonium), 
NO· (nitric oxide) and NO-
 
(nitroxyl anion). Most studies of nitric oxide do not 
differentiate or define the specific species that is exerting biological actions [2]. From this 
point forward, our discussions will be related to NO in general terms.  
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NO functions via multiple mechanisms to exert biological effects. It reacts 
directly or indirectly with proteins, lipids, nucleic acids, metals, other gases (such as 
oxygen) and carbohydrates [1]. Like many other molecules, the effects of NO can be 
either positive or negative depending on the cellular environment and amounts produced. 
Both a lack of NO and an excess of NO can lead to pathological consequences such as 
hypertension and septic shock, respectively [3]. NO is a signaling agent and has been 
implicated in a broad number of functions including neurotransmission, memory, host 
defense, vasodilation, blood flow, respiration, nutrient metabolism and apoptosis [3, 8-
10]. Therefore, the chemical simplicity of this molecule has no bearing on its broad and 
essential functions. 
 
The Citrulline-Nitric Oxide Cycle 
 
 The citrulline-NO cycle, comprised of the enzymes argininosuccinate synthase 
(AS), argininosuccinate lyase (AL) and endothelial nitric oxide synthase (eNOS), is 
responsible for the regulated production of nitric oxide [11]. AS is a homotetrametic 
enzyme with a molecular weight of ~47 kDa per monomer. Each monomer contains 412 
amino acids. It is transcribed from a single gene on chromosome 9 and is expressed in 
virtually all tissues with the highest expression in liver, kidney and brain [12-17]. AL is 
also a homotetramer with a subunit molecular weight of ~50 kDa. The human AL gene is 
found on chromosome 7 and has 464 amino acids per monomer. It is expressed widely, 
similar to AS [13, 17, 18].  There are 3 isoforms of nitric oxide synthase (NOS): neuronal 
NOS (nNOS; NOS1), inducible NOS (iNOS; NOS2) and endothelial NOS (eNOS; 
NOS3). Each is encoded by a separate gene on chromosomes 12, 17 and 7, respectively, 
and they share ~ 50-60% sequence homology [19, 20]. eNOS, the NOS isoform studied 
in this work, is a homodimer with a molecular weight of 135 kDa  per subunit that is 
expressed in endothelium, skeletal and cardiac muscles, kidney tubules and many other 
non-endothelial tissues [21, 22]. eNOS, like nNOS, is a constitutive NOS isoform that is 
regulated by calcium/calmodulin. This is in contrast to iNOS which is active even at low 
calcium concentrations [19]. Besides the substrates necessary to carry out its reaction (see 
Table 1), eNOS requires tetrahydrobiopterin (BH4), flavin adenine dinucleotide (FAD), 
flavin mononucleotide (FMN) and heme as co-factors. The amounts of NO produced by 
constitutive isoforms is ~ 1000 fold less than iNOS [19, 20]. 
 
The following are the reactions catalyzed by each of the enzymes in the 
endothelial citrulline-NO cycle: 
 
Table 1: Reactions Catalyzed by Citrulline-NO-Cycle Enzymes.  
eNOS (EC 1.14.13.39):  
L-arginine + NADPH + H + O2 = L-citrulline + NO + NADP+ 
AS (EC 6.3.4.5): (rate limiting step) 
ATP + L-citrulline + L-aspartate = AMP + diphosphate + argininosuccinate 
AL (EC 4.3.2.1): 
argininosuccinate = furmarate + L-arginine 
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The function of the citrulline-NO cycle as a whole is crucial for the production of 
NO. The availability of arginine is a key factor limiting NO synthesis, despite the fact 
that intracellular concentrations of arginine (0.1-0.8 mM) are greatly in excess of the 
reported eNOS Km (~5 µM) [11]. This phenomenon is termed “the arginine paradox”. 
Although there are transport systems available that have been hypothesized to supply the 
arginine utilized for NO production [23], we and others have shown that endothelial NO 
production is limited by the capacity to regenerate arginine from citrulline [24-27]. In 
fact, cells that express constitutive NOS isoforms, such as endothelial cells and neurons 
have the capacity to regenerate arginine from citrulline [25, 28].  
 
Dysfunction of AS and AL, which are also part of the urea cycle in ureagenic 
tissues, can lead to metabolic defects termed collectively as urea cycle disorders, since 
deficiency in any one of the six enzymes in the urea cycle causes disease [29]. Type I 
citrullinemia is an autosomal recessive disorder caused by AS deficiency (OMIM 
#215700) [30]. Some of the symptoms of this disease include severe vomiting, excess 
levels of citrulline in serum, spinal fluid and urine, hyperammonemia and mental 
retardation. If not treated promptly, it can lead to death. Death in the neonatal period 
occurs in nearly half of cases [29].  Many mutations have been identified in the AS gene 
that can lead to type I citrullinemia [31, 32].  
 
Unlike classical citrullinemia in children that results from a mutation in the AS 
gene and is associated with an overall deficiency of AS, in type II citrullinemia there is 
no mutation in the AS gene (OMIM #603471) [33]. AS protein has normal kinetic 
 5
properties and is quantitatively deficient only in the liver.  The gene that is actually 
defective is SLC25A13. It encodes a mitochondrial Ca2+-dependent aspartate/glutamate 
transporter called citrin [33, 34]. The loss of organization attributable to the mutated 
citrin leads to reduction of AS protein, possibly through destabilization and/or 
degradation. Symptoms of type II citrullinemia include enuresis, delayed menarche, 
insomnia, nocturnal sweats, recurrent vomiting, diarrhea, tremors, episodes of confusion 
after meals, lethargy, convulsions, delusions, hallucinations, and brief episodes of coma. 
Some patients die within a few years of onset [29]. For both type I and type II 
citrullinemia, a low protein diet, medications to reduce ammonia levels (examples: 
sodium benzoate, sodium phenylacetate) or dialysis can be used as treatments to reduce 
ammonia levels [35].  
 
Argininosuccinic aciduria is an autosomal recessive disorder caused by multiple 
possible mutations in the AL gene (OMIM 207900) [36]. Like citrullinemia, 
argininosuccinic aciduria can be early onset (more severe) or late onset. Some symptoms 
of early onset AL deficiency include lethargy, skin lesions, mental retardation, liver 
enlargement and convulsions. Late onset disease is usually mild and symptoms tend to 
occur during illness or periods of stress. Treatment for argininosuccinic aciduria is the 
same as for citrullinemia [35].  
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Endothelial Nitric Oxide and Vascular Health 
 
 NO regulates most normal functions of the endothelium. One primary function of 
NO is vasodilation. This process occurs when NO produced in the endothelium migrates 
to the adjacent smooth muscle layer, binds to the heme moiety of soluble guanylyl 
cyclase (sGC) and activates it. This leads to an increase in cyclic guanosine 
monophosphate (cGMP), which then activates protein kinase G (PKG) and leads to 
vasodilation. Regulation of vessel dilation contributes to blood flow and blood pressure 
control [37, 38].  
 
In addition, NO regulates platelet aggregation. The health of arteries is highly 
dependent on tight control over this process. During injury, platelets migrate to the site of 
injury and form a plug to seal the blood vessel and minimize blood loss. On the other 
hand, uncontrolled platelet aggregation diminishes the fluidity of blood, prevents the 
delivery of oxygen and nutrients to tissues and can lead to thrombosis- a leading event in 
myocardial infarction.  During physiological conditions, the balance is tipped towards 
reducing platelet aggregation. Both endothelial and platelet derived NO lead to the 
activation of PKG, the inhibition of cAMP phosphodiesterase and the reduction of 
cytosolic calcium. This leads to decreased platelet aggregation and adhesion and a 
disaggregation of existing platelet aggregates [39, 40].  
 
 Another key vascular function regulated by NO is angiogenesis, which is defined 
as the formation of new blood vessels. If unchecked, this process can be pathogenic. 
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Physiological angiogenesis is important for improving ischemic conditions and for 
wound healing [41, 42]. Vasodilation is required for angiogenesis as evidenced by the 
fact that many angiogenic factors, such as VEGF, possess vasodilating properties [43, 
44]. NO has been demonstrated to have a direct role in angiogenesis since NO donors 
promote and NO inhibitors diminish angiogenesis [45-48]. NO promotes angiogenesis 
via cGMP elevation and by enhancing the expression of angiogenic factors [41, 42, 48, 
49]. Enhancement of NO production in patients undergoing coronary artery bypass 
grafting by administration of l-arginine in conjunction with VEGF improved 
angiogenesis and surgical outcomes, thus exemplifying the tight association between NO 
signaling and angiogenesis [50].  
 
 NO can be both pro-and anti apoptotic. High concentrations of NO induce cell 
death in macrophages, pancreatic islet cells, tumors and other cell types. There are 
several mechanisms by which NO can promote apoptosis. First, NO can activate the 
mitochondrial apoptosis pathway by increasing the release of cytochrome c. This leads to 
activation of the caspase-dependent apoptosis pathway. NO can also cause DNA damage 
which induces p53 and leads to cell cycle arrest. Excess NO activates pro-apoptotic 
kinase cascades such as c-Jun N-terminal kinase and mitogen activated protein kinases. 
Finally, NO can cause an increase in the release of ceramide, a bioactive sphingolipid that 
can itself induce apoptotic pathways via the death receptor pathway [51-54].  Cytokines, 
high glucose lipids mediate some of the pro-angiogenic properties of NO [55-60]. NO 
deficiency also leads to apoptosis [51-54]. 
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On the other hand, physiological concentrations of NO protect cells from 
apoptosis [51-54]. One mechanism of protection is via the release of cGMP, which 
subsequently diminishes cytochrome c release, caspase activation and ceramide 
accumulation. In addition, NO can lead to suppression of caspase activity by reversible S-
nitrosylation and increase the expression of anti-apoptotic genes such as Bcl-2 and 
HSP70 [54]. Shear stress is an important mechanism that protects endothelial cells from 
TNFα or growth factor withdrawal-induced apoptosis [61]. One mechanism proposed for 
this protective effect is via the upregulation of NOS and superoxide dismutase [62]. 
 
 Considering the plethora of vascular functions regulated by NO, any 
dysregulation of its bioavailability and production has far reaching consequences. In fact, 
endothelial dysfunction is associated with a number of disorders including diabetes, 
obesity, atherosclerosis, metabolic syndrome and hypertension [63-67]. Much of what is 
known related to endothelial dysfunction and impaired NO production is related to the 
expression, activation, localization, interactions and substrate/cofactor availability of 
eNOS [63]. The role of other citrulline-NO cycle components remains relatively 
unexplored. 
 
Endothelial Dysfunction 
 
 There are a number of mechanisms that have been implicated as contributing 
events in endothelial dysfunction, and most are related to impaired function of NO. One 
hallmark of endothelial dysfunction is inflammation [68]. NO possesses anti-
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inflammatory properties that are disrupted in endothelial dysfunction via mechanisms 
involving increased leukocyte adhesion, increased expression of chemokines, increased 
monocyte migration and infiltration of monocytes into the arterial wall [65, 69]. Another 
inflammatory process disrupted in endothelial dysfunction is related to an increased level 
of C-reactive protein (CRP). CRP diminishes the production of NO by reducing eNOS 
expression [69]. Multiple other inflammatory molecules are elevated in endothelial 
dysfunction such as TNFα. Whether elevated TNFα is a cause or consequence of 
endothelial dysfunction is debatable. However, there are multiple mechanisms by which 
TNFα causes endothelial dysfunction such as the inhibition of insulin signaling, an 
increase in lipids such as ceramide and increased apoptosis [70-77]. 
 
 In endothelial dysfunction, there is also an increase in reactive oxygen species 
(ROS). This is one central mechanism by which cardiovascular disease risk factors such 
as diabetes, hypercholesterolemia and hypertension lead to endothelial dysfunction [63]. 
One such species, superoxide, reacts with NO and leads to the production of 
peroxynitrite, a toxic free radical that diminishes the bioavailability of NO and inhibits 
the protective actions of NO [78]. ROS also degrade BH4, an important eNOS co-factor. 
This leads to the uncoupling of NADPH oxidation from eNOS-mediated NO synthesis 
and the subsequent production of superoxide instead of NO [79-81].  
 
Another consequence of increased ROS is the inhibition of dimethylarginine 
dimethylaminohydrolase (DDAH). This leads to increased levels of asymmetric 
dimethylarginine (ADMA), an endogenous eNOS inhibitor [82]. ADMA inhibits eNOS 
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by multiple mechanisms such as further increasing superoxide production and eNOS 
uncoupling, diminishing the interaction of HSP90 with eNOS and redistributing eNOS to 
the mitochondria with subsequent mitochondrial dysfunction [83-86]. ADMA has been 
linked to vascular disease by contributing to reperfusion injury and increasing blood 
pressure [84, 87]. Protective effects at early time points have also been shown via iNOS 
mediated inhibition of intima-media thickness [88].  
 
Elevated lipids also influence the function of the endothelium. For example, 
oxidized LDL reduces eNOS activity by displacing it from the plasma membrane and 
targeting to intracellular sites where it is less active [89]. Elevated ceramide levels due to 
excess saturated fat in the diet or chronic inflammation diminish eNOS activation and 
NO production [60, 90, 91]. Another lipid linked to endothelial dysfunction is 
apolipoprotein CIII (apoCIII), a component of very low density and low density 
lipoprotein that is elevated in insulin resistance and metabolic syndrome.  ApoCIII 
activates pro-inflammatory atherogenic pathways by directly inhibiting insulin signaling 
and reducing the activation of eNOS [92]. In fact, one of the benefits of statin therapy 
beyond cholesterol lowering is the improved function of eNOS and endothelial function. 
One example is improved blood flow to ischemic tissues in diabetes in response to statins 
due to an upregulation of eNOS [93]. There are controversies about whether statins 
improve endothelial function and this is perhaps associated with other factors associated 
with endothelial dysfunction. For instance, simvastatin is able to improve endothelium-
dependent vasodilation in patients with low levels of ADMA but is ineffective in patients 
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with high ADMA. On the other hand, arginine supplementation in combination with 
statins works well with patients with high but not low ADMA [94].  
 
Insulin resistance and diabetes are also tightly associated with endothelial 
dysfunction [73]. In fact, macrovascular complications are quite common in diabetic 
patients leading to the classification of diabetes as a vascular disorder [95]. Endothelial 
cells express insulin receptors and many cardioprotective signaling pathways are 
mediated by insulin [95]. Several derangements can occur when insulin function is 
compromised including an increase in ROS, depletion of BH4, lipid abnormalities and 
hypertension [96-100]. Hyperglycemia, a consequence of diminished insulin action, also 
has direct impacts on eNOS expression and activity and enhances endothelial cell 
apoptosis [58, 101, 102]. Collectively, these imbalances impair the ability of the 
endothelium to produce adequate amounts of NO and all normal endothelial functions are 
compromised leading to a striking association between insulin resistance, diabetes and 
coronary artery disease.  
 
Overall, the mechanisms that lead to endothelial dysfunction are numerous and 
complex. Most of them converge and lead to one major issue- a decrease in the 
production and bioavailability of NO. Therefore, a better understanding of the 
mechanisms that control NO production is essential for the development of effective 
prevention and treatment strategies for vascular disorders.  
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Prevention of Vascular Disorders 
 
 There are multiple medical and surgical approaches to treat cardiovascular 
diseases and they should be employed as early as possible to diminish long-term damage. 
Considering the far reaching consequences of endothelial dysfunction and the fact that by 
the time significant symptoms arise, vascular disease has already progressed 
dramatically, prevention strategies are the best insurance against the development of 
vascular disease [67]. Since most risk factors for heart disease mediate their deleterious 
effects by impairing NO production [63], preventable risk factors need to be addressed 
either with lifestyle modification of medical interventions. Healthy eating and 
maintaining a normal body weight can go an extremely long way towards keeping blood 
pressure within normal limits, preventing diabetes and metabolic syndrome and 
maintaining a healthy level of blood lipids [103, 104]. Cigarette smoking directly impairs 
NO bioavailability [105], so avoiding smoking or quitting is essential. In addition, blood 
pressure and cholesterol, if inadequately responsive to lifestyle measures, should be 
treated pharmacologically [106]. 
 
Argininosuccinate Synthase Functions Related to Nitric Oxide Production  
 
 AS, the focus of this dissertation, has several unique properties that are essential 
for NO production and vascular health. AS is rate limiting for the production of NO 
[107]. This was initially demonstrated in vascular smooth muscle cells when AS 
overexpression enhanced the capacity of transfected cells to produce NO, despite non-
 13
limiting levels of arginine [108]. In endothelial cells, we have demonstrated that 
inhibition of AS activity with siRNA or the AS inhibitor α-methyl-DL-aspartic acid 
diminishes NO production due to reduced AS activity [24, 109]. 
 
 We also demonstrated that the co-fractionation of AS, AL and eNOS in 
plasmalemmal caveolae allowed endothelial cells to effectively distinguish “bulk 
intracellular arginine” from the arginine used for NO production [110]. Our substrate 
utilization studies supported this view by demonstrating that the recycling of citrulline 
back to arginine is an efficient, tightly coupled process [24]. The activity of AS in this 
recycling process is the preferred mechanism for eNOS-mediated NO production, while 
iNOS-mediated NO production in smooth muscle is dependent on arginine transport [26]. 
 
 One additional and unique mechanism of regulation of NO production by AS 
involves expression of endothelium-specific AS variants with different lengths of the 5’ 
untranslated region (5’ UTR). The shortest form of the message represents ~90% of the 
total AS mRNA and encodes for full length AS. The two longer forms contain an out of 
frame upstream open reading frame (uORF) that encodes a 4 kDa protein called 
Argininosuccinate Synthase Regulatory Protein (ARP). Overexpression of ARP leads to 
diminished NO production and siRNA knockdown of ARP leads to an increase in NO 
production in endothelial cells [111]. 
 
 The three dimensional structure of human AS has revealed an interesting feature 
relevant to its role in NO production. It has been demonstrated that nitrosylation of AS at 
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cysteine 132 (C132) leads to inactivation of the enzyme [112]. A mechanism was not 
identified for this activation. The investigators who solved the human AS crystal 
structure used in silico modeling to predict the effect of nitrosylation at this site on the 
catalytic efficiency of AS. The authors noted that C132 is actually buried in the N-
terminal domain. They suggested that a significant structural change would have to take 
place for the nitrosylation to occur. Based on their in silico models, they determined that 
even though C132 is not near the active site, the modification does perturb the orientation 
of amino acids that are part of the active site [113]. This presents the first evidence of a 
possible conformational change caused by a modification at an allosteric site which then 
changes the activity of AS with subsequent effects on NO synthesis. 
 
Regulation of Endothelial Nitric Oxide Production: Protein Expression 
 
 The functions of NO are controlled at the levels of biosynthesis and availability 
because it cannot be stored. Since virtually all phenotypic properties of normally 
functioning endothelial cells are related to NO, its production is tightly controlled [28, 
114, 115]. This tight control requires multiple regulatory mechanisms. One such 
mechanism is the regulation of the expression of the enzymes of the citrulline-NO cycle. 
 
To assess the importance of the expression citrulline-NO cycle components on 
vascular function, animal knockout models have been generated and have yielded 
important information. The eNOS knockout mouse models have by far been the most 
prominent in delineating the importance of the citrulline-NO cycle for vascular health. 
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Deletion of the eNOS gene is not embryonic lethal, but does lead to hypertension, 
impaired wound healing and angiogenesis [116]. In addition, eNOS knockout mice have 
hyperinsulinemia, hyperlipidemia, diminished glucose metabolism [117] and a decrease 
in skeletal muscle oxidative capacity [118]. In contrast, eNOS overexpression ameliorates 
vascular dysfunction by improvements in lipids, blood pressure, myocardial contraction 
and protection against ischemia-reperfusion injury [119, 120] 
 
The lessons we have learned from eNOS knockout mice are complicated by the 
fact that in some instances, a lack of eNOS has some beneficial effects and 
overexpression of eNOS has deleterious effects. For example, eNOS knockout mice have 
decreased formation of diet-induced fatty streaks [121] and endothelium dependent 
relaxation and bradykinin-mediated blood flow are intact due to a compensatory 
upregulation of nNOS [122]. Although physiological levels of NO are beneficial for 
myocardial contractility, overexpression leads to a negative inotropic effect [123]. Due to 
the difficulty in interpreting mouse data related to compensatory functions of the NOS 
isoforms, a triple knockout mouse where eNOS, nNOS and iNOS were deleted was 
recently generated. These mice had a much lower survival rate and displayed a long list 
of metabolic abnormalities including metabolic syndrome, obesity, hyperlipidemia, 
hypertension, and impaired glucose tolerance [124]. Taken together, animal models of 
reduced or enhanced eNOS expression demonstrate the essential role of eNOS in 
mediating vascular health. 
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In contrast, when AS is knocked out in mice, it leads to death a few days after 
birth due to the accumulation of citrulline and a severe arginine deficiency [29, 125]. A 
tissue specific AS knockout mouse model is not available, but if, for example, such a 
model were generated with an endothelium specific deletion of AS, we would predict 
marked endothelial dysfunction based on our tissue culture work. Similarly to the AS 
knockout, AL knockout mice die within 48 hours of birth and are characterized by 
increased ammonia, argininosuccinic acid, glutamine and citrulline and low levels of 
arginine [29, 36].  
 
The role of the expression citrulline-NO cycle components on vascular health can 
be studied at extreme levels utilizing animal models as just described. These scenarios are 
rare in humans, and there are finer levels of regulation that occur in response to a number 
of biological processes and signals. Shear stress is one of the most important 
physiological factors that regulates the function of blood vessels [126-128]. 
Unidirectional, laminar shear stress exerts a protective role on the endothelium by 
diminishing adhesion and platelet aggregation [129] and enhancing NO production [126, 
130]. Shear stress has been shown to increase eNOS expression via a transient activation 
of NfκB in bovine aortic endothelial cells. There is a shear stress responsive element 
(SSRE) in the eNOS promoter that is responsible for the transcriptional regulation by 
NfκB [131]. Other groups have determined that the shear stress-mediated increase in 
eNOS mRNA is due to an increase in transcription and mRNA stabilization [132, 133]. In 
a DNA microarray study of human umbilical vein endothelial cells, shear stress was 
shown to significantly increase AS expression, but not eNOS. The authors suggested this 
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might be due to the fact that shear stress-induced increases in NO synthesis depend on 
arginine synthesis from citrulline via increased AS levels [134]. In a subsequent study by 
a group studying the adhesion of endothelial cells in vein grafts supported the role of both 
eNOS and AS in the response of the endothelium to shear stress [135]. The role of AL in 
shear stress-mediated NO production has not been studied. However, it is clear that there 
is a role for both AS and eNOS in mediating the response of the endothelium to shear 
stress that involves multiple and perhaps overlapping mechanisms depending on the level 
of shear stress and other factors.  
 
 Cytokines regulate vascular function in various ways, and tumor necrosis factor 
alpha (TNFα) is well characterized in this respect. TNFα is a pro-inflammatory cytokine 
with both positive and negative roles in regulating vascular function, depending on the 
length of treatment and tissue type [136]. In general, conditions of chronic TNFα 
elevations are deleterious to the vasculature as evidenced by the fact that humans with 
diabetes, obesity and heart disease have elevated levels of TNFα [55, 71, 73, 75, 137, 
138]. Often times, TNFα-mediated vascular impairment is caused by dysregulation of NO 
production [70, 74, 139, 140]. One mechanism by which TNFα inhibits NO production is 
by altering eNOS and AS expression. Specifically, eNOS expression has been shown to 
be downregulated by TNFα via several mechanisms including decreased mRNA stability 
and inhibition of transcription factor binding [141-143]. In addition, TNFα diminishes AS 
expression and NO production by inhibiting the binding of SP-1 elements to the proximal 
promoter [144]. AL seems to be less amenable to cytokine regulation since in vascular 
smooth muscle cells, retinal endothelium or pancreatic β cells,  treatment with a variety 
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of different cytokines led to co-induction of AS and iNOS while AL remained static 
[145-147].  
 
 Peroxisome proliferator-activated receptor gamma (PPARγ) is a member of the 
nuclear receptor superfamily of ligand-activated transcription factors. PPARγ regulates 
the transcription of genes involved in lipid and glucose metabolism [148], differentiation 
[148-150] and cell growth [148]. Thiazolidinediones (TZDs) are a group of synthetic 
PPARγ agonists that provide cardiovascular benefits such as reduction of blood pressure 
and improvement in insulin-sensitivity [151-153]. In addition, TZDs reduce lesion 
formation in animal models of atherosclerosis [154-156], improve flow-mediated 
vasodilation and decrease vascular smooth muscle cell migration by stimulating 
endothelial NO production [157, 158]. These anti-diabetic compounds also counter the 
effects of the inflammatory response associated with elevated serum levels of TNFα  and 
ceramide. For instance, rosiglitazone impairs TNFα-induced activation of MAPK, 
restoring insulin signaling and leading to normalization of glucose uptake in brown 
adipocytes [159]. In humans with type 2 diabetes, pioglitazone was protective against 
TNF-mediated endothelial dysfunction [76]. In hepatocytes made insulin resistant via 
TNFα treatment, troglitazone is able to restore insulin sensitivity, partially via blocking 
the downstream actions of ceramide [160].  
 
Another mechanism by which TZD’s improve endothelial function is by inducing 
the expression of components of the citrulline-NO cycle. For example, eNOS expression 
and NO production are enhanced by troglitazone by a mechanism that seems to be PPAR 
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independent [161]. Telmisartan, an angiotensin II receptor blocker, has recently been 
identified as a partial PPARγ agonist. Its cardioprotective mechanism is mediated 
partially by the upregulation of eNOS [153]. In addition, troglitazone enhances NO 
production and AS expression by activating a PPAR responsive element in the distal AS 
promoter [162]. There have been no studies on the effects of PPAR agonists on AL. 
Taken together, the positive benefits of TZD’s are multifactorial and lead to improved 
vascular parameters by mechanisms that include the upregulation of eNOS and AS.  
 
 Insulin is an important regulator of vascular function. Insulin mediates its effects 
on vasodilation by stimulating NO release [163, 164]. One mechanism by which insulin 
increases NO production is by increasing the expression of eNOS. Kuboki et al. 
demonstrated that insulin increases eNOS mRNA within 1 hour of treatment. This 
increase was mediated by activation of the PI3-kinase pathway [165]. In another study, 
the mechanism of insulin transcriptional regulation of eNOS was found to involve 
increased binding of SP-1 and AP-1 transcription factors [166]. The link between insulin 
and NO has another important feature. NO itself leads to the secretion of insulin in 
pancreatic islet β-cells [167]. This process is dependent on the recycling of arginine to 
citrulline [168]. This suggests an involvement of both AS and AL. In addition, eNOS 
expression and function is diminished in diabetes. For example, high glucose diminishes 
the expression of eNOS [102]. In addition, insulin enhances the expression of eNOS in 
diabetic rats [169]. The impact of insulin or diabetes on endothelial AS and AL 
expression has not been studied, but one group did note that in the early phases of 
streptozotocin (STZ)-induced type 1 diabetes in rats, AS and eNOS mRNA and protein 
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expression was induced in aorta. This increase then diminished as diabetes progressed. 
There was very little effect on AL mRNA, and possibly a slight induction after 4 weeks, 
but the effects on AL were not studied any further [170]. Thus, glucose, insulin and NO 
metabolism are tightly associated processes that involve both AS and eNOS (and possibly 
AL) expression.  
 
 VEGF is an important mediator of vascular health by regulating vasodilation and 
angiogenesis [171]. VEGF exerts its cardioprotective functions, in part, by increasing the 
expression of eNOS. In human umbilical vein endothelial cells (HUVECs), VEGF 
augments the expression of eNOS in a time and dose-dependent manner. This was linked 
to increased basal and stimulated NO production [172]. Another group obtained similar 
results when using rat aortic rings [173]. In addition, insulin increases the expression of 
both eNOS and VEGF in diabetic rats leading to increased NO production and vascular 
relaxation [169]. The role of VEGF in regulating AS or AL has not been studied. 
Therefore, VEGF and NO signaling pathways are linked by direct effects on eNOS 
expression.  
 
 Ceramide, a bioactive sphingolipid, has been implicated in the development of 
insulin resistance and atherosclerosis [57, 61, 77, 174]. In general, supraphysioloical 
levels of ceramide contribute to endothelial dysfunction [60, 91, 175] and most of what is 
known involves impairment of eNOS activation (which is discussed in the next section). 
However, Li and colleagues demonstrated that ceramide decreases NO production in 
human endothelial cells via a mechanism that involves ROS generation. They found that 
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eNOS expression is enhanced as a compensatory mechanism. This enhanced expression 
was not sufficient to ameliorate the diminished NO synthesis caused by the generation of 
ROS [90]. The direct effects of ceramide on AS and AL expression have not been 
studied. 
 
 The intricate and diverse mechanisms regulating the expression of AS and eNOS 
in the endothelium and other tissues suggests that this is an important mechanism 
mediating vascular biology and warrants continued investigation. For this reason, the 
regulation of AS expression in endothelial cells encompasses Specific Aim 1 of this 
dissertation and is described in Chapter One.  
 
Regulation of Endothelial Nitric Oxide Production: Post-Translational Modifications 
 
 Although controlling the expression levels of AS, AL and eNOS is an important 
mechanism for regulating the levels of NO produced, this mode of regulation seldom 
occurs quickly enough to acutely increase or decrease NO production. Since NO is 
constantly being produced and its levels are frequently adjusted to meet cellular demands, 
post-translational modifications (PTM) have been described as a prominent mechanism in 
regulating NO production. 
 
 The acute regulation of eNOS by reversible phosphorylation is well described. 
Although eNOS is regulated by tyrosine phosphorylation [176, 177], serine/threonine 
phosphorylation is a much more prominent mechanism. There are 5 well characterized 
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sites of eNOS phosphorylation: serine 116 (S116), threonine 497 (T497), S617, S635 and 
S1179 (bovine; these sites are equivalent to S114, T495, S633 and S1177 in human) 
[178-180].  
 
S116 is located in the oxygenase domain of the enzyme [179]. There is 
controversy as to whether this site activates or inactivates eNOS. A recent paper 
demonstrated that mutation of this site to an alanine increased NO production while 
mutation to an aspartic acid diminished NO production. In addition, phosphorylation at 
this site increased the inhibitory interaction of eNOS with caveolin-1 and diminished 
vascular reactivity. Hence, this site seems to be inhibitory for the function of eNOS 
[181].  On the other hand, Drew et al. found that HDL and Apo A1 led to increased NO 
release due to eNOS phosphorylation at several sites, most profoundly at S116. This 
suggested a positive role for S116 [182]. It is possible that there are tissue and stimulus-
specific functions for S116. 
 
There is a great deal of consensus regarding the inhibitory role of T497, which is 
located in the eNOS calmodulin binding domain [179]. In fact, in the study mentioned 
above where they found that S116 does activate eNOS, they also found that HDL and 
Apo A1 diminish phosphorylation at T497  [182]. Many other studies have confirmed 
this inhibitory regulation [81, 183-185]. In particular, several different groups have 
demonstrated that mutation of T497 to aspartic acid (phospho-mimetic) greatly 
diminishes eNOS activity and NO production while the alanine mutation (phospho-null) 
has opposite effects [79, 184].  When this site is phosphorylated, calmodulin cannot bind 
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to and activate eNOS [184]. T497 is constitutively phosphorylated and upon stimulation 
with agents that increase intracellular calcium, such as bradykinin or VEGF, the site is 
dephosphorylated by protein phosphatase 1 (PP1) leading to calmodulin binding [184]. In 
addition, the dephosphorylation of T497 has to occur before the activating 
phosphorylation at S1179 can take place [185]. Protein kinase C has been shown to 
increase phosphorylation at this site [183], thereby diminishing eNOS function. Certain 
PKC isoforms, such as PKCα and PKCε can activate eNOS by leading to 
phosphorylation at S1179 [186, 187]. 
 
Serines 617 and 635 are both in the eNOS autoinhibitory domain, which is part of 
the reductase domain [179]. This domain is reported to keep eNOS in an inhibited state 
that is reversed upon calmodulin binding [19, 188].  These sites are phosphorylated in 
response to bradykinin, ATP and VEGF [179, 182, 189]. Shear stress has also been found 
to lead to the phosphorylation of S635 [190]. The phosphorylation at S617 is transient in 
nature while S635 phosphorylation is more persistent. Akt phosphorylates S617 while 
PKA phosphorylates S635. The mechanism of regulation of eNOS activation by these 
two sites is suggested to involve a two step process. During initial agonist-induced 
activation of eNOS, S617 is phosphorylated and increases eNOS sensitivity to calcium. 
Then, S635 phosphorylation increases eNOS specific activity to levels similar to what 
occurs when S1179 is phosphorylated [189].  
 
The most studied site of eNOS phosphorylation is S1179, located near the C-
terminus in the reductase domain [179]. Phosphorylation at this site leads to an 
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approximately 2-fold activation of eNOS specific activity [189]. This activation is due to 
a decrease in the calcium-dependence of eNOS and an increase in electron flux from the 
reductase domain to the oxygenase domain, which leads to increased NO output [191]. 
This site is phosphorylated by a number of kinases including Akt, AMPK, PKA, PKG 
and calmodulin II protein kinase in response to a variety of stimuli including insulin, 
adiponectin, bradykinin, VEGF, HDL and Apo A1 [127, 130, 182, 183, 185, 186, 192-
202]. For example, fluid shear stress, VEGF and bradykinin lead to the activation of PKA 
and subsequent phosphorylation of eNOS at S1179 [183, 203]. 
 
Although the regulation of eNOS by a complex pattern of stimulus-specific 
phosphorylation and dephosphorylation events has been studied extensively, there have 
been no reports of such studies for AS and AL. Evidence supporting post-translational 
regulation of AS is beginning to accumulate. First, in a proteomic study to identify novel 
phosphoproteins in HeLa cells, AS was found to be phosphorylated at S352 [204]. This is 
the first and only indication of this type of modification of AS. The authors did not 
investigate the biological relevance of this modification. In addition, in vascular smooth 
muscle, AS is reversibly inactivated by nitrosylation in conditions of high NO output by 
iNOS. Their work suggests that AS is at least partially responsible for sensing cellular 
NO levels and adjusting output accordingly in an effort to maintain homeostasis [112]. 
Nitrosylation of cysteine residues has emerged as an extremely important, reversible 
modification that regulates the activity of a number of proteins such as caspase-3, the 
ryanodine receptor and actin [205]. Importantly, eNOS is basally nitrosylated in 
endothelial cells and is then rapidly denitrosylated in response to VEGF stimulation 
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[206]. The nitrosylation of AS in the endothelium has not been studied, but may represent 
an important additional mechanism of regulation.  
 
 Another important PTM that regulates NO production is the acylation of eNOS by 
the irreversible N-myristoylation at glycine 2 (G2) and the reversible thiopalmitoylation 
at cysteine 15 (C15) and C26 [207]. These modifications are crucial for the targeting and 
anchoring of eNOS to the plasma membrane, which is an essential location for the 
production of NO [207-210]. These modifications have not been studied for AS or AL. 
However, we have demonstrated that AS and AL and eNOS co-fractionate with caveolin-
1 in caveolar membrane fractions, which indicates that mechanisms must exist to target 
these enzymes to the plasma membrane in conjunction with eNOS. 
 
Glycosylation is an additional type of PTM that regulates NO production. O-
linked glycosylation occurs at serine and threonine residues, typically in response to the 
flux of excess glucose into the hexosamine biosynthesis pathway. Glycosylation often 
competes with phosphorylation at the same or adjacent sites leading to a ying-yang type 
of regulatory scheme [211, 212]. In endothelial cells, glycosylation of eNOS decreases its 
activity and diminishes phosphorylation at S1179 [213]. The functional relevance of this 
modification was illustrated in diabetes-related erectile dysfunction, where glycosylation 
reduced S1179 phosphorylation at baseline and in response to VEGF and shear stress 
[214]. In this study, it was determined that glycosylation only affects S1179 and not 
T497, S617 or S635. Although glycosylation of AS in endothelial cells has not been 
studied, in Caco-2 cells the expression of AS is stimulated by glutamine via glycosylation 
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of the transcription factor SP-1 [215]. This modification leads to nuclear import of SP-1 
and a subsequent increase in AS transcription. The regulation of AL by glycosylation has 
not been studied. 
 
Taken together, the extensive studies of eNOS PTM by phosphorylation, 
nitrosylation, glycosylation and acylation have a prominent role in regulating the ability 
of the endothelium to produce NO. Due to the few papers in the literature that suggest 
that AS is also regulated by PTM and to the prominent role of serine/threonine 
phosphorylation in regulating eNOS function, Specific Aim 2 is dedicated to the 
thorough investigation of endothelial AS serine/threonine phosphorylation. The findings 
are presented in Chapter Two.  
 
Regulation of Endothelial Nitric Oxide Production: Subcellular Localization and Protein 
Interactions 
 
 The precise location of a protein within the cell is critical for its function. 
Compartmentalization of proteins that are in the same metabolic or signaling pathway 
allows for efficient communication, channeling of substrates and accessibility to 
important regulatory factors. In addition, the regulation of subcellular transport to 
localize these proteins involves several mechanisms including vesicles, cytoskeletal 
components and protein interactions. Furthermore, protein interactions often mediate the 
functions of their interacting partners via mechanisms that do not involve transport such 
as post-translational modification or conformational change [216]. There is a complex 
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network of interacting proteins that are known to regulate NO production via eNOS [180] 
and the scientific community is just beginning to describe similar mechanisms for AS and 
AL. 
 
 The regulation of eNOS is dependent its localization within the cell [217, 218]. 
There are two regions in the cell that have been found to independently produce NO, the 
Golgi and the plasma membrane [219, 220]. Within the plasma membrane, eNOS is 
localized to caveolae [217]. Caveolae are invaginations of the plasma membrane that are 
rich in glycosphingolipids and cholesterol and serve as platforms for the integration of 
signaling pathways. Caveolae are also involved in endocytosis and transcytosis. Caveolin 
is an integral membrane protein that is an important structural component of caveolae 
[218, 221]. Although activation of eNOS by phosphorylation at S1179 does not cause 
translocation from the Golgi to the plasma membrane, the proper localization of eNOS is 
necessary for this phosphorylation to occur [208, 220]. Mistargeting of eNOS also 
attenuates NO release [222, 223]. In the plasma membrane, eNOS is constitutively 
phosphorylated at S1179 and is highly active. In the Golgi, phosphorylation at S1179 is 
diminished and less NO is produced in response to calcium signaling [224]. Furthermore, 
plasma membrane eNOS is more responsive to agonists such as insulin and angiopoietin 
and demonstrates increased binding to HSP90 as compared to Golgi-eNOS [219]. Despite 
this understanding, there is still some doubt as to whether Golgi versus plasma membrane 
NO production is of more or less significance or whether the distinct functions of these 
pools require further study to define their specific purpose in the cell. 
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The targeting of eNOS to Golgi versus plasma membrane is controlled by several 
mechanisms. One key mechanism involves myristoylation and palmitoylation [209]. 
Myristoylation is necessary for eNOS to associate with the membrane, essential for 
optimal eNOS activity, important for compartmentalization in the Golgi and is a 
prerequisite for palmitoylation. Palmitoylation is essential for eNOS targeting to the 
membrane and specifically to caveolae [210].  In a study by Jagnandan and colleagues, 
organelle-specific eNOS constructs were generated in an attempt to determine the 
compartment-specific function of eNOS. The authors found that the nucleus, 
mitochondria cytoplasm and trans-Golgi network are inefficient for NO production as 
compared to the plasma membrane and cis-Golgi network. This is apparently not due to 
insufficient substrate availability since iNOS targeted to the same regions functions 
normally. The relative lack of calcium/calmodulin in these regions may responsible for 
the inefficiency of eNOS, which unlike iNOS is dependent on calcium and calmodulin 
for function [224]. A subsequent study determined that calcium and calmodulin are not 
the reason for disparate function in different organelles. The study found it is actually 
phosphorylation that regulates organelle-specific eNOS function since Golgi localized 
eNOS had reduced phosphorylation at S1179, S635 and S617 [225]. 
 
In addition to acylation as a targeting mechanism, there is an intricate network of 
cytoskeletal components that regulate eNOS function and likely also its translocation. 
Actin is a prominent regulator of eNOS. For example, F-actin is required for shear stress 
mediated eNOS upregulation due to its role in mechanotransduction [226]. In general, the 
interaction of eNOS with actin increases its activity. One mechanism is due to increased 
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interaction with HSP90 [227]. On the other hand, the interaction of eNOS with actinin-4, 
an actin-associated protein, inhibits eNOS activity by preventing calmodulin from 
interacting with and activating eNOS [228]. Vimentin is another important cytoskeletal 
component that regulates eNOS function. Vimentin is an intermediate filament that is 
essential for flow-mediated dilatation [226]. Although the eNOS activity per se has not 
been related to vimentin, the importance of this cytoskeletal component in mediating 
vessel relaxation implies the involvement of eNOS. Vimentin is also an essential 
structural component of caveolae [229]. In addition, the inhibition of microtubules 
(tubulin and microtubule associated proteins) leads to decreased eNOS activity and NO 
production [230]. Furthermore, it has been demonstrated that HSP90 and calmodulin both 
interact with tubulin. The interaction of tubulin with HSP90 is important for eNOS 
activity since disruption of microtubule assembly diminishes the eNOS-HSP90 
interaction and reduces NO output The specific role of the calmodulin-tubulin interaction 
on the function of the citrulline-NO cycle is unclear [230]. As discussed in a latter 
section, both HSP90 and calmodulin are important binding partners of eNOS that 
stimulate its function. This suggests that microtubules also play a role in eNOS function. 
Whether the mechanism is structural or involves eNOS transport is not clear.  
 
Finally, several protein interactions are essential for eNOS cellular transport. One 
well studied interaction is with caveolin-1. AS discussed previously, caveolin-1 is an 
important component of caveolae. It is believed that caveolae function as vesicles that 
regulate eNOS transcytosis and caveolin-1 is required in this process [222]. More 
importantly, caveolin-1 and eNOS both interact with NOSTRIN (eNOS trafficking 
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inducer), which also recruits dynamin, a Golgi localized GTP-ase, and facilitates caveolar 
transport [231]. NOSTRIN transport of eNOS is dependent on the actin cytoskeleton 
[232]. Although NOSTRIN is important for eNOS translocation, it inhibits eNOS activity 
regardless of localization in the cell and overexpression of NOSTRIN leads to 
redistribution of eNOS from the plasma membrane to intracellular vesicular structures 
[232]. The specific regulation of this complex and its trafficking is still unclear. NOSIP 
(eNOS interacting protein) is another important protein that regulates eNOS 
translocation. NOSIP interacts directly with eNOS and inhibits its activity [233]. 
Furthermore, NOSIP is important for the subcellular redistribution of eNOS between the 
caveolae and intracellular compartments [234]. Much like NOSTRIN, NOSIP 
overexpression leads diminished plasma membrane localization of eNOS [233].    
 
To date, there have been no studies delineating the regulation of AS or AL 
intracellular targeting. The localization of AS and AL has been understudied in 
endothelial cells. However, we have demonstrated that AS, AL eNOS and caveolin-1 co-
fractionate in caveolar membrane preparations [110]. In vascular smooth muscle, AS 
demonstrates both cytoplasmic and membrane localization along with a punctuate pattern 
of distribution that suggests mitochondrial localization [108]. Otherwise, no other studies 
have addressed the subcellular localization of AS or AL as part of the citrulline-NO 
cycle. Much more is known about their localization in tissues that produce urea. For 
example, in liver, these enzymes are localized in mitochondria. 
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 In addition to the role protein interactions play in the targeting of eNOS, there are 
several proteins that regulate eNOS functions in other ways. Aside from the role of 
caveolin in AS localization, it has direct effects on inhibiting eNOS activity [235]. The 
interaction of caveolin with eNOS is direct and occurs in a region of eNOS that contains 
a caveolin binding motif [235]. The interaction of eNOS with caveolin is disrupted upon 
stimulation with calcium ionophores, bradykinin or fluid shear stress [236, 237]. Another 
interaction that negatively regulates eNOS function is the bradykinin receptor. This 
interaction is similar to that with caveolin in that it represents a membrane docking 
interaction that is relieved upon treatment with agonists such as bradykinin and calcium 
ionophores [238].  
 
 There are a multitude of proteins that interact with eNOS and enhance its 
function. One prominent interaction is with heat shock protein-90 (HSP90). This 
molecular chaperone activates eNOS via a mechanism that involves phosphorylation at 
S1179 [239]. HSP90 delivers the kinase Akt to eNOS and promotes its phosphorylation 
[240]. Calmodulin is an important positive regulator of eNOS that also interacts with 
HSP90 and is responsible for displacing the eNOS-caveolin interaction [241].  In fact, 
caveolin and calmodulin are involved in the reciprocal regulation of eNOS. Upon agonist 
stimulation and an increase in intracellular calcium, calmodulin binds to eNOS and 
displaces caveolin [242]. In addition, eNOS interacts with the CAT-1 arginine transporter 
and this increases its activation via phosphorylation at S1179 and 635. The mechanism of 
enhanced NO release does not involve arginine transport [243]. 
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In contrast to eNOS, very little is known about protein interactions involving AS 
and AL as part of the citrulline-NO cycle. Recently, the interaction of an NADPH sensor 
protein (HSCARG) with AS was shown to down regulate AS activity in epithelial cells.  
Their results implied that HSCARG regulation of AS activity is crucial for maintaining 
the intracellular balance between redox state and NO levels [244]. This is the first study 
to define a protein interaction with AS that is essential for NO production.  
 
Given the prominence of regulation of NO production by eNOS subcellular 
localization and protein interactions, we hypothesize similar mechanisms exist to regulate 
the role of AS in endothelial NO production. Therefore, Specific Aim 3 of this 
dissertation will explore both the subcellular localization and protein interactions of AS. 
Our findings are described in Chapter Three.  
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SPECIFIC AIMS 
 
Purpose 
 
 Heart disease is the number one killer of Americans. As the incidence of obesity, 
diabetes and metabolic syndrome continues rising at an alarming rate, so will the 
prevalence of endothelial dysfunction [1] . Since endothelial dysfunction is often 
accompanied by diminished or excessive nitric oxide (NO) production [2], it is essential 
to continue our efforts to gain a better understanding of the regulation of NO synthesis. 
Our studies were designed to expand our global understanding of vascular biology by 
assessing the regulation of the citrulline-NO cycle from a different perspective. Since 
much of the focus has been on the regulation of endothelial nitric oxide synthase (eNOS), 
our research is targeted at a better understanding of another equally important component 
of the citrulline-NO cycle, argininosuccinate synthase (AS).  
 
Central Question and Hypothesis 
 
AS is an enzyme that is important for the production of nitric oxide. The central 
question we are addressing with the work described is: How does AS regulate endothelial 
NO production? Due to the fundamental role of AS for vascular biology, we hypothesize 
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that multiple mechanisms regulate AS function to control NO production and support 
endothelial function.  
 
Specific Aim 1 
 
The role of eNOS in the control of NO production is well studied [2]. Much less 
is known about the regulatory role of AS. We and others have demonstrated the 
importance of AS expression for the production of NO [3-14]. We hypothesize that a 
multitude of stimuli alter AS expression to enhance NO production in a manner 
consistent with the substrate needs of eNOS. In Specific Aim 1, described in Chapter 
One, we will first examine the role of AS overexpression in regulating NO production. 
We will then determine whether insulin, vascular endothelial growth factor (VEGF) and 
ceramide impact AS expression coordinately with eNOS.  
 
Specific Aim 2 
 
Although regulation at the level of transcription and translation is an important 
mechanism controlling the level of function of an enzyme, this type of regulation seldom 
accounts for acute changes in enzymatic activity. NO synthesis is a constant and dynamic 
process. It is well documented that eNOS is regulated by a complex set of reversible post-
translational modifications [15-17]. Since AS is the source of substrate for eNOS [9, 11], 
we hypothesize that a similar pattern of post-translational modifications exists for the 
acute regulation of AS function. In Specific Aim 2, described in Chapter Two, we will 
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determine whether AS is an endogenous phosphoprotein, define the biological 
significance of AS phosphorylation, and uncover the possible mechanisms by which AS 
phosphorylation regulates its function. 
 
Specific Aim 3 
 
Post-translational regulation of protein function often involves subcellular 
localization and dynamic protein interactions. There is a complex literature surrounding 
the regulation of eNOS trafficking, activation and function that is driven by protein 
interactions [17-19]. However, very little is known about such regulatory mechanisms 
controlling AS function. In Specific Aim 3, described in Chapter Three, we will define 
the subcellular localization of AS and identify key interacting partners.   
 
Working Model 
  
 It is our belief that the regulation of caveolae-localized AS, in conjunction with 
eNOS, is mediated by an interrelated set of mechanisms that controls the expression, post 
translational modifications and protein interactions that are so critical for the overall 
function of the system. As demonstrated in Figure 1, we hypothesize that agonists and 
antagonists will coordinately regulate the expression, activation and protein interactions 
of AS and eNOS so that the level of NO produced is adequate to meet the current needs 
of the cell. In addition, it is our belief that the multiple mechanisms that regulate AS and 
eNOS are inter-related, yet specific to environmental signals. Although there might be 
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instances where there is some discoordinate regulation of AS and eNOS, such instances 
are necessary in scenarios where an initial change in regulation of one of these two 
enzymes would signal a need for a change in NO production which would then be 
followed by a coordinate regulation of the other enzyme for the express purpose of 
restoring homeostasis. We also believe that there are specific mechanisms that control the 
regulation of the caveolae-localized citrulline-NO complex in comparison to other 
locations within the cell. Importantly, the coordinate, multi-level regulation of AS and 
eNOS is designed specifically to regulate the synthesis of NO in an attempt to support the 
health of the endothelium and ultimately of the cardiovascular system. Any derangements 
of the physiological regulation of this complex, even if minor, would have a great impact 
on vascular health and explains the prominence of vascular disorders seen with a variety 
of metabolic imbalances. 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1: Working Model of the Regulation of the Citrulline-NO Cycle Under 
Physiological Conditions. Figure depicts the central components of our study of the 
citrulline-NO cycle, AS and eNOS, as a caveolae-localized complex that is coordinately 
regulated by agonists and antagonists via expression, phosphorylation and protein 
interactions in an effort to produce adequate amounts of NO to promote vascular health.  
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CHAPTER ONE 
ARGININOSUCCINATE SYNTHASE FUNCTION AND EXPRESSION 
 
Overview 
 
Argininosuccinate synthase (AS) is a key, regulated step of the citrulline-nitric 
oxide (NO) cycle. We have previously demonstrated several levels of regulation of AS 
expression that impact NO production. First, when AS expression is reduced utilizing 
siRNA, NO production, AS enzymatic activity and endothelial cell viability is 
diminished. The loss of endothelial cells is via apoptosis and can be rescued with an NO 
donor, demonstrating the direct role of AS activity and NO production in maintaining 
endothelial cell viability. In addition, TNFα, a cytokine associated with vascular disease, 
leads to decreased expression of AS under conditions of chronic inflammation. This 
decreased expression occurs via a reduction in the ability of SP-1 elements to activate the 
AS proximal promoter, similar to the effects of chronic TNFα treatment on the eNOS 
promoter.   Finally, we have demonstrated that AS expression is increased by the PPARγ 
agonist drug, troglitazone, due to enhanced activity at a distal AS PPAR responsive 
element (PPRE). To expand our understanding of AS transcriptional regulation, we 
explored several pathways. First, we tested whether AS overexpression in endothelial 
cells enhances NO production. Our data demonstrates that AS overexpression 
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significantly increased basal NO production within 6 hours of transfection. Since insulin 
is a key regulator of vasodilation and vascular function, the hypothesis that insulin 
enhances AS expression and NO production was tested. Western blot and real time PCR 
experiments showed that AS protein and mRNA expression were up-regulated by 
physiological doses of insulin. Insulin coordinately regulated eNOS expression. 
Luciferase assay data also suggested that insulin may be activating a distal AS promoter 
element. Nitric oxide assays demonstrated that insulin alone can increase NO production 
and that it also acts synergistically with bradykinin and the calcium ionophore A23187 to 
increase NO production. This suggests that insulin up-regulation of AS is part of the 
mechanism by which it increases NO production. Since VEGF mediates important 
endothelium-specific functions such as angiogenesis and vasodilation, the hypothesis that 
VEGF enhances AS expression and NO production was examined. Western blot analysis 
demonstrated that VEGF increases AS expression. We also demonstrated a time-
dependent increase in NO production in response to VEGF. Finally, we investigated the 
effects of ceramide on AS and eNOS expression. Ceramide is a bioactive sphingolipid 
with roles in cell signaling and apoptosis. Often times, the pathogenic effects of TNFα 
are mediated by ceramide. This prompted the hypothesis that ceramide would diminish 
AS expression under pathogenic conditions. Western blot analyses demonstrated that 
ceramide decreased AS and eNOS expression. In addition, ceramide diminished eNOS 
activation. Collectively, the data in this Chapter suggests that AS expression is highly 
regulated in a manner that is consistent with its role in supporting the catalytic activity of 
eNOS.  
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Materials and Methods 
 
Bovine Endothelial Cell Culture: Bovine aortic endothelial cells (BAEC) were 
isolated by our laboratory from bovine aorta following the procedure of Gospodarowicz 
et al [1], and were used from passages 4-10. The study of bovine AS is supported by the 
extensive use of BAEC in research and the fact that AS shares a high sequence identity 
between human [2], bovine [3], rat [4] and mouse  [5]. BAEC were cultured at 37°C 
under an atmosphere of 5% CO2 in complete Dulbecco’s Modified Eagle’s Medium 
(DMEM) (1 g/L glucose, Mediatech) that contained 10% fetal bovine serum (Hyclone 
Laboratories), 100 units/ml penicillin and 100 μg/ml streptomycin (Mediatech). Cells 
were treated once they reached confluence. 
 
AS Expression Vector: The AS plasmid contains both a V5 and 6X-His tag at its 
C-terminus. The vector map and sequence are below: 
 
 
 
 
 
 
 
 
 
  Figure 2: AS Expression Vector Map 
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 Figure 3: AS Expression Vector Sequence. Green = AS start; Red = AS stop; Turquoise = 
codons mutated to make T131, S180 and S189 variants in Chapter Two.   
 
   1 GACGGATCGG GAGATCTCCC GATCCCCTAT GGTGCACTCT CAGTACAATC TGCTCTGATG 
  61 CCGCATAGTT AAGCCAGTAT CTGCTCCCTG CTTGTGTGTT GGAGGTCGCT GAGTAGTGCG 
 121 CGAGCAAAAT TTAAGCTACA ACAAGGCAAG GCTTGACCGA CAATTGCATG AAGAATCTGC 
 181 TTAGGGTTAG GCGTTTTGCG CTGCTTCGCG ATGTACGGGC CAGATATACG CGTTGACATT 
 241 GATTATTGAC TAGTTATTAA TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA 
 301 TGGAGTTCCG CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC 
 361 CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA GGGACTTTCC 
 421 ATTGACGTCA ATGGGTGGAG TATTTACGGT AAACTGCCCA CTTGGCAGTA CATCAAGTGT 
 481 ATCATATGCC AAGTACGCCC CCTATTGACG TCAATGACGG TAAATGGCCC GCCTGGCATT 
 541 ATGCCCAGTA CATGACCTTA TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA 
 601 TCGCTATTAC CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG 
 661 ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG TTTTGGCACC 
 721 AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC CCCATTGACG CAAATGGGCG 
 781 GTAGGCGTGT ACGGTGGGAG GTCTATATAA GCAGAGCTCT CTGGCTAACT AGAGAACCCA 
 841 CTGCTTACTG GCTTATCGAA ATTAATACGA CTCACTATAG GGAGACCCAA GCTGGCTAGT 
 901 TAAGCTTGGT ACCGAGCTCG GATCCGCCCT GCTCCGCCGA CTGCTGCCGC CGCTGGTCAC 
 961 CCGTCACGAT GTCCGGCAAA GGCTCCGTGG TTCTGGCCTA CAGTGGGGGC CTGGACACCT 
1021 CCTGCATCCT CGTGTGGCTG AAGGAGCAAG GCTATGACGT CATTGCCTAC CTGGCCAACA 
1081 TCGGCCAGAA AGAAGACTTT GAGGAAGCCA GGAAGAAGGC GCTGAAGCTT GGGGCCAAAA 
1141 AGGTGTTCAT TGAGGACATC AGCAAGGAGT TTGTGGAGGA GTTCATCTGG CCGGCCATCC 
1201 AGTCCAGCGC ACTGTACGAG GACCGATACC TCCTGGGCAC CTCTCTCGCC AGGCCCTGCA 
1261 TCGCCCGCAA GCAGGTGGAG ATCGCCCAGC GAGAAGGAGC CAAGTATGTG TCTCACGGCG 
1321 CCACAGGAAA GGGGAACGAC CAGATCCGGT TTGAGCTCAC CTGCTACTCG CTGGCCCCAC 
1381 AGATCAAGGT CATCGCTCCC TGGAGGATGC CCGAGTTCTA TAACCGCTTC CAGGGCCGCA 
1441 ACGATCTGAT GGAGTATGCG AAGCAACATG GAATCCCCGT CCCAGTCACC CCCAAGAACC 
1501 CGTGGAGCAT GGACGAGAAC CTGATGCATA TCAGCTACGA GGCTGGAATC CTGGAGAACC 
1561 CCAAGAACCA AGCGCCTCCA GGCCTCTACA CAAAGACCCA GGACCCGGCC AAAGCCCCCA 
1621 ACAGCCCGGA CATGCTCGAG ATCGAGTTCA AGAAAGGGGT CCCCGTGAAG GTGACCAACG 
1681 TCGGGGATGG CACCACCCAC AGCACAGCGT TGGAGCTTTT CCTGTACCTG AATGAAGTCG 
1741 CTGGCAAGCA CGGCGTGGGC CGCATCGACA TCGTGGAAAA CCGCTTCATC GGGATGAAGT 
1801 CCCGGGGTAT CTACGAGACC CCAGCGGGGA CGATCCTTTA CCACGCTCAT TTAGACATCG 
1861 AGGCCTTCAC CATGGACCGG GAAGTGCGCA AAATCAAGCA AGGCCTCGGC TTGAAATTCG 
1921 CCGAGCTGGT CTACACGGGT TTCTGGCACA GCCCCGAGTG TGAATTTGTC CGCCACTGCA 
1981 TTGCCAAGTC CCAGGAGCGC GTGGAAGGGA AAGTGCAGGT GTCCGTCTTC AAGGGCCAGG 
2041 TGTACATCCT TGGCCGGGAG TCCCCACTGT CCCTCTACAA TGAGGAGCTC GTGAGCATGA 
2101 ACGTGCAGGG AGACTACGAG CCGGTTGATG CCACTGGTTT CATCAACATC AATTCCCTCA 
2161 GGCTGAAGGA ATATCATCGC CTCCAGAACA AGGTCACCGC CAAAAAGAAT TCTGCAGATA 
2221 TCCAGCACAG TGGCGGCCGC TCGAGTCTAG AGGGCCCGCG GTTCGAAGGT AAGCCTATCC 
2281 CTAACCCTCT CCTCGGTCTC GATTCTACGC GTACCGGTCA TCATCACCAT CACCATTGAG 
2341 TTTAAACCCG CTGATCAGCC TCGACTGTGC CTTCTAGTTG CCAGCCATCT GTTGTTTGCC 
2401 CCTCCCCCGT GCCTTCCTTG ACCCTGGAAG GTGCCACTCC CACTGTCCTT TCCTAATAAA 
2461 ATGAGGAAAT TGCATCGCAT TGTCTGAGTA GGTGTCATTC TATTCTGGGG GGTGGGGTGG 
2521 GGCAGGACAG CAAGGGGGAG GATTGGGAAG ACAATAGCAG GCATGCTGGG GATGCGGTGG 
2581 GCTCTATGGC TTCTGAGGCG GAAAGAACCA GCTGGGGCTC TAGGGGGTAT CCCCACGCGC 
2641 CCTGTAGCGG CGCATTAAGC GCGGCGGGTG TGGTGGTTAC GCGCAGCGTG ACCGCTACAC 
2701 TTGCCAGCGC CCTAGCGCCC GCTCCTTTCG CTTTCTTCCC TTCCTTTCTC GCCACGTTCG 
2761 CCGGCTTTCC CCGTCAAGCT CTAAATCGGG GGCTCCCTTT AGGGTTCCGA TTTAGTGCTT 
2821 TACGGCACCT CGACCCCAAA AAACTTGATT AGGGTGATGG TTCACGTAGT GGGCCATCGC 
2881 CCTGATAGAC GGTTTTTCGC CCTTTGACGT TGGAGTCCAC GTTCTTTAAT AGTGGACTCT 
2941 TGTTCCAAAC TGGAACAACA CTCAACCCTA TCTCGGTCTA TTCTTTTGAT TTATAAGGGA 
3001 TTTTGCCGAT TTCGGCCTAT TGGTTAAAAA ATGAGCTGAT TTAACAAAAA TTTAACGCGA 
3061 ATTAATTCTG TGGAATGTGT GTCAGTTAGG GTGTGGAAAG TCCCCAGGCT CCCCAGCAGG 
3121 CAGAAGTATG CAAAGCATGC ATCTCAATTA GTCAGCAACC AGGTGTGGAA AGTCCCCAGG 
3181 CTCCCCAGCA GGCAGAAGTA TGCAAAGCAT GCATCTCAAT TAGTCAGCAA CCATAGTCCC 
3241 GCCCCTAACT CCGCCCATCC CGCCCCTAAC TCCGCCCAGT TCCGCCCATT CTCCGCCCCA 
3301 TGGCTGACTA ATTTTTTTTA TTTATGCAGA GGCCGAGGCC GCCTCTGCCT CTGAGCTATT 
3361 CCAGAAGTAG TGAGGAGGCT TTTTTGGAGG CCTAGGCTTT TGCAAAAAGC TCCCGGGAGC 
3421 TTGTATATCC ATTTTCGGAT CTGATCAAGA GACAGGATGA GGATCGTTTC GCATGATTGA 
3481 ACAAGATGGA TTGCACGCAG GTTCTCCGGC CGCTTGGGTG GAGAGGCTAT TCGGCTATGA 
3541 CTGGGCACAA CAGACAATCG GCTGCTCTGA TGCCGCCGTG TTCCGGCTGT CAGCGCAGGG 
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Figure 3 (continued) 
3601 GCGCCCGGTT CTTTTTGTCA AGACCGACCT GTCCGGTGCC CTGAATGAAC TGCAGGACGA 
3661 GGCAGCGCGG CTATCGTGGC TGGCCACGAC GGGCGTTCCT TGCGCAGCTG TGCTCGACGT 
3721 TGTCACTGAA GCGGGAAGGG ACTGGCTGCT ATTGGGCGAA GTGCCGGGGC AGGATCTCCT 
3781 GTCATCTCAC CTTGCTCCTG CCGAGAAAGT ATCCATCATG GCTGATGCAA TGCGGCGGCT 
3841 GCATACGCTT GATCCGGCTA CCTGCCCATT CGACCACCAA GCGAAACATC GCATCGAGCG 
3901 AGCACGTACT CGGATGGAAG CCGGTCTTGT CGATCAGGAT GATCTGGACG AAGAGCATCA 
3961 GGGGCTCGCG CCAGCCGAAC TGTTCGCCAG GCTCAAGGCG CGCATGCCCG ACGGCGAGGA 
4021 TCTCGTCGTG ACCCATGGCG ATGCCTGCTT GCCGAATATC ATGGTGGAAA ATGGCCGCTT 
4081 TTCTGGATTC ATCGACTGTG GCCGGCTGGG TGTGGCGGAC CGCTATCAGG ACATAGCGTT 
4141 GGCTACCCGT GATATTGCTG AAGAGCTTGG CGGCGAATGG GCTGACCGCT TCCTCGTGCT 
4201 TTACGGTATC GCCGCTCCCG ATTCGCAGCG CATCGCCTTC TATCGCCTTC TTGACGAGTT 
4261 CTTCTGAGCG GGACTCTGGG GTTCGCGAAA TGACCGACCA AGCGACGCCC AACCTGCCAT 
4321 CACGAGATTT CGATTCCACC GCCGCCTTCT ATGAAAGGTT GGGCTTCGGA ATCGTTTTCC 
4381 GGGACGCCGG CTGGATGATC CTCCAGCGCG GGGATCTCAT GCTGGAGTTC TTCGCCCACC 
4441 CCAACTTGTT TATTGCAGCT TATAATGGTT ACAAATAAAG CAATAGCATC ACAAATTTCA 
4501 CAAATAAAGC ATTTTTTTCA CTGCATTCTA GTTGTGGTTT GTCCAAACTC ATCAATGTAT 
4561 CTTATCATGT CTGTATACCG TCGACCTCTA GCTAGAGCTT GGCGTAATCA TGGTCATAGC 
4621 TGTTTCCTGT GTGAAATTGT TATCCGCTCA CAATTCCACA CAACATACGA GCCGGAAGCA 
4681 TAAAGTGTAA AGCCTGGGGT GCCTAATGAG TGAGCTAACT CACATTAATT GCGTTGCGCT 
4741 CACTGCCCGC TTTCCAGTCG GGAAACCTGT CGTGCCAGCT GCATTAATGA ATCGGCCAAC 
4801 GCGCGGGGAG AGGCGGTTTG CGTATTGGGC GCTCTTCCGC TTCCTCGCTC ACTGACTCGC 
4861 TGCGCTCGGT CGTTCGGCTG CGGCGAGCGG TATCAGCTCA CTCAAAGGCG GTAATACGGT 
4921 TATCCACAGA ATCAGGGGAT AACGCAGGAA AGAACATGTG AGCAAAAGGC CAGCAAAAGG 
4981 CCAGGAACCG TAAAAAGGCC GCGTTGCTGG CGTTTTTCCA TAGGCTCCGC CCCCCTGACG 
5041 AGCATCACAA AAATCGACGC TCAAGTCAGA GGTGGCGAAA CCCGACAGGA CTATAAAGAT 
5101 ACCAGGCGTT TCCCCCTGGA AGCTCCCTCG TGCGCTCTCC TGTTCCGACC CTGCCGCTTA 
5161 CCGGATACCT GTCCGCCTTT CTCCCTTCGG GAAGCGTGGC GCTTTCTCAT AGCTCACGCT 
5221 GTAGGTATCT CAGTTCGGTG TAGGTCGTTC GCTCCAAGCT GGGCTGTGTG CACGAACCCC 
5281 CCGTTCAGCC CGACCGCTGC GCCTTATCCG GTAACTATCG TCTTGAGTCC AACCCGGTAA 
5341 GACACGACTT ATCGCCACTG GCAGCAGCCA CTGGTAACAG GATTAGCAGA GCGAGGTATG 
5401 TAGGCGGTGC TACAGAGTTC TTGAAGTGGT GGCCTAACTA CGGCTACACT AGAAGAACAG 
5461 TATTTGGTAT CTGCGCTCTG CTGAAGCCAG TTACCTTCGG AAAAAGAGTT GGTAGCTCTT 
5521 GATCCGGCAA ACAAACCACC GCTGGTAGCG GTGGTTTTTT TGTTTGCAAG CAGCAGATTA 
5581 CGCGCAGAAA AAAAGGATCT CAAGAAGATC CTTTGATCTT TTCTACGGGG TCTGACGCTC 
5641 AGTGGAACGA AAACTCACGT TAAGGGATTT TGGTCATGAG ATTATCAAAA AGGATCTTCA 
5701 CCTAGATCCT TTTAAATTAA AAATGAAGTT TTAAATCAAT CTAAAGTATA TATGAGTAAA 
5761 CTTGGTCTGA CAGTTACCAA TGCTTAATCA GTGAGGCACC TATCTCAGCG ATCTGTCTAT 
5821 TTCGTTCATC CATAGTTGCC TGACTCCCCG TCGTGTAGAT AACTACGATA CGGGAGGGCT 
5881 TACCATCTGG CCCCAGTGCT GCAATGATAC CGCGAGACCC ACGCTCACCG GCTCCAGATT 
5941 TATCAGCAAT AAACCAGCCA GCCGGAAGGG CCGAGCGCAG AAGTGGTCCT GCAACTTTAT 
6001 CCGCCTCCAT CCAGTCTATT AATTGTTGCC GGGAAGCTAG AGTAAGTAGT TCGCCAGTTA 
6061 ATAGTTTGCG CAACGTTGTT GCCATTGCTA CAGGCATCGT GGTGTCACGC TCGTCGTTTG 
6121 GTATGGCTTC ATTCAGCTCC GGTTCCCAAC GATCAAGGCG AGTTACATGA TCCCCCATGT 
6181 TGTGCAAAAA AGCGGTTAGC TCCTTCGGTC CTCCGATCGT TGTCAGAAGT AAGTTGGCCG 
6241 CAGTGTTATC ACTCATGGTT ATGGCAGCAC TGCATAATTC TCTTACTGTC ATGCCATCCG 
6301 TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC ATTCTGAGAA TAGTGTATGC 
6361 GGCGACCGAG TTGCTCTTGC CCGGCGTCAA TACGGGATAA TACCGCGCCA CATAGCAGAA 
6421 CTTTAAAAGT GCTCATCATT GGAAAACGTT CTTCGGGGCG AAAACTCTCA AGGATCTTAC 
6481 CGCTGTTGAG ATCCAGTTCG ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT 
6541 TTACTTTCAC CAGCGTTTCT GGGTGAGCAA AAACAGGAAG GCAAAATGCC GCAAAAAAGG 
6601 GAATAAGGGC GACACGGAAA TGTTGAATAC TCATACTCTT CCTTTTTCAA TATTATTGAA 
6661 GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT TGAATGTATT TAGAAAAATA 
     6721 AACAAATAGG GGTTCCGCGC ACATTTCCCC GAAAAGTGCC ACCTGACGTC 
 
 
AS Overexpression: Experimental plasmids (2 μg/well of a 6 well dish) were 
transiently transfected into BAEC using either Lipofectamine 2000 (Invitrogen) or 
Fugene (Roche) in serum free Opti-MEM I (Invitrogen) as indicated. After 4 h, media 
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was replaced with Dulbecco’s modified Eagle’s medium containing 10% serum and cells 
were cultured for 6 or 24 h. 
 
Western Blot: For western blots, equal amounts of protein (measured via BCA 
assay, Pierce) from clarified lysates were separated on polyacrylamide gels (BioRad), 
transferred onto polyvinylidene fluoride membranes (PVDF, Millipore) and blotted with 
indicated antibodies [AS, eNOS, phospho-eNOS (S1177) (BD Biosciences)]. Where 
appropriate, GAPDH (Novus Biologicals) was used as a loading control.  
 
RNA Isolation and Real Time PCR: Total RNA was isolated using Tri Reagent 
following the manufacturer’s instructions (Sigma). RNA was treated with DNase 
(Ambion DNA-free). Two μg of RNA was reverse transcribed using the High Capacity 
cDNA Reverse Transcription Kit per the manufacturer’s instructions (Applied 
Biosystems). A 20 μl reaction was prepared with 10 μl 2X reaction mix (10X RT buffer, 
dNTP’s, 10X RT random primers, 10 X MultiScribe Reverse Transcriptase, RNase 
inhibitor and nuclease-free water) and 10 μl RNA. The following thermal cycler 
parameters were utilized for the reverse transcription: 25°C for 10 min, 37°C for 120 
min, 85°C for 5 sec and hold at 4°C. Real time quantitative PCR was performed using the 
AS specific primers ASL200 and ASR352 utilizing a taq-man probe and with the eNOS 
specific primers eNOSL1075 and eNOSR1226 utilizing SYBR green as described 
previously by our laboratory [6, 7]. Results were normalized to GAPDH utilizing the 
primers GAPDHL351 and GAPDHR508. Primer sequences are below:  
 
 Table 2: Primers Used for Real Time PCR.  
ASL200 5’-TCA GCA AGG AGT TTG TGG AGG AGT-3’ 
ASR352 5’-ACA CAT ACT TGG CTC CTT CTC GCT-3’ 
eNOSL1075 5’-TAC ATG AGC ACG GAG ATT GG-3’ 
eNOSR1226 5’-AGC ACA GCC AGG TTG ATC TC-3’ 
GAPDHL351 5’-CAT GTT TGT GAT GGG CGT GAA CCA-3’ 
GAPDHR508 5’-TGA TGG CGT GGA CAG TGG TCA TAA-3’ 
 
Luciferase Vector Construction: For the luciferase vector, the 189 and 3075 base 
pair (bp) regions of the AS promoter were constructed as described previously [6, 8]. 
Briefly, luciferase reporter constructs were designed to include the AS promoter and 5’-
UTR up to the AUG start codon cloned upstream of the luciferase gene. The left primers 
ASL189 (5’-GCACTCGAGATCTGCAGGTGGCTGTGAA) and ASL-3075 (5’-
GTACCTCCACTGAAATTGAA) and were combined with ASRluc, (5’- 
ATAGAATGGCGCCGGGCGTTTCTTTATGTTTTTGGCGTCTTCCATCGTGACGT
GACCAGCGGC) to amplify the AS promoter with an XhoI site on the 5’ end and an 
NcoI site on the 3’ end which were used to clone into the vector pGL3Basic (Promega). 
This strategy took advantage of an NcoI site within the luciferase gene, close to the start 
codon, to allow for the AS 5’-UTR to be cloned adjacent to the start codon. 
 
Luciferase Assays:  BAEC were cultured as described above and plated in a 24 
well plate prior to transfection. Experimental plasmids (200 ng each) and renilla control 
plasmid pRL-TK (50 ng) were transiently transfected into BAEC using Transit-LT1 
(Mirus) in serum free media. After 4 hours liposomes were removed and incubation 
continued for 24 hours. Cells were treated with insulin (10 nM, 2 hours). Cells were lysed 
 69
 70
using passive lysis buffer (Promega). Ten μl lysate was assayed for luciferase and renilla 
activity using a Dual-Luciferase Reporter Assay System (Promega) according to the 
manufacturer’s instructions. Luciferase and renilla activity were measured as relative 
light units (RLUs) using a luminometer (Turner Designs). All results were normalized to 
renilla expression. 
 
AS Promoter Analysis: The AS promoter elements that are identified in the 
discussion were found by doing a promoter search with 2 KB of the AS promoter. The 
promoter sequence for human AS mRNA with accession number NM_000050 was found 
utilizing the Transcriptional Regulatory Element Database (TRED) 
(http://rulai.cshl.edu/cgi-bin/TRED/tred.cgi?process=home). The promoter sequence was 
then analyzed utilizing the Transcription Element Search System (TESS) database 
(http://www.cbil.upenn.edu/cgi-bin/tess/tess). 
 
Nitric Oxide Assays: Nitric oxide released into tissue culture medium was 
measured utilizing the fluorescent probe 2,3-diaminonaphthalene (DAN) as described 
previously [9]. BAEC’s were serum starved overnight prior to all treatments except in the 
A23187 experiments. Briefly, at the indicated time points after treatment with insulin, 
A23187 (calcium ionophore), ionomycin (calcium ionophore), bradykinin or VEGF as 
indicated, aliquots of tissue culture medium were collected. Then, freshly prepared DAN 
reagent in 0.62 M HCl was added to culture supernatant, mixed immediately and 
incubated for 15 minutes. The reaction was stopped with a final concentration of 2.8 M 
NaOH and the samples were read on a BMG Fluostar Galaxy Spectrofluorometer 
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exciting at 360 nm and emitting at 405 nm. Total protein was measured via the BCA 
assay, and data are presented as pmol nitrite produced per mg protein or as fold change 
over control.  
 
To measure intracellular NO production in fixed cells, the NO-specific 
fluorescent dye, 4,5-diaminofluorescein diacetate (DAF-2 DA), was utilized as described 
by Montagnani et al [10]. Briefly, BAEC’s grown to confluence were loaded with DAF-2 
DA (final concentration 1 µM, 20 min, 37 C) and then rinsed three times, kept in the 
dark, and maintained at 37 C. Cells were treated as indicated. Fluorescence intensity was 
imaged utilizing a Nikon Eclipse E1000 Fluorescence Microscope.  
 
Statistical Analyses: Statistical analysis was conducted with a Student’s T-test of 
at least 3 independent experiments. Data is presented as the average +/- the standard error 
of the mean.  
 
Results 
 
AS Overexpression Enhances Endothelial NO Production: We hypothesized that 
since AS is an important mediator of the ability of eNOS to produce NO, its 
overexpression would enhance basal NO production. As seen in Figure 4A,  transient 
overexpression of AS utilizing constant amounts of AS plasmid with increasing amounts 
of transfection reagent led to the generation of BAEC’s that expressed increasing 
amounts of AS. This led to enhanced production of NO that reached a plateau at the mid-
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range of AS overexpression, likely due to the inability of eNOS to process the excess 
substrate without any additional stimulation of its activity. In a similar experiment, the 
empty vector was also transfected with constant plasmid DNA and increasing amounts of 
transfection reagent (Figure 4B). The results confirmed that it is the overexpression of AS 
per se that leads to the increase in NO production. These experiments were carried out 
after 24 hours of AS overexpression and significant cell loss was visually noted. To 
determine whether the cell loss was due to some condition associated with 
overexpression or to the enhanced NO production, the experiment was repeated but the 
NO measurement was conducted after only 6 hours of AS overexpression since no 
significant cell loss was noted at that time point. As shown in Figure 4C, NO production 
was enhanced at the 6 hour time point and this corresponded with a small but detectable 
overexpression of AS. This suggested that the cell loss was caused by the AS-mediated 
increase in NO production. Figure 4D demonstrates that AS overexpression does not 
have a consistent effect eNOS expression which suggests the effects on NO production 
are directly associated with the overexpression of AS. 
 
 
 
 
 
 
 
 
 
Figure 4:  AS Overexpression Enhances Nitric Oxide Production. (A) BAEC were serum 
starved overnight then transfected with 2 μg AS plasmid DNA with increasing amounts of 
Fugene transfection reagent (4, 5, 6, and 8 μl which correspond to AS0, AS1, AS2, AS3 and 
AS4, respectively). Graph demonstrates a nitric oxide assay with data presented as fold NO 
produced compared to control. Blot demonstrates expression levels of AS that correspond to 
the NO values. * p < 0.007 (n = 3). (B) Nitric oxide assay of BAEC overexpressing AS or an 
empty vector conducted as in A, except Fugene amounts were 3, 4, 5, 6, 7 and 8 µl and this 
time the empty vector was transfected with all conditions. (F3:D2 = 3 μl Fugene and 2 μg 
plasmid DNA, etc.). Data is presented as pmol nitrite/mg protein (n = 1). (C) NO assay in cells 
transiently transfected with the AS expression vector for 6 hours. This time, Lipofectamine 
2000 was the transfection reagent used. Graph demonstrates a nitric oxide assay with data 
presented as fold NO produced as compared to control. Blot demonstrates expression levels of 
AS that correspond to the NO values (n = 2). (D) Representative blot demonstrating the lack of 
effect of AS expression on eNOS expression (n = 2). 
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D Overexpressed AS ?
 
Endogenous AS ? 
 
eNOS ? 
 
 
AS Expression and Function are Enhanced by Insulin: Insulin is known to 
enhance NO production and is a key mediator of vascular health. Part of its 
atheroprotective properties stem from direct effects on eNOS expression. We 
hypothesized that AS expression would also be enhanced by insulin. To test this, time 
course experiments were carried out and it was determined that insulin enhances AS 
expression most consistently after 2-4 hours of treatment (Figure 5A). We then conducted 
dose response experiments to test the impact of 1-1000 nM insulin (2 hours) on AS and 
eNOS expression. Insulin enhanced AS and eNOS expression coordinately. The highest 
expression was seen at the 100 nM dose, but 10 nM still led to a significant increase in 
expression (Figure 5 B & C). Additional experiments were conducted with the 2 hour 
time and 10 nM dose and the effects of insulin on AS expression were confirmed (Figure 
5 D & E). 
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Figure 5: Insulin Increases AS and eNOS Protein Expression. (A) BAEC were serum starved 
ON and cells were treated with insulin (100 nM) for the indicated times (n = 3). (B) BAEC were 
serum starved overnight then treated with insulin (1-1000 nM) for 2 hours. Representative western 
blot demonstrating expression of AS and eNOS. GAPDH was used as a loading control. Data is 
represented as fold change over control. (C). Densitometry of 2 independent experiments 
normalized to GAPDH. (D) Representative blot demonstrating expression of AS and eNOS in 
response to 10 nM insulin treatment for 2 hours. (E) Densitometry of C normalized to GAPDH 
demonstrating fold change over control (n = 5). * p < 0.004 
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To determine whether the increase in AS protein expression was related to an 
increase in mRNA, real time PCR experiments were carried out. The data demonstrated 
that insulin also increases AS mRNA (Figure 6A). A similar trend was noted for insulin 
effects on eNOS mRNA. (Figure 6B).  
 
Figure 6: Insulin Increases AS and eNOS mRNA Expression. BAEC were serum starved 
overnight then treated with insulin (10 nM) for 2 hours. (A) Real time PCR results demonstrating 
AS in control (gray bar) versus insulin treated cells (black bar). * p < 0.02 (n = 4). (B) Real time 
PCR demonstrating increase in eNOS expression with insulin treatment. (n = 2)  
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To determine whether insulin mediates the expression of AS by enhancing 
activity at specific AS promoter regions, we tested the effect of insulin on a proximal 
promoter construct (189 bp) versus a full length promoter construct (3075 bp). Luciferase 
assay data suggested that there may be distal AS promoter elements regulated by insulin 
(Figure 7). 
 
Figure 7: Insulin Enhances AS Promoter Activity at a Distal Element. BAEC were 
ser m starved overnight then treated with insulin (10 nM) for 2 hours. Luciferase assay 
res lts comparing 189 versus 3075 base pair promoter constructs. Gray bars represent 
vehicle treated cells and black bars represent insulin treated cells. Data is presented as 
relative luciferase units normalized to renilla expression. (n = 1) 
 
u 
u
 
 
 
Luciferase Assay
0
1
2
3
4
5
6
189 3075
RL
U
Control
Insulin
 
 
 
 
 
 
 
 
Insulin is known to enhance NO production. To assess whether insulin was 
leading to an increase in NO production in our system and to correlate increased AS 
expression to a functional enhancement of the citrulline-NO cycle, we utilized two 
methods. First, we treated the cells with insulin, bradykinin, A23187 (calcium ionophore) 
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or a combination of treatments and measured NO released into the medium. Although 
this assay was not sensitive enough to reliably measure the effect of insulin alone, we 
were able to detect an increase with bradykinin that was enhanced by insulin (Figure 8A). 
Insulin also demonstrated the ability to enhance NO production above what the calcium 
ionophore A23187 can do alone (Figure 8B). We then utilized a probe that can measure 
intracellular NO levels in fixed cells. With this assay, we did see an increase in NO 
production with insulin treatment alone as evidenced by a visually determined increase in 
green fluorescence (Figure 8C). As expected, this increase was less than what was seen 
with the calcium ionophore ionomycin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Insulin Enhances Stimulated and Basal NO Production. (A) BAEC were 
serum starved overnight then treated with insulin (100 nM), bradykinin (10 µM) or both 
for 4 hours. NO assay was conducted by measuring nitrite released into the medium 
before and after treatment (n = 3). (B) BAEC were treated with insulin (100 nM), 
A23187 (1 μM) or both for 4 hours. NO assay was conducted as in A (n = 1). (C) BAEC 
were serum starved overnight then loaded with 1.0 μM DAF2-DA for 20 minutes. Cells 
were then treated with insulin (100 nM) or ionomycin (2 μM) for 10 minutes. Cells were 
fixed and imaged utilizing fluorescent microscopy (ex 480 nM; em 510 nM). 
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VEGF Regulates AS Expression and Enhances Endothelial NO Production: 
VEGF is an important mediator of endothelial function. We tested the hypothesis that 
part of the mechanism of VEGF-mediated vascular protection is associated with an 
increase in AS expression. First, we measured the time dependency of NO production in 
response to VEGF. As seen in Figure 9A, after 10 minutes of VEGF treatment, there was 
a statistically significant increase in NO production over untreated cells that continued to 
increase up to our final time point of 2 hours. Then, western blot analyses were 
conducted. The results demonstrated that VEGF increases AS and eNOS expression 
within 2 hours of treatment (Figure 9B).  Importantly, as demonstrated and discussed 
further in Chapter Three, AS activity is required for maximum effects of VEGF on NO 
production (Figure 16, Page 122). 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 9: VEGF Increases Endothelial Nitric Oxide Production and Upregulates AS 
and eNOS Expression. (A) Nitric oxide assay measuring NO release into tissue culture 
medium (pmol nitrite/mg protein) by BAEC’s treated with VEGF (100 ng/ml) from 5 
minutes to 2 hours. Diamonds represent control samples and squares represent VEGF treated 
samples. * p < 0.02; ** p < 0.0003 (n = 3). (B) Representative western blot of BAEC’s 
treated with VEGF (100 ng/ml) for 2 hours. Blot demonstrates expression of AS and eNOS. 
GAPDH was used as a loading control. (n = 2 for AS and n = 1 for eNOS) 
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Ceramide Diminishes AS and eNOS Expression and Suppresses eNOS Activation: 
Chronic elevations in ceramide impair vascular function and diminish eNOS expression. 
Often times, ceramide mediates the pathogenic effects of TNFα on insulin signaling and 
other pathways. To test whether chronic ceramide elevations impact AS and eNOS 
expression, western blot analyses were conducted. When BAEC were treated with 
ceramide (10 µM) for 16 or 24 hours, AS and eNOS expression was diminished in a time 
dependent manner (Figure 10A). In addition, the increase in eNOS phosphorylation seen 
with insulin treatment was diminished when BAEC were pre-treated with ceramide 
(Figure 10B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Ceramide Diminishes AS and eNOS Expression and Suppresses eNOS 
Signaling.  (A) Representative western blot of BAEC’s treated with ceramide (10 μM) for 
indicated times after overnight serum starvation. Blot demonstrates expression of AS and 
eNOS. GAPDH was used as a loading control (n = 1). (B) Representative blot of BAEC 
that were serum starved for 2.5 hours prior to pre-treatment with ceramide (cer; 10 μM) 
for 5 minutes followed by insulin treatment for 30 minutes (ins; 100 nM). Blot depicts 
eNOS phosphorylation (peNOS S1177) and total eNOS. GAPDH was used as a loading 
control (n = 1).   
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Discussion 
 
 In this Chapter, we made several important observations. First, we demonstrated 
that transient overexpression of AS leads to enhanced NO production. This increase was 
above the basal contribution of the endogenous citrulline-NO cycle. These findings are 
supported by the work of Xie et. al [11] which demonstrates that overexpression of AS in 
vascular smooth muscle cells (VSMC) increases NO production when cells are 
stimulated with lipopolysaccharide (LPS) and interferon gamma (IFNγ). Under those 
conditions, the effects they noted were related to inducible nitric oxide synthase (iNOS) 
and not eNOS. Even with stimulation, they saw about a 3-4 fold increase in NO 
production in stably transfected VSMC. In our case, we were monitoring basal effects 
and noted ~2 fold increase in NO production when AS was transiently overexpressed 
compared to untransfected or empty vector transfected controls. Our results implied that 
the effects we saw involved the AS-eNOS axis and not the AS-iNOS axis since a 
stimulant was not provided to induce iNOS. The fact that we saw the effects by 6 hours 
also suggested that iNOS is not involved since such as short time period of time without 
any stimulation would preclude iNOS induction. Further, the expression of eNOS was not 
consistently affected by AS overexpression nor did any small variations in eNOS 
expression correlate with the increases in NO production. This suggests the increase in 
NO production was a direct result of AS overexpression. 
 
Furthermore, our studies support our previous work that demonstrates a 
significant loss of NO production and endothelial cell viability when AS is knocked 
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down with siRNA [12]. In those studies, reducing AS expression was directly linked to 
reduced expression of Bcl-2 and increased caspase activity. Thus, the cell loss was 
attributed to apoptosis. Further, it was demonstrated that apoptosis could be rescued with 
an NO donor. Therefore, apoptosis was mediated by the diminished production of NO as 
a direct consequence of decreased AS expression and activity. The work presented here 
alludes to the converse scenario. An increase in AS expression led to a significant 
increase in NO production, despite saturating levels of NO in the medium and without a 
change in eNOS activity or expression. In addition, the increase in NO production caused 
a significant cell loss, likely due to apoptosis. The fact that alterations of AS expression 
by overexpression or via treatment with various stimulants was associated with enhanced 
nitric oxide production also supports the body of evidence that demonstrates that AS is 
rate limiting for NO production. In addition, it is known that the recycling of arginine 
from citrulline is the preferred source of substrate for eNOS-mediated NO production, 
despite available transport systems and excess intracellular arginine levels [13, 14]. 
Therefore, our work also supports the mounting evidence that in endothelial cells, the 
citrulline-NO cycle is a tightly coupled system that generates a dedicated source of 
arginine for eNOS-mediated NO production [15, 16]. 
 
A second set of findings that are collectively important to note is that physiologic 
(insulin, VEGF) or pathogenic (ceramide) biological molecules affect AS expression 
coordinately with eNOS. This coordinate regulation is essential for the appropriate level 
of NO to be produced. Since AS is rate limiting for the production of NO by eNOS [11, 
13, 14, 17], it is logical that its expression and function must be controlled in a manner 
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consistent with the substrate needs of eNOS. A possible exception to this would be in 
cases where NO levels have gone beyond physiological concentrations, which might lead 
to a decrease in AS function in order for NO production to be reduced. Although 
ultimately, this would lead to a coordinate downregulation of eNOS function, the initial 
response might be one of discoordinate regulation.  
 
Several important biological treatments were explored in this Chapter and each 
one has important implications. We noted modest, yet significant increases in AS and 
eNOS expression in response to insulin. This work is supported by the work of 
Oyadomari et al. [18] who demonstrated that in rats with type 1 diabetes due to 
streptozotocin (STZ) treatment, AS and eNOS expression in whole aorta is enhanced 
initially and then decreases with longer duration of diabetes. The regulation is coordinate, 
much like what we see in cell culture models, and suggests the initial increase is a 
compensatory response while the end result is dysregulation of the citrulline-NO cycle. 
There is some controversy related to whether eNOS expression is diminished in animal 
models of diabetes or vascular disease [19]. This is likely due to differences in the animal 
models themselves and the treatment protocols utilized. In addition, mechanisms other 
than expression levels may underlie some forms of vascular disorders. Despite the 
controversy, it is clear that eNOS dysfunction is a hallmark of vascular disorders. Our 
work certainly demonstrates that AS is also a very important player and more research is 
needed to delineate the role of AS in diabetic animals and humans.  
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The role of insulin in regulating AS expression may be due to the direct effects of 
insulin in regulating the AS promoter. Although the results presented regarding enhanced 
AS promoter activity at a distal site in response to insulin are preliminary, there are 
several AS promoter elements that are known to be insulin responsive such as SP-1, USF 
and HIF1α [20-22]. Therefore, it is possible that there are several regions in the AS 
promoter that might regulate the insulin-mediated upregulation of AS mRNA and protein 
seen in our studies. In addition, we saw similar increases in eNOS expression and it has 
already been demonstrated that eNOS has at least two insulin responsive elements: SP-1 
and AP-1 [23].  
 
Our work suggests that the functional consequence of insulin up-regulation of AS 
expression is an increase in NO production. The increases we noted with insulin were 
generally modest and were most prominent when other stimulants, such as bradykinin, 
were used. This leads to our hypothesis that insulin is not necessarily a “stimulant” for 
NO production. Rather, we believe that the function of normal insulin signaling is to 
allow for NO stimulating pathways to be basally activated and ready for additional 
stimulation by vasodilators. Without insulin signaling, the optimal function of stimulants 
would be blunted. One key deficiency in our understanding of the upregulation of AS 
expression by insulin and the concomitant increase in NO production is whether these 
effects are direct or simply due to known effects on eNOS. To fill in this gap, future work 
is needed to determine whether insulin increases AS enzymatic activity. 
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Despite some of the gaps in our understanding of how insulin directly affects AS 
activity, our work with VEGF, another important mediator of vascular health with direct 
effects on the endothelium [24], supports the hypothesis that AS plays a direct role. Like 
insulin, we found that VEGF leads to a coordinate upregulation of AS and eNOS protein 
expression with a concomitant and significant increase in NO production. Our first hint 
that AS activity is directly involved comes from experiments that demonstrate that the 
maximal increase in VEGF-mediated NO production is blunted by a specific AS 
inhibitor. This data is presented and further discussed in Chapter Three, Figure 16, Page 
122. Whether the effect of VEGF on AS protein expression is due to an increase on 
mRNA expression or stability is yet to be determined. However, there is some evidence 
in the literature that VEGF regulates the expression of some genes such as tissue factor 
and metallothionein via promoter activation [25]. It is possible there is a similar 
mechanism in place for AS. Another important finding from this work is the novel link 
between AS and angiogenic pathways. Although the function of AS in arginine 
regeneration has been associated with tumor survival and angiogenesis [26], a link 
between AS activity per se and angiogenic factors has not previously been described. 
Additionally, the AS-VEGF axis has not been defined in endothelium. 
 
Our finding that chronic ceramide treatment diminishes AS and eNOS expression 
demonstrated that pathogenic environments lead to a dysfunction of the citrulline-NO 
cycle as a whole and not just eNOS. The effects of ceramide on AS expression have not 
been studied and most studies related to eNOS have determined that ceramide causes 
inhibition of eNOS activation, not expression. In fact, the only study that assessed eNOS 
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expression in response to ceramide in human endothelial cells found that although NO 
production was diminished due to elevations in ROS, eNOS expression was enhanced in 
an ineffective compensatory mechanism when treated for 10 or 16 hours [27]. In our 
study, both AS and eNOS expression were diminished in a time dependent manner at 16 
or 24 hours when using the same dose used by the previous study [27]. The discordance 
of results may be due to the cell type used or the differences in ceramide preparations 
from different manufacturers. More likely, the issue is related to the fact that ceramide 
can have both beneficial and inhibitory effects [28] and this might explain the disparity. 
Overall, this implies that multiple mechanisms are disrupted in disease states that 
ultimately lead to the inability of the endothelium to produce adequate amounts of NO 
with downstream consequences such as atherosclerosis or myocardial infarctions.  
 
The pathways we have studied related to the regulation of AS expression: TNFα, 
PPARγ agonists, insulin, VEGF and ceramide are relevant not just individually but also 
due to the fact that there is a great deal of cross talk between these pathways. One 
example is that ceramide mediates the pathogenic effects of chronic elevations of TNFα 
by inhibiting insulin actions [29]. Also, one mechanism by which PPAR agonists 
improve insulin sensitivity and improve NO function is by reducing the damaging effects 
of TNFα [30]. VEGF signaling, NO production and angiogenesis are all impaired in 
insulin resistant conditions [31-34]. These associations and the pivotal role of AS 
function in all these pathways improve our global understanding of vascular biology. 
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Another important observation about AS expression is that in tissues where its 
function is in the urea cycle, such as liver, expression is very high [35]. On the other 
hand, in tissues where AS functions with iNOS to produce NO (such as vascular smooth 
muscle and glial cells), its expression tends to be very low or even undetectable basally 
but is highly inducible by cytokines leading to iNOS induction and high output NO 
production [36-38]. Our findings suggest that in the endothelium, AS expression is 
basally repressed and this repression is removed in response to stimuli to increase NO 
output. This proposed de-repression mechanism leads to a modest change in AS 
expression in response to the multiple mechanisms we have explored up to this point (~ 
2-3 fold). It turns out that eNOS transcriptional regulation in general also changes on the 
order of about 2-3 fold [39]. Although this might seem insignificant, the modest increases 
in NO associated with this change in expression can lead to pronounced changes in 
vascular tone. Since in the endothelium, eNOS functions to produce constant yet 
relatively low levels of NO, our model of modest changes in AS expression fits well with 
this functional paradigm. 
 
 Thus far, we have found an important pattern of coordinate regulation of AS and 
eNOS expression. It is important to note in this discussion that the studies led by Laura 
Pendleton in our lab have uncovered a unique translational regulatory mechanism that 
involves the expression of different lengths of AS message due to increasing lengths of 
the 5’ UTR [40]. The longer forms of message are endothelium specific and encode for a 
unique, small protein called Argininosuccinate Synthase Regulatory Protein (ARP). This 
protein regulates AS translation in trans since it suppresses the translation of the short 
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form of message that actually encodes for full length AS [7].  So far, this mechanism is 
unique to AS and seems to allow regulation of tissue-specific AS function. Thus, this is 
one example of regulation of AS that may be completely distinct from eNOS regulation. 
On the other hand, this may turn out to be a novel global paradigm that allows for the 
vast complexity of human biology despite a relatively small genome.  
 
 Overall, the studies presented in this Chapter further define the central role of AS 
for NO production and vascular health by uncovering several mechanisms that regulate 
its expression and lead to concomitant changes in endothelial NO production. These 
findings are significant since vascular disorders are sometimes characterized by reduced 
levels of eNOS expression [41-45]. Thus, we predict an important role of AS expression 
in health and disease.  
 
References 
 
[1] D. Gospodarowicz, J. Moran, D. Braun, and C. Birdwell, Clonal growth of bovine 
vascular endothelial cells: fibroblast growth factor as a survival agent, Proc Natl Acad Sci 
U S A 73 (1976) 4120-4124. 
 
[2] H. G. Bock, T. S. Su, W. E. O'Brien, and A. L. Beaudet, Sequence for human 
argininosuccinate synthetase cDNA, Nucleic Acids Res 11 (1983) 6505-6512. 
 
[3] J. A. Dennis, P. J. Healy, A. L. Beaudet, and W. E. O'Brien, Molecular definition of 
bovine argininosuccinate synthetase deficiency, Proc Natl Acad Sci U S A 86 (1989) 
7947-7951. 
 
[4] L. C. Surh, A. L. Beaudet, and W. E. O'Brien, Molecular characterization of the 
murine argininosuccinate synthetase locus, Gene 99 (1991) 181-189. 
 
 94
[5] L. C. Surh, S. M. Morris, W. E. O'Brien, and A. L. Beaudet, Nucleotide sequence of 
the cDNA encoding the rat argininosuccinate synthetase, Nucleic Acids Res 16 (1988) 
9352. 
 
 
[6] B. L. Goodwin, L. C. Pendleton, M. M. Levy, L. P. Solomonson, and D. C. Eichler, 
Tumor necrosis factor-alpha reduces argininosuccinate synthase expression and nitric 
oxide production in aortic endothelial cells, Am J Physiol Heart Circ Physiol 293 (2007) 
H1115-1121. 
 
[7] L. C. Pendleton, B. L. Goodwin, L. P. Solomonson, and D. C. Eichler, Regulation of 
endothelial argininosuccinate synthase expression and NO production by an upstream 
open reading frame, J Biol Chem 280 (2005) 24252-24260. 
 
[8] B. L. Goodwin, K. D. Corbin, L. C. Pendleton, M. M. Levy, L. P. Solomonson, and 
D. C. Eichler, Troglitazone up-regulates vascular endothelial argininosuccinate synthase, 
Biochem Biophys Res Commun 370 (2008) 254-258. 
 
[9] T. P. Misko, R. J. Schilling, D. Salvemini, W. M. Moore, and M. G. Currie, A 
fluorometric assay for the measurement of nitrite in biological samples, Anal Biochem 
214 (1993) 11-16. 
 
[10] M. Montagnani, H. Chen, V. A. Barr, and M. J. Quon, Insulin-stimulated activation 
of eNOS is independent of Ca2+ but requires phosphorylation by Akt at Ser(1179), J Biol 
Chem 276 (2001) 30392-30398. 
 
[11] L. Xie, and S. S. Gross, Argininosuccinate synthetase overexpression in vascular 
smooth muscle cells potentiates immunostimulant-induced NO production, J Biol Chem 
272 (1997) 16624-16630. 
 
[12] B. L. Goodwin, L. P. Solomonson, and D. C. Eichler, Argininosuccinate synthase 
expression is required to maintain nitric oxide production and cell viability in aortic 
endothelial cells, J Biol Chem 279 (2004) 18353-18360. 
 
[13] L. Xie, Y. Hattori, N. Tume, and S. S. Gross, The preferred source of arginine for 
high-output nitric oxide synthesis in blood vessels, Semin Perinatol 24 (2000) 42-45. 
 
[14] L. J. Shen, K. Beloussow, and W. C. Shen, Accessibility of endothelial and inducible 
nitric oxide synthase to the intracellular citrulline-arginine regeneration pathway, 
Biochem Pharmacol 69 (2005) 97-104. 
 
[15] B. R. Flam, D. C. Eichler, and L. P. Solomonson, Endothelial nitric oxide production 
is tightly coupled to the citrulline-NO cycle, Nitric Oxide 17 (2007) 115-121. 
 
 95
[16] W. C. Sessa, M. Hecker, J. A. Mitchell, and J. R. Vane, The metabolism of L-
arginine and its significance for the biosynthesis of endothelium-derived relaxing factor: 
L-glutamine inhibits the generation of L-arginine by cultured endothelial cells, Proc Natl 
Acad Sci USA 87 (1990) 8607-8611. 
 
[17] G. Hao, L. Xie, and S. S. Gross, Argininosuccinate synthetase is reversibly 
inactivated by S-nitrosylation in vitro and in vivo, J Biol Chem 279 (2004) 36192-36200. 
 
[18] S. Oyadomari, T. Gotoh, K. Aoyagi, E. Araki, M. Shichiri, and M. Mori, 
Coinduction of endothelial nitric oxide synthase and arginine recycling enzymes in aorta 
of diabetic rats, Nitric Oxide 5 (2001) 252-260. 
 
[19] D. Fulton, M. B. Harris, B. E. Kemp, R. C. Venema, M. B. Marrero, and D. W. 
Stepp, Insulin resistance does not diminish eNOS expression, phosphorylation, or binding 
to HSP-90, Am J Physiol Heart Circ Physiol 287 (2004) H2384-2393. 
 
[20] T. Kietzmann, A. Samoylenko, U. Roth, and K. Jungermann, Hypoxia-inducible 
factor-1 and hypoxia response elements mediate the induction of plasminogen activator 
inhibitor-1 gene expression by insulin in primary rat hepatocytes, Blood 101 (2003) 907-
914. 
 
[21] L. M. Cagen, X. Deng, H. G. Wilcox, E. A. Park, R. Raghow, and M. B. Elam, 
Insulin activates the rat sterol-regulatory-element-binding protein 1c (SREBP-1c) 
promoter through the combinatorial actions of SREBP, LXR, Sp-1 and NF-Y cis-acting 
elements, Biochem J 385 (2005) 207-216. 
 
[22] M. J. Griffin, and H. S. Sul, Insulin regulation of fatty acid synthase gene 
transcription: roles of USF and SREBP-1c, IUBMB Life 56 (2004) 595-600. 
 
[23] B. Fisslthaler, T. Benzing, R. Busse, and I. Fleming, Insulin enhances the expression 
of the endothelial nitric oxide synthase in native endothelial cells: a dual role for Akt and 
AP-1, Nitric Oxide 8 (2003) 253-261. 
 
[24] S. Kliche, and J. Waltenberger, VEGF receptor signaling and endothelial function, 
IUBMB Life 52 (2001) 61-66. 
 
[25] B. Joshi, D. Ordonez-Ercan, P. Dasgupta, and S. Chellappan, Induction of human 
metallothionein 1G promoter by VEGF and heavy metals: differential involvement of 
E2F and metal transcription factors, Oncogene 24 (2005) 2204-2217. 
 
[26] B. J. Dillon, V. G. Prieto, S. A. Curley, C. M. Ensor, F. W. Holtsberg, J. S. 
Bomalaski, and M. A. Clark, Incidence and distribution of argininosuccinate synthetase 
deficiency in human cancers: a method for identifying cancers sensitive to arginine 
deprivation, Cancer 100 (2004) 826-833. 
 
 96
[27] H. Li, P. Junk, A. Huwiler, C. Burkhardt, T. Wallerath, J. Pfeilschifter, and U. 
Forstermann, Dual effect of ceramide on human endothelial cells: induction of oxidative 
stress and transcriptional upregulation of endothelial nitric oxide synthase, Circulation 
106 (2002) 2250-2256. 
 
[28] P. P. Ruvolo, Intracellular signal transduction pathways activated by ceramide and 
its metabolites, Pharmacol Res 47 (2003) 383-392. 
 
[29] T. Teruel, R. Hernandez, and M. Lorenzo, Ceramide mediates insulin resistance by 
tumor necrosis factor-alpha in brown adipocytes by maintaining Akt in an inactive 
dephosphorylated state, Diabetes 50 (2001) 2563-2571. 
 
[30] S. S. Solomon, L. S. Usdan, and M. R. Palazzolo, Mechanisms involved in tumor 
necrosis factor-alpha induction of insulin resistance and its reversal by 
thiazolidinedione(s), Am J Med Sci 322 (2001) 75-78. 
 
[31] R. D. Feldman, and G. S. Bierbrier, Insulin-mediated vasodilation: impairment with 
increased blood pressure and body mass, Lancet 342 (1993) 707-709. 
 
[32] M. A. Vincent, M. Montagnani, and M. J. Quon, Molecular and physiologic actions 
of insulin related to production of nitric oxide in vascular endothelium, Curr Diab Rep 3 
(2003) 279-288. 
 
[33] G. Doronzo, I. Russo, L. Mattiello, G. Anfossi, A. Bosia, and M. Trovati, Insulin 
activates vascular endothelial growth factor in vascular smooth muscle cells: influence of 
nitric oxide and of insulin resistance, Eur J Clin Invest 34 (2004) 664-673. 
 
[34] F. Bourgoin, H. Bachelard, M. Badeau, S. Melancon, M. Pitre, R. Lariviere, and A. 
Nadeau, Endothelial and vascular dysfunctions and insulin resistance in rats fed a high-
fat, high-sucrose diet, Am J Physiol Heart Circ Physiol 295 (2008) H1044-H1055. 
 
[35] A. Husson, C. Brasse-Lagnel, A. Fairand, S. Renouf, and A. Lavoinne, 
Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle, Eur J 
Biochem 270 (2003) 1887-1899. 
 
[36] Y. Hattori, E. B. Campbell, and S. S. Gross, Argininosuccinate synthetase mRNA 
and activity are induced by immunostimulants in vascular smooth muscle. Role in the 
regeneration or arginine for nitric oxide synthesis, J Biol Chem 269 (1994) 9405-9408. 
 
[37] A. K. Nussler, T. R. Billiar, Z. Z. Liu, and S. M. Morris, Jr., Coinduction of nitric 
oxide synthase and argininosuccinate synthetase in a murine macrophage cell line. 
Implications for regulation of nitric oxide production, Journal of Biological Chemistry 
269 (1994) 1257-1261. 
 
 97
[38] A. Schmidlin, and H. Wiesinger, Argininosuccinate synthetase: localization in 
astrocytes and role in the production of glial nitric oxide, Glia 24 (1998) 428-436. 
 
[39] C. D. Searles, Transcriptional and posttranscriptional regulation of endothelial nitric 
oxide synthase expression, Am J Physiol Cell Physiol 291 (2006) C803-816. 
 
[40] L. C. Pendleton, B. L. Goodwin, B. R. Flam, L. P. Solomonson, and D. C. Eichler, 
Endothelial argininosuccinate synthase mRNA 5'-untranslated region diversity. 
Infrastructure for tissue-specific expression, J Biol Chem 277 (2002) 25363-25369. 
 
[41] N. Makino, T. Maeda, M. Sugano, S. Satoh, R. Watanabe, and N. Abe, High serum 
TNF-alpha level in Type 2 diabetic patients with microangiopathy is associated with 
eNOS down-regulation and apoptosis in endothelial cells, J Diabetes Complications 19 
(2005) 347-355. 
 
[42] L. Agnoletti, S. Curello, T. Bachetti, F. Malacarne, G. Gaia, L. Comini, M. 
Volterrani, P. Bonetti, G. Parrinello, M. Cadei, P. G. Grigolato, and R. Ferrari, Serum 
from patients with severe heart failure downregulates eNOS and is proapoptotic: role of 
tumor necrosis factor-alpha, Circulation 100 (1999) 1983-1991. 
 
[43] M. Tsutsui, H. Shimokawa, T. Morishita, Y. Nakashima, and N. Yanagihara, 
Development of genetically engineered mice lacking all three nitric oxide synthases, J 
Pharmacol Sci 102 (2006) 147-154. 
 
[44] B. S. Oemar, M. R. Tschudi, N. Godoy, V. Brovkovich, T. Malinski, and T. F. 
Luscher, Reduced endothelial nitric oxide synthase expression and production in human 
atherosclerosis, Circulation 97 (1998) 2494-2498. 
 
[45] T. Fujii, M. Onimaru, Y. Yonemitsu, H. Kuwano, and K. Sueishi, Statins restore 
ischemic limb blood flow in diabetic microangiopathy via eNOS/NO upregulation but not 
via PDGF-BB expression, Am J Physiol Heart Circ Physiol 294 (2008) H2785-2791. 
 
 
 98
 
 
 
CHAPTER TWO 
ARGININOSUCCINATE SYNTHASE PHOSPHORYLATION 
 
Overview 
 
Argininosuccinate synthase (AS) is essential for endothelial nitric oxide (NO) 
production and its regulation in this capacity has been studied primarily at the 
transcriptional level. The dynamics of vascular function suggest that an acute regulation 
system may mediate AS function.  This premise underlies our hypothesis that AS is 
phosphorylated in vascular endothelium. Since serine/threonine phosphorylation has been 
identified as the key mechanism mediating acute nitric oxide production, we focused on 
these modifications. We began our studies by conducting a bioinformatic analysis of the 
AS protein sequence utilizing 4 different databases. We identified 31 putative sites of AS 
serine/threonine phosphorylation that were positive hits in at least 2 of the 4 databases.  
Immunoprecipitation and immobilized metal affinity chromatography demonstrated that 
AS is an endogenous phosphoprotein. An in vitro kinase screen revealed that protein 
kinase A (PKA) and protein kinase c alpha (PKCα), kinases that enhance NO production 
via eNOS activation, phosphorylate AS. Vascular endothelial growth factor (VEGF) was 
identified as a candidate pathway for regulating AS phosphorylation since it activated 
PKA, PKCα and eNOS. In addition, α-methyl-DL-aspartic acid (MDLA), an AS 
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inhibitor, diminished maximal VEGF-mediated NO production.  Immunoprecipitation 
studies suggested that VEGF enhances AS phosphorylation. We then focused our studies 
on identifying specific sites of AS phosphorylation utilizing proteomics. Thus far, we 
have been able to identify the following sites of AS serine/threonine phosphorylation: 
T131, S134, S180, S189, S328. Analysis of the AS 3-dimensional structure revealed 
important structure-function hypotheses related to the identified sites. Site directed 
mutagenesis of T131, S180 and S189 to generate phospho-null (alanine substitution) and 
phospho-mimetic (aspartic acid substitution) variants revealed a decrease and partial 
recovery of NO production compared to wild type, respectively. In silico modeling of 
phosphorylation sites utilizing the human AS crystal structure revealed that T131, S134 
and S328 are the most accessible sites for modification by phosphorylation. Overall, our 
data demonstrates that regulation of AS by serine/threonine phosphorylation is an 
important mechanism for ensuring NO homeostasis. Our work suggests that targeting the 
kinases that lead to AS phosphorylation is one avenue to normalize AS function and 
offers an attractive therapeutic option for vascular disorders. 
 
Materials and Methods 
 
Bioinformatics: The following bioinformatic databases were utilized to identify 
putative AS phosphorylation sites and kinases: NetworKIN 
(http://networkin.info/search.php), Phospho-Motif 
(http://www.hprd.org/PhosphoMotif_finder), NetPhosK 
(http://www.cbs.dtu.dk/services/NetPhosK/) and Group Based Prediction System 
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(http://bioinformatics.lcd-ustc.org/gps2/). Additionally, kinase motifs were identified by 
searching for specific motifs in the AS sequence utilizing Expasy Prosite (Scan Prosite 
Tool: http://www.expasy.ch/tools/scanprosite/). Multiple sequence alignments were 
conducted utilizing ClustalW (http://www.ebi.ac.uk/Tools/clustalw2/index.html). The 3-
dimensional human AS crystal structure was generated utilizing ViewerLite software 
version 5.0 (Accelrys Corporation, San Diego, California) or iSee software from the 
Structural Genomics Consortium (http://www.sgc.ox.ac.uk/iSee/).  
 
Bovine Aortic Endothelial Cell Culture: See Chapter One, Page 64 
 
In Vivo 32P Orthophosphate Labeling: BAEC were serum starved for 4 hours in 
phosphate-free DMEM. Cells were transfected with V5-His tagged AS for 24 hours (see 
Chapter One, Page 64 for a full description of this vector) and then biosynthetically 
labeled with [32Pi] according to the procedure of Michel et al [1]. Labeled cells were 
treated with 10 μM bradykinin for 1 hour. Cell lysates were prepared and 
immunoprecipitations were carried out using antibodies directed against the V5-tag of 
overexpressed AS. Following the isolation of immune complexes with protein G-agarose 
(Santa Cruz), the complex was eluted by heating in SDS-PAGE sample buffer. The 
samples were fractionated via SDS-PAGE (4-20% gradient gels; Bio-Rad). After drying 
the gel, detection of phosphorylated AS was via Phosphor Imaging (GE Healthcare). 
 
Immunoprecipitation and Western Blot: To determine whether AS is an 
endogenous phosphoprotein, immunoprecipitations (IP) were carried out utilizing a 
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phospho-serine/threonine antibody (BD Biosciences) and an AS antibody (Everest 
Biotech). To assess regulation of AS phosphorylation by VEGF, IP were carried out 
utilizing an AS antibody (Everest Biotech). After serum starvation overnight, complete 
medium with serum was replenished for 2 hours to restore maximal basal 
phosphorylation levels or cells were treated with VEGF (100 ng/ml) as indicated in figure 
legends. BAEC lysates were prepared from 150 mm dishes by adding 1 ml NP-40 buffer 
(50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1% NP-40) plus protease and phosphatase 
inhibitors (Calbiochem and Pierce, respectively) and scraping. Lysates were centrifuged 
at 12,000 x g at 4°C for 10 minutes.  Equal amount of total protein (measured by BCA 
assay, Pierce) from clarified lysates was incubated with 200 µl Dynabeads protein G 
(Invitrogen) per ml lysate at 4°C for 1 hour for pre-clearing. Supernatants were collected 
and incubated with corresponding antibodies at 4°C for 4 hours. The antibody-antigen 
complex was then incubated with 200 µl/ml Dynabeads Protein G for 1 hour at 4°C. IP’s 
with same species normal IgG antibodies (Santa Cruz) were conducted in parallel as 
negative controls. Whole cell lysate (WCL) was utilized as a positive control for antibody 
reactivity. For western blotting methods, refer to Chapter One, Page 68. Membranes were 
blotted with indicated antibodies [eNOS, phospho-eNOS (S1177) (BD Biosciences); 
PKA, phospho-PKA (T497), phospho-PKA substrate, phospho-PKC substrate, phospho-
serine/threonine-phenylalanine (Cell Signaling Technologies); phospho-serine 
(Millipore)]. Where appropriate, GAPDH (Novus Biologicals) was used as a loading 
control.  
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Affinity Chromatography: Two different methods were utilized to separate 
phosphorylated and non-phosphorylated protein. First, the Phosphoprotein Enrichment 
Kit from Pierce was utilized. Procedures were conducted according to supplied 
instructions. In brief, cells were washed in HEPES buffered saline and lysed in included 
lysis buffer + 0.25% CHAPS and protease/phosphatase inhibitors (HALT Protease and 
Phosphatase inhibitor cocktails, Pierce). An equal amount of protein (measured with the 
Coomassie Plus Protein Assay; Pierce) diluted to 0.5 mg/ml was placed in supplied 
columns and incubated on a platform rocker for 30 minutes at 4°C. The flow through was 
collected and after washing, phosphoproteins were eluted with supplied elution buffer. 
Flow through and eluted fractions were concentrated using iCON Concentrators (Pierce). 
Total protein was measured and western blots were conducted as above. The presence of 
AS in the phosphoprotein fraction was monitored using a total AS antibody (BD 
Biosciences). To demonstrate effectiveness of separation and enrichment of 
phosphoproteins, membranes were probed with [phospho-Akt (S473) (Cell Signaling 
Technologies)]. Additionally, cytochrome C (Cell Signaling Technologies), a non-
phosphorylated protein, was used as a negative control. For the λ-phosphatase 
experiments, once cell lysates were collected, cells were treated 700 μg of λ-phosphatase 
per 100 μg protein for 20 minutes at 37°C. The IMAC procedure then was continued as 
above. 
 
The second method involved the Qiagen PhosphoProtein Purification Kit. 
Procedures were according to supplied directions. In brief, after collecting cells by 
trypsinization and washing cell pellet in HEPES buffered saline, cellular proteins were 
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extracted in lysis buffer containing 0.25% (w/v) CHAPS, protease/phosphatase inhibitors, 
and benzonase for 30 min at 4°C and centrifuged at 10,000g at 4°C for 30 min to remove 
insoluble material. Total protein was diluted to a concentration of 0.1 mg/ml in a total of 
25 ml of lysis buffer and was applied to a lysis buffer-equilibrated PhosphoProtein 
purification column at room temperature. The column was washed with lysis buffer and 
the phosphoproteins were eluted with 2 ml of PhosphoProtein Elution Buffer. The yield 
of phosphorylated protein was determined by the BCA assay. The flow-through samples 
were passed through two additional columns to ensure complete removal of 
phosphoproteins from the sample. The eluted and flow-through fractions were then 
concentrated by ultrafiltration in a 10-kDa cutoff Amicon Ultra column (Millipore 
Corporation) and equal amount of protein from each sample was subjected to SDS-
PAGE. The presence of AS in the phosphoprotein fraction was monitored using a total 
AS antibody (BD Biosciences). To demonstrate effectiveness of separation and 
enrichment of phosphoproteins, membranes were probed with phospho-eNOS (S1177) 
(BD Biosciences). α-tubulin was utilized as a loading control. 
   
Purification of Bovine Argininosuccinate Synthase:  Bovine AS (NP_776317) 
was subcloned into the pET-28(c)+ vector (Novagen) and expressed in E. coli. The 
protein was subsequently purified via the fused His tag by affinity chromatography 
utilizing Ni-NTA His-bind resin per the manufacturer’s instructions (Novagen). 
Successful purification was verified via SDS-PAGE. Purity was ~90% as determined by 
densitometry as shown below: 
 
 Figure 11: SDS-PAGE Demonstrating AS purification 
 
AS 
 
 
 
 
 
 
In Vitro Kinase Screen: Purified AS was utilized to run in vitro kinase reactions 
according to the manufacturer’s instructions (SignalChem, Vancouver, BC). Kinases 
were selected by conducting a bioinformatic search for putative AS kinases and then 
choosing a subset of those kinases for the screen based on their known role in regulating 
NO production. The following kinases were screened: AMP-activated protein kinase 
(AMPK; subunits A1/B1/G1 and A1/B1/G2), casein kinase II (CKII; subtype α1), 
glycogen synthase kinase 3 beta (GSK3β), protein kinase A (PKA- catalytic unit cα), 
protein kinase C alpha (PKCα) and protein kinase G (PKG- subtype 1). In brief, reactions 
contained the following components: active protein kinase, 10X reaction buffer, protein 
kinase activator, 33P-ATP and 5-10 µg recombinant, His-tag purified AS. A positive 
control to test for kinase activity was carried out with the appropriate peptide substrate 
and a blank reaction was carried out with all assay components except substrate. The 
assays were initiated by the addition of 33P-ATP and the reaction mixtures were 
incubated at 30°C for 45 minutes. The assays were terminated by spotting the reaction 
mixture onto a phosphocellulose P81 plate. After 3 15-minute washes in 1% phosphoric 
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acid, the radioactivity on the P81 plates was counted via scintillation counting. For 
imaging, in vitro kinase reactions were carried out essentially as above except they were 
terminated upon addition of SDS-PAGE sample buffer. Reactions were fractionated on 
10% SDS-PAGE gels (BioRad) and exposed to film. For the dose response experiments, 
the reactions were carried out as above, with the exception that AS protein (substrate) 
concentration was varied from 2.5-12.5 µg. To determine if pre-phosphorylation of AS 
was required for CKII or GSK3β to phosphorylate AS, an in vitro phosphorylation 
reaction was carried out with AS and PKC using cold ATP followed by the in vitro 
reaction with CKII or GSK3β utilizing radiolabeled ATP. 
 
Nitric Oxide Assays:  See Chapter 1, Page 70 for the methodology employed to 
measure NO released into the medium utilizing the DAN assay. For the VEGF 
experiments, cells were treated with VEGF +/- an AS inhibitor, α-methyl-DL-aspartic 
acid (MDLA; Sigma) as indicated. The experiments with wild type and mutant AS were 
carried out by overexpressing AS (see below). 
 
Generation of AS Variants and Transient Transfections: The AS expression 
vector, fully described in Chapter One, Page 64, was utilized to mutate identified 
phosphorylation sites to determine their role in NO production utilizing procedures 
routinely conducted by our laboratory [2]. Briefly, phosphorylated residues were mutated 
to alanines to mimic a non-phosphorylated state and to aspartic acid to mimic a 
constitutively phosphorylated state following the “Quick Change” protocol utilizing Pfu 
Turbo DNA Polymerase (Stratagene). We compared the NO production of wild type 
versus phospho-mutant AS in BAEC’s since we have demonstrated a consistent and 
reproducible increase in NO production when wild type AS is overexpressed in BAEC’s 
(See Chapter One, Figure 4, Page 73).  
 
Primers were designed according to the guidelines from Strategene for the 
successful use of their “Quick Change” protocol. For the S180A/S189A, the S189A 
variant was used as the template and the S180A primers were used to introduce the 
additional mutation. All variants were verified by sequencing. The following primers 
were utilized: 
 
Table 3: Primers Used for Site Directed Mutagenesis 
 
Variant Wild Type Sequence Sense Primer Antisense Primer 
T131A C CGG TTT GAG CTC 
GCC TGC TAC TCG CTG 
G 
C CAG CGA GTA GCA 
GGC GAG CTC AAA 
CCG G 
T131D 
C CGG TTT GAG 
CTC ACC TGC TAC 
TCG CTG G 
C CGG TTT GAG CTC 
GAC TGC TAC TCG CTG 
G 
C CAG CGA GTA GCA 
GTC GAG CTC AAA 
CCG G 
S180A CAA GAA CCC GTG GGC 
CAT GGA CGA GAA CCT 
G 
C AGG TTC TCG TCC 
ATG GCC CAC GGG 
TTC TTG 
S180D 
CAA GAA CCC GTG 
GAG CAT GGA CGA 
GAA CCT G 
CAA GAA CCC GTG GGA 
CAT GGA CGA GAA CCT 
G 
C AGG TTC TCG TCC 
ATG TCC CAC GGG 
TTC TTG 
S189A AGA ACC TGA TGC ATA 
TCG CCT ACG AGG CTG 
GAA TCC 
AGA ACC TGA TGC 
ATA TCG ACT ACG 
AGG CTG GAA TCC 
S189D 
AGA ACC TGA TGC 
ATA TCA GCT ACG 
AGG CTG GAA TCC 
GGA TTC CAG CCT CGT 
AGG CGA TAT GCA TCA 
GGT TCT 
GGA TTC CAG CCT 
CGT AGT CGA TAT 
GCA TCA GGT TCT 
 
Experimental plasmids were transiently transfected into BAEC using 
Lipofectamine 2000 (Invitrogen) in serum free Opti-MEM I (Invitrogen). Two μg AS 
plasmid DNA was used per well of a 6-well dish or 10 μg per 100 mm dish. After 4 h, the 
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medium was replaced with Dulbecco’s modified Eagle’s medium containing 10% serum 
and cells were cultured for 24 h. 
 
Purification of Overexpressed AS: Two methods were utilized to partially purify 
the AS expression vector. In order to obtain sufficient material for mass spectrometry 
analysis, at least 3 100-mm dishes were transfected per treatment group as described 
above and lysates were pooled. Cells were treated with either 20 or 100 nM okadaic acid, 
a serine/threonine phosphatase inhibitor, in an attempt to enhance phosphorylation signal 
for the experiments to characterize the AS expression vector.  
 
The first method involved immunoprecipitation of overexpressed AS with a V5 
antibody. Lysates were prepared utilizing NP-40 lysis buffer (50 mM Tris HCl, pH 7.4, 
150 mM NaCl, 1% NP-40) plus protease and phosphatase inhibitors (Calbiochem and 
Pierce, respectively) and scraping. Clarified lysates were pre-cleared with a protein G 
bead slurry (Protein G Plus Agarose, Santa Cruz) for 1 hour. Immunoprecipitation was 
conducted with an antibody against the V5 tag of the AS expression construct 
(Invitrogen) by incubating the pre-cleared lysate with antibody for 2 hours at 4°C. The 
protein G bead slurry was added to samples and incubated overnight at 4°C. Purified AS 
and associated proteins were eluted with 2X SDS-PAGE sample buffer.  
 
The second method involved purification via the 6X-his tag of the AS expression 
vector. Magnetic Ni-NTA agarose beads (Qiagen) were utilized according to the 
manufacturer’s instructions. Briefly, cells were lysed in Buffer B-Tween + 1% NP-40 
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(100 mM NaH2PO4, 10 mM Tris·Cl, 8 M urea and 0.05% tween, pH 8.0). Lysates were 
cleared by centrifugation. Ni-NTA agarose beads were added (20 μl/ml) to the lysates 
and incubated with end-over-end rotation for 2 hours at 4°C. Cells were washed in Buffer 
C-Tween (same as buffer B, pH 6.3) and eluted with Buffer E-Tween (same as buffer B, 
pH 4.5).  
 
To monitor expression levels, western blots were conducted as described 
previously (purified samples and whole cell lysates were compared) and membranes were 
probed with an AS antibody. To assess whether the purified vector was phosphorylated, 
membranes were probed with a phospho-serine antibody (Zymed). To visualize 
effectiveness of purification, duplicate gels were run, coomassie stained, dried by vacuum 
and photographed.  
 
Liquid Chromatography and Tandem Mass Spectrometry: AS was transiently 
overexpressed in BAEC’s. Twenty four hours after transfection, cells were deprived of 
serum overnight. Cells were treated with insulin, bradykinin, insulin + bradykinin and 
okadaic acid. Overexpressed AS was purified by its fused 6X-His tag using Ni-NTA 
agarose magnetic beads (Qiagen) as described above. Proteins were separated by SDS-
PAGE to identify the AS band (51 kD). A duplicate gel was run to confirm expression of 
the AS plasmid by western blot. Gel bands of interest were excised and destained.  The 
protein disufides were reduced with triscarboxyethylphosphine and then the cysteines 
were alkylated with iodoacetamide.  In-gel trypsin digestion was used for proteolysis.  
The resulting peptides were extracted and concentrated prior to liquid chromatography 
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coupled to tandem mass spectrometry (LC-MS/MS) analysis.  Nanoflow reverse phase 
liquid chromatography was used to separate the peptides by hydrophobicity (LC 
Packings, Dionex, Sunnyvale, CA).  Online detection was accomplished with an 
electrospray linear ion trap mass spectrometer (LTQ, Thermo, San Jose, CA).  Peptide 
molecular weight measurements preceded ion selection, fragmentation, and fragment ion 
detection in MS/MS.  Tandem mass spectra were assigned to peptide sequences using 
Mascot and Sequest database search algorithms.  Sequence assignments were validated 
by manual inspection of the data. 
 
In-Silico Modeling of AS Three Dimensional Structure: In silico models of AS 
with identified phosphorylation sites were generated by the University of South Florida 
Department of Chemistry by Dr. Wayne Guida and Daniel Santiago utilizing a Molecular 
Dynamics approach. Modeling was dependent on the original X-ray structure (PDB ID: 
2NZ2). Substrate binding affinity was measured when sites were not phosphorylated 
versus phosphorylated (comparative docking). The methodology is composed of four 
phases:  
I.   Substrates were docked to original enzyme structure. 
II. Phosphorylation models were created for each possible serine/threonine residue. 
III. Low energy conformer for each phosphorylation model was identified. 
IV. Substrates were docked into phosphorylation models and docking scores were 
compared. 
Statistical Analyses: See Chapter One, Page 71. 
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Results 
 
AS is an Endogenous Phosphoprotein: Since serine/threonine phosphorylation is a 
prominent mechanism that regulates acute eNOS function, we focused on these 
modifications. To assess whether endogenous AS is phosphorylated, several approaches 
were taken. First, a bioinformatic search for AS serine/threonine phosphorylation 
utilizing four different databases was conducted. The benefit of utilizing multiple 
databases is that they each utilize slightly different approaches. For example, NetPhos 2.0 
utilizes trained neural networks for predictions [3]. On the other hand, NetworKin 
predicts in vivo kinase-substrate relationships by augmenting the information gained from 
kinase substrate motifs with context for kinases and phosphoproteins [4]. Phospho-Motif 
predictions are based on known consensus kinase motifs as well as additional motifs that 
are curated from the literature [5]. Finally, Group Based Prediction System improves on 
the methods of standard prediction systems by grouping kinases into hierarchical 
structures and developing and approach to minimize false positives [6]. By cross 
referencing results from the 4 databases, the number of false positives should be reduced. 
Through these in silico experiments, 31 sites were identified that were positive hits in at 
least 2 of the 4 databases (Table 4). 
 
 
 
 
 
T able 4: Predicted AS serine/threonine phosphorylation sites. Data was generated by 
ross-referencing results from 4 different databases and choosing only sites that were 
positive hits in at least 2 of 4 databases. 
c 
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Position Peptide 
2 --MSGKG 
6 GKGSVVL 
17 GLDTSCI 
65 EDISKEF 
80 IQSSALY 
91 LLGTSLA 
92 LGTSLAR 
115 KYVSHGA 
119 HGATGKG 
131 FELSCYS 
174 VPVTPKN 
Position Peptide 
180 NPWSMDE 
189 MHISYEA 
208 GLYTKTQ 
210 YTKTQDP 
219 APNSPDM 
242 GDGTTHS 
243 DGTTHST 
246 THSTALE 
278 GMKSRGI 
284 IYETPAG 
288 PAGTILY 
Position Peptide 
301 EAFTMDR 
328 FWHSPEC 
341 IAKSQER 
352 VQVSVFK 
365 GRESPLS 
368 SPLSLYN 
376 ELVSMNV 
396 NINSLRL 
410 NKVTAK- 
 
To evaluate whether the in silico identification of AS phosphorylation was 
occurring endogenously, immunoprecipitation of BAEC lysates was carried out with a 
phospho-serine/threonine antibody followed by immunoblotting with an AS antibody. As 
seen in Figure 12, AS co-immunoprecipitates when cellular proteins that are 
phosphorylated at serine and/or threonine residues are enriched. Similar results were 
obtained with the reverse immunoprecipitation, but in this case, the best results were 
obtained when probing with a phospho-serine and a phospho-serine/threonine/tyrosine 
antibody (Figure 12). In addition, in vivo 32P orthophosphate labeling was utilized to 
determine if AS is phosphorylated. AS was overexpressed, labeled with 32P then treated 
with bradykinin. Lysates were prepared and overexpressed AS was purified via 
immunoprecipitation. As shown in Figure 12, AS is phosphorylated basally and this 
increased upon bradykinin treatment.  
Figure 12: AS is an Endogenous Phosphoprotein, Part I. (A) Representative blot (n = 3) 
of immunoprecipitation of BAEC lysates utilizing a phospho-serine/threonine antibody (IP 
pS/T) or a same-species normal IgG (IP IgG). The membrane was probed with an AS 
antibody (IB AS). WCL; whole cell lysate. (B) Representative blot (n = 3) of 
immunoprecipitation of BAEC lysates utilizing an AS antibody (IP AS) or a same-species 
normal IgG (IP IgG). The membrane was probed with a phospho-serine or a phospho-
serine/threonine/tyrosine antibody (IB pS and IB pS/T/Y, respectively); pAS = phospho-AS. 
(C) Phosphor-image demonstrating the level of 32P incorporation in response to bradykinin 
stimulation (10µM) in BAEC’s where either AS (AS-V5-His) or an empty vector were 
overexpressed and immunoprecipitated (n = 1). 
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To further validate that AS is indeed an endogenous phosphoprotein in the 
endothelium, we utilized immobilized metal affinity chromatography (IMAC) to separate 
and enrich phosphorylated protein from total protein. This was done with two different 
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methods since the different resins utilized to bind phosphorylated proteins have affinity 
for some phosphoproteins and not others [7].  With the first method, the western blot 
analysis in Figure 13A demonstrated that a fraction of AS eluted from the column as a 
phosphorylated protein.  As a control, membranes were re-probed with a phospho-Akt 
antibody. Phospho-Akt was observed in the eluted phosphoprotein fraction with a relative 
absence in the flow-through fraction (Figure 13A). As a negative control, membranes 
were re-probed with a cytochrome c antibody (cytochrome c is not phosphorylated) and 
no cytochrome c was observed in the eluted phosphoprotein fraction (Figure 13A).  
 
Figure 13B demonstrates the similar results that were obtained with the second 
method. A fraction of AS eluted as a phospho-protein. This time, phospho-eNOS was 
utilized as a positive control to demonstrate the effectiveness of the separation of 
phosphoprotein from total protein (Figure 13B). In addition, these experiments were 
conducted with various treatments in an attempt to monitor changes in AS 
phosphorylation. There were no obvious changes in the amount of AS eluted in the 
phosphoprotein fraction. Because of the high affinity of these resins for phosphorylated 
proteins, it is nearly impossible to detect changes in binding to the column with a total 
protein antibody since a treatment may cause a change in phosphorylation sites rather 
than a net increase or decrease in phosphorylation. It became evident that this technique 
could not be used to monitor changes in phosphorylated AS without having a phospho-
AS antibody. This was demonstrated in subsequent experiments where dephosphorylation 
reactions were carried out with λ-phosphatase prior to the IMAC experiments. While 
decreases in phosphorylation were noted when using a site specific phospho-Akt 
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antibody, there was little to no change in the amount of AS eluted when a total AS 
antibody was used. In order for these experiments to have worked, AS needed to be 
completely dephosphorylated prior to IMAC in order to see a significant change.  
 
Finally, to make sure that the IMAC data was not an artifact, IMAC was 
conducted and then AS was immunoprecipitated from the eluted phosphoprotein fraction. 
As shown in Figure 13C, AS was successfully immunoprecipitated from the eluted 
fraction suggesting that the signal noted with IMAC is indeed a fraction of AS that elutes 
as a phosphoprotein and not simply a non-specific band at the AS molecular weight. 
Taken together, the immunoprecipitation, 32P labeling and phosphoprotein affinity 
chromatography strongly suggest that AS is an endogenous phosphoprotein in vascular 
endothelium. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: AS is an Endogenous Phosphoprotein, Part II. (A) Representative blot (n = 3) 
demonstrating separation of phosphorylated protein from total protein utilizing immobilized metal 
affinity chromatography (IMAC). The top panel shows the membrane was probed with AS. 
Phospho-Akt was utilized as a positive control and cytochrome c was used as a negative control. 
(B) Representative blot of IMAC conducted as in (A) but with a different resin (n = 3). The blot 
shows the level of AS, phospho-eNOS or α-tubulin in the eluted (E) or flow through (FT) 
fractions in response to treatment with insulin (100 nM), okadaic acid (50 nM; OA) or H89 (n = 
3). (C) Representative blot of the eluted phospho protein fraction of BAEC’s treated without 
(vehicle) or with λ-phosphatase (λ-pptase) prior to IMAC conducted as in (A) (n = 2). (D) 
Representative blot demonstrating IMAC conducted as in (B). The data represents AS expression 
in the whole cell lysate (WCL), the eluted IMAC fraction (IMAC) or from the IMAC fraction 
after immunoprecipitation with an AS antibody (IMAC + IP) in cells treated with okadaic acid 
(OA) at the doses indicated (n = 1). 
 
 
 
 
 
 
 
 
 
 
 
A 
AS 
pAkt 
Cyt c 
Ph
os
ph
op
ro
te
in
 
N
on
-P
ho
sp
ho
pr
ot
ei
n 
To
ta
l P
ro
te
in
 
 
AS 
peNOS 
α-tubulin 
C
on
tro
l, 
E 
C
on
tro
l, 
FT
 
In
su
lin
, E
 
In
su
lin
, F
T 
O
A
, E
 
O
A
, F
T 
H
89
, E
 
H
89
, F
T 
B 
 
 
 
 
 
 
AS 
pAkt 
V
eh
ic
le
 
λ-
pp
ta
se
 
C 
 
 
 
 
 115
 
IMAC + IP WCL IMAC 
AS 
C
on
tro
l 
O
A
 2
0 
nM
 
O
A
 1
00
 n
M
 
C
on
tro
l 
O
A
 2
0 
nM
 
O
A
 1
00
 n
M
 
C
on
tro
l 
O
A
 2
0 
nM
 
O
A
 1
00
 n
M
 
D 
 
 
 
 
 
 
Biological Relevance of AS Phosphorylation: In order to establish the biological 
significance of AS phosphorylation, we conducted a targeted in vitro kinase screen. First, 
we identified putative AS kinases utilizing four bioinformatic databases. From that list of 
kinases, the following were selected for the screen due to their known role in nitric oxide 
biology: AMP-activated protein kinase (AMPK), casein kinase II (CKII), glycogen 
synthase kinase 3 beta (GSK3β), protein kinase A (PKA) and protein kinase C alpha 
(PKCα). Akt1 was used as a negative control due to the lack of the consensus Akt 
phosphorylation motif in the AS protein sequence (R-X-R-X-X-S/T). The kinase screens 
were carried out with purified recombinant bovine AS and as shown in Figure 14A, 
PKCα and PKA were identified as AS kinases due to their ability to phosphorylate AS in 
vitro.  Although there was an increase in counts above the blank reaction with AMPK and 
Akt1, this was below the threshold considered significant (Figure 14A). SDS-PAGE 
fractionation of in vitro kinase reaction products and visualization by film exposure 
confirmed that PKCα and PKA, but not Akt1, phosphorylate AS (Figure 14B). Repeat in 
vitro kinase reactions for GSK3β and CKII were carried out, but AS was pre-
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phosphorylated with PKCα. CKII and GSK still were unable to phosphorylate AS in 
vitro (Figure 14C). 
 
Figure 14: AS is Phosphorylated by PKCα and PKA. (A) In vitro kinase assays. Gray bars 
represent the incubation of purified AS minus kinase (Blank). Black bars represent the incubation 
of purified AS with the indicated kinase (Kinase). Kinase activity is represented as counts per 
minute (CPM). * p < 0.0002; ** p < 0.00003; (n = 3 for PKC, PKA and Akt; n = 1 or 2 for 
remaining kinases). (B) Representative image of in vitro kinase reactions as described in (A) but 
only showing PKCα, PKA and Akt. pAS; phosphorylated AS (n = 2). (C) AS was pre-
phosphorylated with PKC (using cold ATP) then in vitro kinase reactions were carried out with 
GSK3β and CKII as in (A) (n = 1).  
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To test the dose-dependence of PKCα and PKA phosphorylation of AS, in vitro 
kinase reactions were conducted with a constant level of PKCα or PKA and varying AS 
concentrations (2.5 µg to 12.5 µg). The results demonstrate dose-dependent 
phosphorylation of AS by PKCα that plateaus at 5 µg of AS (Figure 15A). With PKA, 
the level of phosphorylation was linear up to 7.5 µg AS (Figure 15B).  In addition, there 
are numerous PKA and PKC motifs in the AS protein sequence, and this supports the in 
vitro data generated (Table 5). 
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Figure 15: Dose Dependence of AS Phosphorylation. (A) In vitro kinase reactions carried 
out with a constant concentration of PKCα and increasing concentrations of AS (2.5-12.5 
μg). Activity is represented as corrected CPM after subtracting blank (n = 1). (B) In vitro 
kinase reactions carried out with a constant concentration of PKA and increasing 
concentrations of AS (2.5-12.5 μg). Activity is represented as corrected CPM after 
subtracting blank (n = 3). 
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Table 5: Possible Sites Phosphorylated by PKA or PKCα. Data generated with 
bioinformatics databases. Only sites that were positive hits in at least 2 of 4 databases are 
shown.  
 
 
 
Kinase Possible Sites 
PKA S2, S6, S115, T119, T174, S180, S219, S278, S352, S365, 
S396, T410 
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 PKCα S2, S6, T91, S115, T119, T174, T208, S219, T242, S352, 
S365, S396, T410 
 
 
To further support the biological significance of AS phosphorylation, we 
considered several candidate pathways that could regulate AS phosphorylation. Insulin, 
VEGF and bradykinin pathways were all tested. Preliminary data looked positive for all 
three pathways since all demonstrated the ability to enhance AS phosphorylation. The 
data was strongest with vascular endothelial growth factor (VEGF). Since both PKA and 
PKCα have been linked to VEGF and NO production, this pathway was investigated 
further. In Chapter One, Figure 9A, we demonstrated that VEGF significantly enhances 
NO production starting at 10 minutes and continuing up to 2 hours. In order to assess 
whether PKA, PKCα and eNOS were activated during acute stimulation of NO 
production by VEGF, we measured their phosphorylation after treatment with VEGF for 
10 minutes. Indeed, PKA, PKCα and eNOS had increased levels of phosphorylation in 
response to VEGF, suggesting that these are key events that contributed to the enhanced 
production of NO (Figure 16A).  
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Although eNOS is known to be activated during VEGF stimulation to enhance 
NO production, it is not known whether AS activity is also enhanced and necessary for 
increased NO production during VEGF stimulation. To study this, the 2 hour time point 
was used in order to clearly distinguish VEGF-stimulated NO production under AS-
inhibited and uninhibited conditions. BAEC’s were pre-treated for 1 hour with the AS 
inhibitor α-methyl-DL-aspartic acid (MDLA, 10 mM), an aspartic acid analogue that 
competitively inhibits AS [8]. The cells were then treated with VEGF (100 ng/ml) for 2 
hours. As shown in Figure 16B, the VEGF-mediated increase in NO production was 
substantially diminished when endothelial cells were pre-treated with MDLA. When this 
experiment was repeated with a 10 minute treatment with VEGF, the AS inhibitor MDLA 
essentially abolished both basal and VEGF-stimulated NO production (Figure 16C). 
 
To determine whether the requirement for AS activity for maximal VEGF-
mediated NO production was related to AS phosphorylation, BAEC’s were treated with 
100 ng/ml VEGF for 10 minutes. Lysates were prepared and immunoprecipitations were 
carried out utilizing an AS antibody. Subsequent western blotting with phospho-
serine/threonine, phospho-PKC substrate and a phospho-PKA substrate antibody revealed 
that AS phosphorylation was enhanced by VEGF treatment (Figure 16D). 
 
 
 
 
 
 Figure 16: VEGF is a Candidate Pathway for Regulating AS Phosphorylation. (A) 
Representative western blot (n = 3) of BAEC treated with VEGF (100 ng/ml, 10 minutes). 
Membranes were immunoblotted with phospho-PKCα (pPKCα), total PKCα, phospho-PKA 
(pPKA), total PKA, phospho eNOS (peNOS), total eNOS and GAPDH (GAPDH). (B) NO 
assay of cells treated with MDLA alone (pre-treated for 1 hour), VEGF alone (2 hours) or 
VEGF + MDLA. *** p < 0.00005; * p < 0.05; n = 3 (C) Experiment conducted as in (B) with 
the exception that treatment with VEGF was for 10 minutes (n = 1). (D) Immunoprecipitation 
of cell lysates that were treated +/- VEGF (100 ng/ml, 10 min) with an AS antibody (IP AS) 
or a same-species normal IgG (IP IgG) followed by probing with phospho-serine/threonine 
(pS/T), phospho-PKC substrate (pPKC Substrate) and phospho-PKA substrate  (pPKA 
Substrate) antibodies. IgG = non-specific IgG band; pAS = phosphorylated AS band (n = 3). 
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Identification of Specific Sites of AS Phosphorylation: In order to assess the best 
methodology to pursue mass spectrometry identification of AS phosphorylation, two 
approaches were taken to purify sufficient amounts of AS. For these experiments, we 
decided to utilize overexpression. Although this scenario is somewhat artificial, the low 
stoichiometry of phosphorylation prompted us to take measures to maximize the 
possibility of detecting phosphorylated-AS peptides. The first purification method 
involved immunoprecipitating overexpressed AS utilizing a V5 antibody to pull it down 
via its V5 tag. The expression levels of AS with his method were excellent and 
overexpressed AS was sufficiently purified (Figure 17A and B, respectively). In addition, 
AS, but not the empty vector control demonstrated phosphorylation at serine residues 
both basally and in response to okadaic acid treatment (a phosphatase inhibitor). There 
was no apparent increase in phosphorylation with treatment (Figure 17A). One possible 
problem with this methodology involves the fact that the heavy chain IgG (~55 kD) is 
inevitably pulled down (Figure 17B). Since it is close to the overexpressed AS molecular 
weight (~51 kD), IgG might interfere with the identification of AS.  
 
 
 
 
 
 
 
 
Figure 17: Overexpression and Purification of AS Utilizing Immunoprecipitation. (A) 
Immunoprecipitation was utilized to purify overexpressed AS-V5-His utilizing a V5 antibody. Blot 
compares samples that were treated with increasing concentrations of okadaic acid (OA) as indicated. 
Left side of blot shows immunoprecipitated samples (IP V5) and right side shows whole cell lysate 
(WCL) of samples expressing AS (AS-V5-His) or an empty vector. Top blot was probed with AS 
antibody and both overexpressed (AS: OE) and endogenous AS (AS: E) can be detected. Bottom blot 
was probed with a phospho-serine (pS) antibody. (B) Image of duplicate gel that was coomassie stained. 
Red box indicates AS (51 kD). Black box indicates non-specific heavy chain IgG band (~50-55 kD). 
Protein marker is indicated by arrow. 
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This prompted us to test a second method that involved utilizing Ni-NTA 
magnetic beads to affinity purify overexpressed AS via its 6X-His tag. This method 
allowed for excellent enrichment and purification of the overexpressed AS (Figure 18A 
and B). It also allowed for a significant amount of endogenous AS to co-purify (Figure 
18A). Considering the effectiveness of this method and the lack of IgG interference, it 
was chosen for downstream mass spectrometry experiments. In addition, as shown in 
Chapter One, Figure 4, AS overexpression leads to enhanced NO production, suggesting 
that overexpressed AS functions similarly to the endogenous enzyme. Overall, this data 
supports the use of the overexpression system to identify specific sites of AS 
phosphorylation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 18: Overexpression and Purification of AS Utilizing Ni-NTA. (A) Ni-NTA agarose was 
utilized to purify overexpressed AS-V5-His. Blot compares samples that were treated with increasing 
concentrations of okadaic acid (OA) as indicated. Left side of blot shows purified samples (NI-NTA 
Purified) and right side shows whole cell lysate (WCL) of samples expressing AS (AS-V5-His) or an 
empty vector. Top blot was probed with AS antibody and both overexpressed (AS: OE) and 
endogenous AS (AS: E) can be detected. Bottom blot was probed with a phospho-serine (pS) antibody. 
(B) Image of duplicate gel that was coomassie stained. Red box indicates AS (51 kD). Protein markers 
are indicated by arrows. 
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In order to identify specific sites of AS phosphorylation, AS was overexpressed 
and cells were treated with okadaic acid, insulin, bradykinin, and insulin + bradykinin. 
AS was purified utilizing Ni-NTA agarose magnetic beads and cellular protein was 
separated utilizing SDS-PAGE. The band corresponding to overexpressed AS was 
excised and prepared for liquid chromatography-tandem mass spectrometry (LC-MS/MS) 
analysis. We have thus far identified the following sites of AS phosphorylation: T131, 
Y133, S134, S180, S189, Y207 and S328. The sites that have been identified on several 
occasions are T131, S180 and S189 while the remaining sites have not yet been 
confirmed. Assessment of the cumulative data did not provide clear determination as to 
whether any particular treatment enhanced phosphorylation at a specific site. We did note 
that the patterns of AS phosphorylation are indeed dynamic. Attempts were made to 
relatively quantitate the phosphorylation of AS +/- different treatments utilizing data 
from the liquid chromatography phase to enhance peptide identification via mass 
spectrometry. This data was also inconclusive. However, there were trends noted that 
suggested changes in phosphorylation patterns. In addition, the peptide 131-TCYS-134 
contains multiple possible modifications. Their close proximity makes it impossible to 
determine which site is actually modified (i.e. T131 vs. S134). Figure 19 is an example of 
the data generated via LC-MS/MS. The spectrum at the top shows that under control 
conditions, T131 is not phosphorylated. The spectrum below it indicated that upon 
okadaic acid treatment, T131 becomes phosphorylated. The mass to charge ratio (m/z) 
difference of a peptide phosphorylated by a serine or threonine modification is ~80. The 
m/z difference of 11 between the non-phosphorylated vs. phosphorylated T131 was 
derived by the fact that the non-phosphorylated peptide was alkylated (m/z = 57). The 
m/z difference between the non-phosphorylated and phosphorylated peptide with a 
charge of +2 was calculated as follows: (80-57)/2 = 11. 
Figure 19: Identification of AS Phosphorylation Sites Utilizing Liquid Chromatography-
Tandem Mass Spectrometry. AS was overexpressed and cells were treated with okadaic acid (100 
nM) for 30 min. After purification and SDS-PAGE, the band corresponding to overexpressed AS 
was excised digested, and subjected to liquid chromatography-tandem mass spectrometry. Figure 
shows mass spectra of control (top) and okadaic acid (bottom) treated samples. In the control 
samples, T131 is not phosphorylated while in the okadaic acid samples, T131 is phosphorylated.  
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Although AS is the focus of this work, we did identify some novel eNOS 
phosphorylation sites that are worth noting. These experiments were carried out by 
immunoprecipitating eNOS as described in Chapter Three, Page 166, and subjecting the 
eNOS band to LC-MS/MS to identify phosphorylation sites. The novel sites of bovine 
eNOS phosphorylation were: T60, T62, T389, and S485. 
 
Since the focus of this work is serine/threonine phosphorylation, further 
investigation into biological significance was conducted for only those modifications. 
First, to determine the evolutionary relevance of the sites, a multiple sequence alignment 
was conducted. As seen in Figure 20, T131, S134, S180, S189 and S328 are 100% 
conserved among mammals with the exception that humans have a serine at position 131 
while other mammals have a threonine. The sites that were completely conserved even 
down to insects and E. coli were S180 and S189. The only minor substitution was a 
threonine at position 189 in E. coli. Overall, the mammalian AS sequences depicted in 
the figure are about 95% identical. Sequence identity then declines with the lowest being 
25% for the E. coli sequence compared to human or bovine (per ClustalW analysis). With 
such a low level of conservation among some of the non-mammalian species, the 
persistence of phosphorylatable residues at some of the positions strongly suggests 
biological importance. 
 
 
 
 
Figure 20: Multiple sequence alignment of AS Phosphorylation Sites. Panels show the peptide 
containing T131 and S134 (A), S180 and S189 (B) or S328 (C). Sites are highlighted in blue. 
 
 
 
 Human   FELSCYSLAPQIKVIA 143 
 131
 Bovine   FELTCYSLAPQIKVIA 143 
 Rat   FELTCYSLAPQIKVIA 143 
 A 
 Mouse   FELTCYSLAPQIKVIA 143 
 Dog   FELTCYSLAPQIKVIA 143 
 Frog   FELTCYSLYPEVKIIA 144 
 Zebrafish  FELTCYALYPQVQVIA 142 
 Fruit Fly  FELCAYALKPDLKIIA 142 
 Yeast   FELSFYALKPDVKCIT 142 
 E. coli  FYRYGLLTNAELQIYK 155 
 
 
 
 Human   KNPWSMDENLMHISYE 191 
 Bovine   KNPWSMDENLMHISYE 191 
 Rat   KSPWSMDENLMHISYE 191 
B 
 Mouse   KSPWSMDENLMHISYE 191 
 Dog   KNPWSMDENLMHISYE 191 
 Frog   KDPWSMDENIMHISYE 192 
 Zebrafish  KAPWSMDANLMHISYE 190 
 Fruit Fly  ATPWSTDANILHISYE 190 
 Yeast   AKPWSTDENQAHISYE 190 
 E. coli  EKAYSTDSNMLGATHE 203 
  
 
 
 Human   LKFAELVYTGFWHSPE 330 
 Bovine   LKFAELVYTGFWHSPE 330 
 Rat   LKFAELVYTGFWHSPE 330 
C 
 Mouse    LKFAELVYTGFWHSPE 330 
 Dog   LKFAELVYTGFWHSPE 330 
 Frog   QRFAEQIYNGFWYSPE 331 
 Zebrafish  IKFSELIYNGFWFSPE 329 
 Fruit Fly  DRMADYVYNGFWFSPE 330 
 Yeast   PNYSRLIYNGFLLHPE 334 
 E. coli  RQLGRLLYQGRWFDSQ 340 
 
 
To further elucidate the biological role of these sites, an in silico experiment was 
conducted to identify putative kinases. As seen in Table 6, several important kinases were 
identified as possible kinases for the identified sites including PKA, AMPK, CKII and 
GSK3β. Interestingly, PKC motifs were not found at any of the AS phosphorylation sites 
identified so far. 
 
Table 6: Putative Kinases for Identified AS Serine/Threonine Phosphorylation Sites. 
Data was generated based on motif searches with Prosite or via bioinformatic databases. 
 
 
RESIDUE PUTATIVE KINASES 
T131 AMPK 
CKI & CKII 
MAPK 
S134 CKI 
S180 PKA 
CKII 
PKG 
S189 CKII 
MAPK 
S328 GSK3 
CKII 
MAPK 
 
Another methodology to explore biological significance involves utilizing the 3-
dimensional structure of an enzyme to assess possible structure-function relationships. As 
indicated in Table 7, each of the identified AS serine/threonine phosphorylation sites is 
linked to physiologically relevant pathways. T131 and S134 are located in the N-
terminal, nucleotide binding domain of AS, which has been shown to be involved in 
conformational change during catalysis in the E. coli enzyme. T131/S134 are also 
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adjacent to cysteine 132, a site that is reversibly nitrosylated in vascular smooth muscle 
and functions as a negative regulator of AS enzyme activity under conditions of 
excessive NO production. S180 is in the N-terminal domain but is part of the catalytic 
cleft. It is hypothesized to interact with ATP {per e-mail conversation with Dr. Jonas 
Uppenberg [9]}. Interestingly, S180 is mutated in citrullinemia (S180 ? N), a disease 
characterized by diminished AS function. S189 is also in the N-terminal domain as part 
of the catalytic cleft and hydrogen bonds with citrulline. S328 is located in the catalytic 
domain. Additionally, it is adjacent to the AS caveolin-1 binding motif (discussed in 
Chapter Three), suggesting a role in regulating the interaction between AS and caveolin.  
 
Table 7: Hypothesized Biological Significance of AS Phosphorylation. Identified AS 
serine/threonine phosphorylation sites, their hypothesized relevance based on the literature and 
3D structure analysis and the number of times that each site was identified in bioinformatic 
databases. 
 
 
 
 
RESIDUE HYPOTHESIZED BIOLOGICAL ROLE DATABASE 
FREQUENCY 
T131/S134 Located in the nucleotide domain which is hypothesized to be 
involved in conformational change upon catalysis. Near cysteine 
132, a site known to be nitrosylated under conditions of excess 
NO production. This site inhibits AS activity. It is possible that 
the phosphorylation and nitrosylation serve as “on-off” switches 
in response to cellular NO needs.  
3/1 
S180 Located in the catalytic cleft and putatively binds ATP. This site 
is known to be mutated in citrullinemia, suggesting that it is 
important for AS activity. 
4 
S189 Also located in the catalytic cleft. Forms a hydrogen bond with 
citrulline so it is important for AS activity. 
2 
S328 This site is located in the catalytic domain. It is in close 
proximity to T131. Additionally, it is adjacent to the AS caveolin 
binding motif, suggesting a role in regulating this putative 
interaction. 
2 
 133
Figure 21 shows the 3-dimensional structure of an AS monomer, dimer and 
tetramer and illustrates its intricate complexity. The location of the identified 
phosphorylation sites with respect to the 3-dimensional structure of AS is depicted in 
Figure 22. 
Figure 21: The AS 3-Dimensional Structure. AS monomer (A), homo-dimer (B) and 
homo-tetramer (C) as illustrated by the Structural Genomics Consortium iSEE software (A) 
or generated by the USF Department of Chemistry (B, C).  
 
 
 
 
  A 
 
 
 
 
 
 
 
B C  
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Figure 22: Structure-Function Relationships of AS Phosphorylation Sites. (A) AS 3D structure 
(monomer) with location of identified phosphorylation sites in relation to domains (modified from 
Structural Genomics Consortium iSee software). The N-terminal domain is in green, the catalytic 
domain is in orange, the C-terminal domain is in gray and the protruding loop that links the N-
terminal and catalytic domains is in purple. (B) AS 3D structure (monomer) with location of 
identified phosphorylation sites in relation to substrates (citrulline and aspartate) (modified from 
ViewerLite-generated structure). Arrows point to the residues and substrates. Phosphorylated 
residues are identified in ball and stick form in black. Aspartate and citrulline are in CPK form (gray 
and purple, respectively).  
 
 
 
 
 
 
 
 
A
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Mechanism of AS Regulation by Phosphorylation: To understand the role of 
specific AS phosphorylation sites on enzyme activity, phospho-null (S/T ? A) and 
phospho-mimetic (S/T ? D) variants were generated for T131, S180 and S189, the 3 
sites that were confirmed several times by mass spectrometry. First, the effect of alanine 
mutations was tested. As shown in Figure 23A, preventing phosphorylation at any of 
these sites significantly reduced the ability of endothelial cells to produce NO. 
Mimicking constitutive phosphorylation at those sites yielded some recovery of NO 
production, especially with the S180D variant, but NO levels did not reach those of the 
wild-type enzyme (Figure 23B). A repeat experiment where the phospho-null and 
phospho-mimetic variants were compared head-to-head confirmed the observations made 
when the variants were tested individually (Figure 23C).  Since the S180 and S189 have 
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such essential catalytic functions, a double variant was created where both sites were 
mutated to alanine. As shown in Figure 23D, the double mutation did not further diminish 
NO production as compared to the single mutation.  
 
 Figure 23: Role of T131, S180 and S189 on Endothelial Nitric Oxide Production. 
BAEC’s were transiently transfected with wild type (WT) empty vector (EV) or variants 
(T131A, T131D, S180A, S180D, S189A, S189D, S180A189A). (A) Comparison of WT AS 
to phospho-null alanine variants (n = 2). (B) Comparison of control (C- untransfected), EV 
and WT AS to phospho-mimetic (aspartic acid) variants (n = 1). (C) Head to head 
comparison of EV and WT versus phospho-null and phospho mimetic variants (n = 2). (D) 
Comparison of control, empty vector and wild type AS to single and double alanine mutants 
at positions 180 and 189 (n = 3). * p < 0.02; ** p < 0.007
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 The work with the AS phospho-null and phospho-mimetic variants led to an 
important observation. Consistently, when BAEC’s were transiently transfected with 
wild-type AS, there was a high degree of cell loss that increased over time. Theoretically, 
this was due to the role of AS in maintaining endothelial cell viability by maintaining 
appropriate amounts of NO as demonstrated in Chapter One. The phospho-null variants 
of AS never demonstrated any significant cell loss or even visible cell stress. This highly 
suggested that all 3 sites have a role in AS function.  
 
 Another approach that was utilized to assess biological significance of AS 
serine/threonine phosphorylation involved the use of computational modeling. Since the 
human crystal structure of AS was solved recently, we now have an invaluable tool to 
study structure-function relationships. The theory behind this line of experiments was that 
certain amino acids may enhance or interfere with substrate binding while others might 
be more accessible to modification by phosphorylation. To test these theories, all the 
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identified serine or threonine phosphorylation sites [T131 (S131 in human structure), 
S134, S180, S189 and S328] were modeled plus or minus the phosphate modification and 
plus or minus substrates. The Molecular Dynamics method was then utilized to measure 
substrate binding affinity. Serines 180 and 189 were found to flank citrulline. 
Phosphorylation at either of these sites led to significantly diminished affinity for 
substrates. In addition, in the tetrameric structure those sites are completely buried in the 
active site (Figure 24). S131, S134 and S328 lie in close proximity in the 3-dimensional 
structure (Figure 25). In the dimer, these 3 serines are partially covered by the "free" C-
terminal helix that is part of the dimer-dimer interface.  Although this region is partially 
buried, there is surface exposure.  S328 has its oxygen facing away from solvent.  The 
oxygen of S131 is hydrogen bonded to H327.  S134 has its proton hydrogen-bonded to 
the backbone carbonyl of H327 leaving its oxygen exposed to solvent and ready for 
nucleophilic attack. In Figure 26, a close up view of these sites is shown that 
demonstrates that S134 and S328 are more accessible than S131. S131 has its hydroxyl 
group buried by the loop where S328 is located.  In this figure it is also evident that S131 
and S134 are in the outer portion of an alpha helix. In summary, the in silico modeling of 
AS plus or minus phosphorylation at identified sites revealed that the most likely 
candidates for modification by phosphorylation are S131, S134 and S328.  
 
 
 
 
 
 Figure 24: Close Up of Human AS Active Site. Serines 180 (left) and 189 (right) are shown 
in yellow . Aspartate (left) and citrulline (right) are shown in green. ATP would bind in the 
empty space in the lower left quadrant of the figure.  
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Figure 25: In Silico Modeling of AS Residues with Good Accessibility for Modification 
by Phosphorylation. Close up of human AS structure showing S131 (bovine T131), S134 
and S328. On top of the figure is the free c-terminal helix that forms the dimer-dimer 
interface. This helix partially buries these sites.  
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Figure 26: Close-Up View of S131, S134 and S328. Carbon residues are labeled in gold. 
S134 and 328 are on the upper left and upper right. S131 is on the lower left.   
 
 
 
 
 
 
 
 
 
 
 
 143
 144
Discussion 
 
In this Chapter we identified the first biologically significant post-translational 
modification of AS in the endothelium. The majority of AS regulation has been studied at 
the level of transcription/translation [10] and very little is known about the post-
translational regulation of AS. The work described in this Chapter is the first 
comprehensive investigation of one post-translational mechanism for regulating AS 
function. 
 
Although there have not been any post-translational modifications of AS 
identified in endothelial cells, the post-translational modification of AS was recently 
noted by Hao et. al [11]. They found that AS is nitrosylated and inactivated in vascular 
smooth muscle under conditions of excess NO production via iNOS, suggesting that the 
activity of AS is at least partially responsible for sensing cellular NO levels and adjusting 
NO output accordingly. This addition of an NO-derived nitrosyl group to the AS protein 
sequence also suggests a feedback mechanism where NO levels that exceed a certain 
threshold lead to a decrease in NO output. In addition, in a phospho-proteomics study 
utilized to identify phosphoproteins in HeLa cells, AS was found to be phosphorylated 
(S352) [12]. However, the scope of the paper was such that the biological relevance of 
AS phosphorylation was not explored. In our work, the finding that AS is an endogenous 
endothelial phosphoprotein was enhanced by the identification of PKA and PKCα as AS 
kinases and the regulation of this phosphorylation by VEGF. 
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The importance of tight control of NO production is highlighted by vascular 
endothelial cells where virtually all phenotypic properties are related to NO bioactivity. 
Because of this, cardiovascular risk factors often mediate their deleterious effects by 
compromising these controls which leads to endothelial dysfunction. The finding that 
PKA and PKCα phosphorylate AS in addition to their known phosphorylation and 
activation of eNOS [13-18] suggests that during VEGF stimulation, these kinases act 
coordinately on eNOS and AS via phosphorylation to enhance NO production in 
endothelial cells.  The specificity of the phosphorylation of AS by PKA and PKCα is 
supported by the fact that Akt, an essential kinase in regulating NO production [19-22], 
did not phosphorylate AS. Additionally, the substrate-dependence of the reaction and the 
multiple motifs found in the AS sequence suggest that PKA and PKCα are bona fide AS 
kinases. 
 
The specific effects of PKA and PKCα on AS function are not clear. Although the 
evidence at this time compels us to believe that both kinases activate AS, this may in fact 
not be the case. First, we have to consider the limitations of the tools we utilized to assess 
whether PKA or PKCα-mediated AS phosphorylation was indeed enhanced by VEGF. 
Second, we need to be able to test the effect of each kinase on the specific activity of AS. 
Finally, we need to know specifically which sites are phosphorylated by these kinases. 
All this work is currently underway. 
 
Although there is still a substantial amount of work that needs to be done to 
acquire a full understanding of PKA and PKCα-mediated AS phosphorylation, the 
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literature does support our data and hypotheses. So far, the story with PKA and NO 
production seems fairly clear. Under many conditions (VEGF, bradykinin, shear stress), 
PKA increases eNOS phosphorylation at activating sites [13-16]. Our level of 
understanding of the role of PKCα (and PKC in general) in regulating NO production is 
not so clear. In many instances, PKC, and PKCα specifically, decrease NO production by 
a variety of mechanisms [14, 17]. One notable mechanism involves the increase of eNOS 
phosphorylation during VEGF stimulation by PKC at an inactivating site thus reducing 
its activity [14]. In fact, in that particular study, PKA and PKC acted reciprocally. On the 
other hand, a couple of examples link PKCα to enhanced NO production. First, in vivo 
studies demonstrated that overexpression of PKCα in rat femoral arteries results in an 
increase in eNOS-mediated blood flow [18]. In another instance, PKCα was shown to be 
important for the maintenance of vascular integrity during chronic inflammation. This 
involved the activation of VEGF by decay-accelerating factor [23]. In addition, PKCα 
enhances eNOS expression [24]. Therefore, it is evident that the phosphorylation of AS 
by PKCα and PKA is a very significant finding that requires careful and extensive 
investigation. 
 
There were several other kinases that were not able to phosphorylate AS in vitro 
in our initial studies, but which warrant continued investigation. AMPK did demonstrate 
some increase in 33P ATP incorporation, but it was not found to be significant. AMPK 
has an extremely important role in regulating NO production and energy metabolism [25, 
26], two functions it shares with AS. For example, AMPK activates eNOS and thus 
increases NO production in response to adiponectin, shear stress insulin and VEGF 
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stimulation [26-29]. Also, AMPK helps to normalize some of the endothelial defects 
caused by high glucose by activating eNOS through interactions with HSP90 [30]. 
AMPK also protects endothelial cells against high-glucose induced apoptosis [31]. Since 
AS is involved in anti-apoptotic cascades in the endothelium, part of the protection by 
AMPK could be mediated by AS activation. In addition, the pathways we have linked to 
AS- insulin, VEGF, TNFα, ceramide and PPARγ- have also been linked to AMPK 
function [28, 32-35]. We did try two different combinations of AMPK catalytic and 
regulatory subunits for the in vitro kinase screens and neither gave a significant result. 
There is the possibility that something present or absent in the in vitro reaction is 
preventing significant phosphorylation of AS by AMPK. We do hypothesize that if 
AMPK phosphorylates AS, it is likely an activating modification. 
 
Also, CKII and GSK3β have important roles in regulating NO production but 
failed to demonstrate the ability to phosphorylate AS in vitro. For example, GSK3β is a 
downstream target of Akt, a major regulator of eNOS function [36, 37]. In addition, 
GSK3β regulates angiogenesis in endothelial cells [38, 39]. In one study, it was 
determined that GSK3β is downstream not just of Akt signaling, but also PKA and 
MAPK [39]. The mechanism by which GSK3β regulates angiogenesis involves a 
downregulation of matrix attachment and migration [39]. Considering the regulation of 
VEGF-mediated NO production by AS activity, it is certainly possible that GSK3β 
phosphorylates AS. Thus far, eNOS has not been found to be phosphorylated by GSK3β.  
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In addition, CKII has been shown to phosphorylate calmodulin and this 
inactivates eNOS [40]. Furthermore, CKII phosphorylates and inactivates protein 
phosphatase 2A and leads to decreased SP-1 binding to the eNOS promoter and 
ultimately to decreased eNOS expression [41]. CKII has not been shown to 
phosphorylate eNOS. An interesting link between CKII and NO metabolism that has not 
been explored is the fact that it phosphorylates PKA and HSP90 [42, 43], two important 
proteins that regulate NO production.  
 
Often times, both GSK3β and CKII require their substrates to first be 
phosphorylated by another kinase before they can phosphorylated their target [44-46]. 
We believe that these two kinases may indeed phosphorylate AS, but only when priming 
phosphorylation occurs first. We did attempt to pre-phosphorylate AS with PKCα and 
then tried the in vitro kinase reactions with CKII and GSK3β. We also obtained negative 
results, suggesting that another kinase needs to pre-phosphorylate AS at sites that are 
specifically adjacent to the motifs recognized by CKII and GSK3β. Considering the 
negative regulation of eNOS by both GSK and CKII, it is possible that these kinases may 
act to diminish AS activity.  
 
Finally, although AS was also not a good substrate for PKG in vitro, we did 
identify this kinase as a possible interacting partner with AS and eNOS in BAEC’s 
(discussed in Chapter Three). PKG is associated with multiple functions of the 
endothelium including vasodilation, angiogenesis, improvement of vasodilation during 
recovery from heart failure and the up-regulation of the mitochondrial oxidative stress 
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protection system [47-53].  In addition, PKG co-localizes with eNOS in endothelial 
caveolae [54], suggesting that it is part of the functional signaling microdomain necessary 
for citrulline-NO cycle function. Since we have identified AS to be part of this 
microdomain ([55]; See also Chapter Three), it is quite possible that PKG has direct 
effects on endothelial AS function. Although most of what is known about PKG 
regulation of vascular health occurs specifically in smooth muscle, PKG does 
phosphorylate eNOS at S633 and S1179 [56]. Thus, there is still a possibility that our in 
vitro kinase screening results are simply false negatives and that there are in fact 
mechanisms of PKG regulation of AS that occur specifically in the endothelium.  
 
The biological importance of AS phosphorylation by identification of AS kinases 
is strengthened by our identification of VEGF as one pathway for post-translational 
regulation of AS. Our finding that AS activity is necessary for maximal activation of NO 
production by VEGF draws a clear link between AS function and the endothelium-
specific biological roles of VEGF such as angiogenesis and vasodilation [28, 52, 57-60]. 
The decrease seen with the data generated at the two hour time point represented a state 
where continued stimulation by VEGF allowed for sufficient activation of eNOS and 
possibly the utilization of compensatory mechanisms so that NO could still be produced 
at levels significantly above controls. In comparison, when this experiment was 
conducted at the 10 minute time point, which represented and acute scenario of AS and 
eNOS activation, MDLA alone led to a dramatic reduction in basal NO production and 
abolished the VEGF-mediated increase in NO production. This represents a situation 
where there is insufficient time for additional compensatory mechanisms to emerge in an 
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effort to restore the cell’s capability to respond to the VEGF stimulation. This also 
highlights just how critical acute activation of AS is for a suitable response to simulation.  
 
Furthermore, the implication that VEGF stimulates AS phosphorylation is 
significant due to the known mechanisms by which VEGF leads to activation of eNOS 
with concomitant increases in NO production [14, 52, 61, 62]. The data showing an 
increase in AS phosphorylation signal with a phospho-PKA and phospho-PKC substrate 
antibodies suggests that VEGF leads to the phosphorylation of AS by PKA and PKCα. 
Although not shown due to difficulty in generating a clear image, it does seem that there 
are several bands that are near the AS molecular weight that are phosphorylated by PKA 
and PKC in response to VGEF and other treatments. Additionally, when AS is purified 
via immunoprecipitation, two bands near the AS molecular weight are noted when a gel 
is coomassie stained. Therefore, it is possible that there are multiple phosphorylated AS 
species. 
 
Considering that VEGF and eNOS expression and function are diminished in 
diabetes and cardiovascular disorders [63, 64], the inclusion of AS in this regulatory 
scheme suggests that there are multiple unexplored roles of AS in these diseases. This 
work is supported by the findings of Shen et al. demonstrating that AS activity is 
essential for endothelial NO production mediated by eNOS (not iNOS) and that inhibiting 
its activity with MDLA diminishes maximal NO production by the calcium ionophore 
A23187 [65].  This supports both the functional importance of AS for endothelial NO 
production and links AS to calcium signaling, which is part of the mechanism by which 
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VEGF mediates NO production [61]. Additionally, there is reciprocal regulation between 
NO and VEGF designed to restore homeostasis [66] leading to the distinct possibility that 
there are mechanisms that will diminish the response of AS to VEGF. Although eNOS is 
critically important for the regulation of vascular NO production, our work demonstrates 
that the function of the citrulline-NO cycle as a whole is essential and warrants further 
study to provide a more global understanding of such an important system. 
 
The regulation of NO production via reversible phosphorylation is exemplified 
extensively by eNOS. There are at least 5 known sites of eNOS serine/threonine 
phosphorylation that either activate or inactivate its function. These sites are responsive 
to a variety of stimuli [67-69]. We have noted a similar mechanism for AS. Our 
molecular biology studies demonstrated time and time again, that AS is phosphorylated 
basally and that this changes, qualitatively or quantitatively, upon stimulation. Our mass 
spectrometry analysis identified 5 sites of serine/threonine phosphorylation and 2 of 
tyrosine phosphorylation. The phosphorylation at these sites was dynamic and responsive 
to stimuli. One example was the enhancement of AS phosphorylation at T131 in response 
to okadaic acid, a serine/threonine phosphatase inhibitor. Specifically, okadaic acid has 
been shown to diminish the activation of ceramide activated protein phosphatases [70], 
which suggests a link between ceramide and AS activity in addition to its effects on AS 
expression demonstrated in Chapter One, Figure 10. If indeed there is a direct 
relationship between ceramide and the regulation of AS on multiple levels, this would 
mimic very closely what is known about ceramide and eNOS [71, 72].  
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There were significant difficulties in obtaining reproducible and reliable data 
related to quantitation of AS phosphorylation due to the low stoichiometry of 
phosphorylation, the labile nature of these modifications and possibly due to the methods 
used to overexpress and purify AS. At times, the precise site that was actually 
phosphorylated was ambiguous due to close proximity of more than one phosphorylated 
site. These types of problems are common and this is precisely why these types of 
projects are known to be extremely difficult to accomplish [73]. We do know, without a 
doubt, that AS is indeed phosphorylated and we will continue to optimize our methods so 
that characterization of the function of each relevant phosphorylation site can be 
achieved. It is possible that one way to solve these issues is to assess organelle-specific 
AS phosphorylation by, for example, enriching caveolar fractions. There may be distinct 
areas of the cell where phosphorylation is more prominent and assessing this in whole 
cell preparations may be diluting the results. This will be further discussed in Chapter 
Three. Despite the limitations, our collective findings strongly suggest that AS is 
regulated by a complex interplay of phosphorylation-dephosphorylation evens that 
generate a cellular barcode that defines AS function.  
 
Based on our in silico studies, it is also likely that there are several kinases that 
phosphorylate AS, mediating the differential signaling necessary to maintain tight control 
over endothelial NO production. Table 6 lists possible kinases that can phosphorylate AS 
at indentified phosphorylation sites. Several of them have been discussed in previous 
sections: PKA (S180), AMPK (T131), GSK3β (S328), and CKII (T131, S180, S189, 
S328). This section will focus on some of the other kinases identified.  
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Besides CKII, CKI was also found to be a putative kinase for T131 and S134. 
There have not been any direct studies of CKI in the nitric oxide system. CKI and CKII 
have both overlapping and distinct substrate specificities, although they each recognize a 
different motif in their targets [74]. CKI does phosphorylate glycogen synthase which 
implies a role in glucose metabolism [75]. Thus, a link to nitric oxide function is possible.  
 
Mitogen activated protein kinase (MAPK) family members were identified as 
additional putative kinases for T131, S189 and S328. Members of the 
MAPK/extracellular signal-regulated kinase (ERK) family are known to have multiple 
roles in regulating NO production. One example is an increase in eNOS expression by 
angiotensin II which is mediated by MAPK [76].  In addition, MAPK activates PPARγ in 
response to NO and may represent a cardioprotective mechanism [77]. In addition, 
MAPK activates eNOS by increasing phosphorylation at S1177 and decreasing 
phosphorylation at T495 in response to black tea polyphenols [78]. ERK is also involved 
in mediating the pro-angiogenic effects of NO [79]. Thus, it is possible that at least one 
MAPK family member is involved in regulating AS activity by phosphorylation. Overall, 
the combination of in vitro and in silico experiments to identify AS kinases strongly 
suggested that multiple kinases control the dynamic phosphorylation of AS. 
 
Our investigation of the mechanism of AS phosphorylation by site-directed 
mutagenesis suggested that T131, S180 and S189 are all important for AS function. This 
data combined with the in silico modeling of the human AS crystal structure with or 
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without phosphorylation at all the serine/threonine sites identified by mass spectrometry 
led to additional implications. First, T131, S134 and S328 are the sites with the highest 
possibility of being phosphorylated. This certainly supports the mutagenesis data with 
T131 that showed significantly diminished NO production in the phospho-null variant 
and partial recovery with the phospho-mimetic variant. It will be interesting to correlate 
these findings, future molecular biology experiments and the information we have on 
bioinformatic database frequency. This will allow us to gauge how bioinformatic 
database frequency relates to true biological significance.  
 
 In addition, the decrease in AS-mediated NO production seen with S180 and 
S189 is most likely due to the direct interactions of these sites with substrates [9]. If 
phosphorylation can indeed occur at these sites, then the effects we saw are likely due to 
alterations in substrate binding. Alternatively, even if phosphorylation does not actually 
occur at those sites, the data we obtained is likely due to the fact that the alanine mutants 
are missing the hydroxyl side chain of the serine and again this would alter substrate 
binding and inhibit NO production. Further, although the quaternary structure of AS 
suggests that these sites are not accessible for phosphorylation, it is possible that they are 
phosphorylated only in the monomeric configuration. Perhaps phosphorylation of AS 
monomers is a mechanism that triggers the formation of the active tetramer and this has 
mechanism has not yet been defined. In addition, even seemingly inaccessible sites may 
become accessible upon conformational change due to physical interactions with kinases 
or proteins that can deliver kinases to substrates such as heat shock proteins.  
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Finally, an intriguing possibility related to AS phosphorylation is the proximity of 
T131 and S134 to the identified nitrosylaiton of AS at C132 in vascular smooth muscle 
[11]. The nitrosylation of this site in endothelium and the putative cross-talk between AS 
phosphorylation and nitrosylation have not been studied. Furthermore, in endothelial 
cells, eNOS has been found to be basally nitrosylated (inactive) then de-nitrosylated 
(active) in response to VEGF stimulation [80]. It is a possibility that a similar mechanism 
regulates AS due to the important link we made between VEGF signaling and AS 
function. 
 
There are two other types of post-translational modifications that were not 
addressed experimentally in this work, but are worth mentioning. First, as discussed 
further in Chapter Three, acylation is an important mechanism for the subcellular 
targeting of eNOS with important functional consequences [81]. An in silico search for 
acylation motifs is the AS sequence suggested that these modifications do not occur in 
AS. Further, it has recently been determined that eNOS that is phosphorylated at serine 
1177 and thus active, is inactivated by glycosylation at this site in diabetes [82]. A global 
investigation of proteins modified by O-glycosylation found that AS can be glycosylated 
[83]. Thus, it is clear that the barcode of dynamic post-translational modifications of AS 
including phosphorylation, nitrosylation and glycosylation illustrate an intricate 
mechanism of AS regulation that defines its tissue-specific functions and highlights the 
biological relevance of this enzyme.  
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In summary, this Chapter has presented the first comprehensive exploration of AS 
regulation by dynamic serine/threonine phosphorylation. Although deciphering and 
understanding the phosphoproteome is one of the most complex tasks in proteomics [73], 
the findings we have to this point have greatly increased our understanding of AS 
regulation and will open up multiple avenues of important experimentation with far 
reaching implications for vascular biology. 
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CHAPTER THREE 
ARGININOSUCCINATE SYNTHASE SUBCELLULAR LOCALIZATION AND 
PROTEIN INTERACTIONS 
 
Overview 
 
Argininosuccinate synthase (AS) is an essential mediator of endothelial health by 
providing a dedicated source of arginine for nitric oxide (NO) production and promoting 
endothelial cell viability. Our laboratory has previously demonstrated that AS is present 
in endothelial caveolar fractions along with endothelial nitric oxide synthase (eNOS) and 
argininosuccinate lyase (AL), the core components of the citrulline-NO cycle. The 
studies in this Chapter were designed to define the subcellular localization of AS in 
relationship to these components, to determine whether there are interactions that are 
essential for nitric oxide metabolism and to begin characterizing additional novel 
components of the nitric oxide metabolome. Utilizing immunofluorescence microscopy, 
we found that AS localizes to perinuclear regions and the plasma membrane. Further, 
eNOS localization overlaps AS localization suggesting functional relevance . We also 
found that AS colocalizes with caveolin-1, a key regulator of eNOS function, in distinct 
plasma membrane regions and the Golgi. Utilizing co-immunoprecipitation studies, we 
found that AS interacts with HSP90 and caveolin-1. These two proteins are intimately 
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involved in the regulation of endothelial nitric oxide production. We determined that AS 
and co-localizes with HSP90 utilizing immunofluorescence. We also identified a caveolin 
binding motif in the AS protein sequence that suggests a direct interaction. Finally, to 
begin characterizing the nitric oxide metabolome from a more global perspective, we 
utilized co-immunoprecipitations followed by mass spectrometry. We identified several 
putative interacting partners that are either novel or understudied in the regulation of NO 
production. Overall, our work defines a tightly coupled system for the regulation of nitric 
oxide production and highlights the intricate and dynamic nature of citrulline-NO cycle 
localization and interactions. 
 
Materials and Methods 
 
Immunofluorescence: BAEC were plated out on chamber slides. Cells were fixed 
with 3.7% paraformaldehyde and permebealized with 0.05% triton X-100. After 
blocking, cells were incubated with the following antibodies: AS (Everest Biotech), 
eNOS, HSP90 and caveolin-1 (BD Biosciences). Cells were then incubated with 
fluorescently labeled secondary antibodies (Invitrogen). Images were generated with a 
Nikon Eclipse E1000 Fluorescent Microscope running Genus 2.81 software from Applied 
Imaging.  On all experiments, negative controls were conducted by staining one chamber 
with secondary antibodies only. 
 
Immunoprecipitation and protein identification using LC-MS/MS:  Co-
immunoprecipitation studies were conducted with the following antibodies: AS (Everest 
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Biotech), HSP90, caveolin-1, eNOS (BD Biosciences), calmodulin I, NOSIP, PKG, AL 
(Santa Cruz), AMPKα, PKCα, PKAcα, CKII, and Akt (Cell Signaling Technology) 
utilizing the methods described in Chapter Two, Page 101. 
 
For samples that were utilized for mass spec, processing occurred very rapidly 
due to the labile nature of post-translational modifications and some protein-protein 
interactions. In addition, RIPA buffer was utilized as the lysis and wash buffer since it is 
more stringent and diminishes the possibility of non-specific interactions. Eluted protein 
complexes were subject to SDS-PAGE, bands of interest were excised, then digested 
proteins were subjected to liquid chromatography-tandem mass spectrometry as 
described in Chapter Two, Page 108. 
 
 Bioinformatics: The AS caveolin binding motif was identified utilizing Expasy 
Prosite (Scan Prosite Tool: http://www.expasy.ch/tools/scanprosite/) by searching for the 
following motif in the AS protein sequence: [WFY] - X - X - X - X - [WFY] - X - X - 
[WFY]. The motif was then identified on the 3D crystal structure of AS utilizing 
ViewerLite software version 5.0 (Accelrys Corporation, San Diego, California).  
 
Results 
 
AS Subcellular Localization Overlaps with eNOS and Caveolin-1: The subcellular 
localization of endothelial AS has not previously been characterized and we believe that 
it is a key regulatory feature of the citrulline-NO cycle. We hypothesized that for optimal 
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function of the citrulline-NO cycle, AS and eNOS should localize to the same regions 
within the cell. Utilizing immunofluorescence microscopy, we demonstrated that AS and 
eNOS colocalize and distribute in endothelial cells in a similar fashion, predominantly in 
the Golgi and the cytoplasmic membrane (Figure 27). We have previously demonstrated 
that caveolin-1 and AS co-fractionate in crude caveolar cell extracts, but we did not 
determine whether these two proteins were in the same or independent caveolar regions. 
Since eNOS and caveolin-1 colocalize and physically interact, we hypothesized that there 
would be distinct regions of overlap in the localization of AS and caveolin-1. As shown 
in Figure 25, AS co-localizes with caveolin-1 in distinct membrane regions and the 
Golgi, much like what is seen with eNOS.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: AS Colocalizes with eNOS and Caveolin-1. Immunofluorescence 
microscopy images demonstrating the localization of AS in the Golgi and plasma 
membrane along with its colocalization with eNOS (A) and caveolin-1 (B). AS is red, 
eNOS or caveolin are green and the merged image shows regions of co-localization in 
yellow. The nucleus is stained in blue. Arrows point to selected areas of colocalization in 
the Golgi and plasma membrane (n = 3). (C) Secondary only negative control. 
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AS Protein Interactions: In order to begin deciphering key AS interacting 
partners, a series of immunoprecipitations (IP) were carried out. When utilizing AS as the 
IP antibody, two interactions were consistently noted: HSP90 and caveolin-1 (Figure 28). 
These interactions were verified by immunoprecipitaing with HSP90 and caveolin-1 then 
probing with AS (Figure 28).  
 
Figure 28: AS Co-Immunoprecipitates with HSP90 and Caveolin-1. (A) 
Representative blot (n = 3) of BAEC lysates that were immunoprecipitated with an AS 
antibody (IP AS). The membrane was probed with HSP90 (IB HSP90) and caveolin-1 
(IB Cav-1). (B) Representative blot (n = 2) of BAEC lysates that were 
immunoprecipitated with an HSP90 antibody (IP HSP90). The membrane was probed 
with AS (IB AS). (C) Representative blot (n = 2) of BAEC lysates that were 
immunoprecipitated with a caveolin-1 antibody (IP Cav-1). The membrane was probed 
with AS (IB AS). 
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These results prompted us to assess the subcellular localization of AS and HSP90. 
As shown in Figure 29, there appears to be co-localization between AS and HSP90, 
although the specific regions are difficult to discern since HSP90 is widely distributed in 
the cytoplasm.  
Figure 29: AS Colocalizes with HSP90. (A) Immunofluorescence microscopy images 
demonstrating colocalization of AS with HSP90 (n = 1). AS is red, HSP90 is green and 
the merged image shows regions of co-localization in yellow. The nucleus is stained in 
blue. (B) Secondary only negative control. 
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Since eNOS has a caveolin binding motif, we decided to search for the same 
motif in the AS protein sequence. We identified the sequence 317-FAELVYTGF-325 
which fits the pattern of the caveolin binding motif found in eNOS: [WFY]-X-X-X-X-
[WFY]-X-X-[WFY] (Figure 30). This implies a direct interaction between AS and 
caveolin.  
Figure 30: AS has a Caveolin Binding Motif. Three dimensional structure of Human 
AS (PDB ID 2NZ2) demonstrating the region containing the following caveolin 
binding motif: [WFY]-X-X-X-X-[WFY]-X-X-[WFY]. The motif corresponds to the 
sequence: 317-FAELVYTGF-325. Identified phosphorylation sites and substrates are 
also shown as described in Figure 22, Chapter Two, Page 135.  
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It is also important to note that the investigation of AS protein interactions via 
immunoprecipitation was quite comprehensive and many other proteins were explored. 
We did obtain some positive preliminary results with AS interactions with eNOS, AL, 
PKA, PKCα and calmodulin. Taken together, our results demonstrate that there are key 
protein interactions that potentially mediate AS function and the function of the 
citrulline-NO cycle as a whole. 
 
Proteomic Examination of the Nitric Oxide Metabolome: In order to begin 
characterizing the NO metabolome, we utilized immunoprecipitation with an AS or 
eNOS antibody followed by LC-MS/MS. BAEC cell lysates were collected in RIPA 
buffer and immunoprecipitation was conducted. Putative interacting components were 
separated by SDS-PAGE then specific bands were cut from the gel and subjected to mass 
spectrometry for protein identification. This revealed several interesting interacting 
partners that are relevant to known regulatory mechanisms of NO production.  A list of 
the most relevant interactions and their known or potential roles in NO biology is shown 
in Table 8. Some interactions were specific for AS while others were identified with both 
AS and eNOS antibodies. Interestingly, AS and eNOS did not seem to interact with each 
other with this methodology, although the interaction has been noted previously with 
other methodologies (Brenda Flam, unpublished results). Another interaction that was 
missing from the list was the well documented eNOS-HSP90 interaction. The AS-HSP90 
interaction was confirmed with the mass spec data. Table 9 shows all 85 proteins found to 
co-IP with either AS or eNOS.  
 
Table 8: The Basal Nitric Oxide Metabolome. Table showing a few of the 
interactions identified utilizing basal cell lysates that were immunoprecipitated with an 
AS antibody. After separation via SDS-PAGE, bands were excised, digested and 
subjected to liquid chromatography-tandem mass spectrometry. Table also shows role 
of these interacting partners in regulating NO metabolism (n = 1). 
 
 
 
 
 
 
PROTEIN FUNCTION IP ANTIBODY 
cGMP-dependent protein 
kinase 
Kinase activated by soluble guanylyl-
cyclase. Important for vasodilation and 
regulates eNOS. 
AS 
eNOS 
Dynamin 
Large GTP-binding protein residing 
within similar membrane compartments 
as eNOS. Interacts with eNOS and 
increases its activity. 
AS 
Golgi SNAP Receptor 
Complex 
Involved in transport from the ER to the 
Golgi apparatus as well as in intra-Golgi 
transport. Disruption of intracellular 
trafficking has been associated with 
cardiovascular disorders. 
AS 
eNOS 
HSP90 Interacts with eNOS and increases its activity.  AS 
Kininogen-1 precursor 
Cleaved into several products, including 
bradykinin, which is an important 
regulator of vasodilation. eNOS is 
known to interact with the bradykinin 
receptor. This interaction is inhibitory 
and is released upon treatment with 
bradykinin. 
AS 
eNOS 
Prohibitin 
Mitochondrial protein that protects 
endothelial cells from reactive-oxygen 
species damage. 
AS 
eNOS 
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 Table 9: Putative AS and eNOS Interacting Partners. Complete list of all proteins identified 
via IP with an AS and/or eNOS antibody followed by mass spec as described in Table 8 above.  
Actin, cytoplasmic 2 - Bos taurus (Bovine) 
Trypsin precursor - Sus scrofa (Pig) 
Tropomyosin alpha-1 chain - Bos taurus (Bovine) 
Myosin-10 - Bos taurus (Bovine) 
Myosin regulatory light chain 2, smooth muscle isoform - Bos taurus (Bovine) 
Myosin-9 - Canis familiaris (Dog) 
Actin-like protein 3 - Bos taurus (Bovine) 
Histone H2A type 1 - Bos taurus (Bovine) 
Ornithine decarboxylase antizyme - Bos taurus (Bovine) 
Cationic trypsin precursor - Bos taurus (Bovine) 
Actin, alpha skeletal muscle - Bos taurus (Bovine) 
Myosin light polypeptide 6 - Bos taurus (Bovine) 
ADP/ATP translocase 2 - Tachyglossus aculeatus aculeatus (Australian echidna) 
Vimentin - Bos taurus (Bovine) 
Kininogen-1 precursor - Bos taurus (Bovine) 
Ribonuclease pancreatic - Hippopotamus amphibius (Hippopotamus) 
Histone H2A type 2-C - Bos taurus (Bovine) 
Ribonuclease pancreatic - Antilocapra americana (Pronghorn) 
Dynamin-1-like protein - Bos taurus (Bovine) 
Ubiquitin - Bos taurus (Bovine) 
130 kDa phosphatidylinositol 4,5-biphosphate-dependent ARF1 GTPase-activating protein - Bos taurus (Bovine) 
Actin-related protein 2/3 complex subunit 4 - Bos taurus (Bovine) 
Myosin-Id - Bos taurus (Bovine) 
Heterogeneous nuclear ribonucleoprotein A1 - Bos taurus (Bovine) 
Actin-related protein 2/3 complex subunit 3 - Bos taurus (Bovine) 
Serum albumin precursor - Bos taurus (Bovine) 
Histone H2B type 1-K - Bos taurus (Bovine) 
Golgi SNAP receptor complex member 1 - Bos taurus (Bovine) 
Alpha-S1-casein precursor - Bos taurus (Bovine) 
Glycoprotein GIII precursor - Bovine herpesvirus 1.1 (strain Cooper) (BoHV-1) (Infectious bovine rhinotracheitis 
virus) 
Prohibitin-2 - Bos taurus (Bovine) 
Abnormal spindle-like microcephaly-associated protein homolog - Ovis aries (Sheep) 
Alpha-enolase - Bos taurus (Bovine) 
Actin-related protein 2/3 complex subunit 1B - Bos taurus (Bovine) 
60S ribosomal protein L4 - Bos taurus (Bovine) 
Junction plakoglobin - Bos taurus (Bovine) 
Polymeric-immunoglobulin receptor precursor - Bos taurus (Bovine) 
Tubulin alpha-1A chain - Sus scrofa (Pig) 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 12 - Bos taurus (Bovine) 
Pyruvate kinase isozyme M1 - Felis silvestris catus (Cat) 
von Willebrand factor precursor - Canis familiaris (Dog) 
Tyrosine-protein kinase SYK - Sus scrofa (Pig) 
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Table 9 (continued) 
Endoplasmin precursor - Bos taurus (Bovine) 
Gamma-aminobutyric-acid receptor subunit alpha-3 precursor - Bos taurus (Bovine) 
Elongation factor 1-alpha 1 - Bos taurus (Bovine) 
Histone H3.1 - Bos taurus (Bovine) 
60S acidic ribosomal protein P0 - Bos taurus (Bovine) 
cGMP-dependent protein kinase 1, alpha isozyme - Bos taurus (Bovine) 
Calpain-1 catalytic subunit - Oryctolagus cuniculus (Rabbit) 
Beta-casein precursor [Contains: Casoparan] - Bos taurus (Bovine) 
Ribosome recycling factor, mitochondrial precursor - Bos taurus (Bovine) 
Heterogeneous nuclear ribonucleoproteins A2/B1 - Bos taurus (Bovine) 
Rho guanine nucleotide exchange factor 9 - Bos taurus (Bovine) 
52 kDa Ro protein - Bos taurus (Bovine) 
Telomerase reverse transcriptase - Canis familiaris (Dog) 
Fatty acid-binding protein, adipocyte - Sus scrofa (Pig) 
Nitric oxide synthase, inducible - Bos taurus (Bovine) 
Desmoglein-1 precursor - Canis familiaris (Dog) 
Heat shock 70 kDa protein 4 - Canis familiaris (Dog) 
Alpha-S2-casein precursor [Contains: Casocidin-1 - Bos taurus (Bovine) 
Serpin H1 precursor - Bos taurus (Bovine) 
Coiled-coil domain-containing protein 113 - Bos taurus (Bovine) 
Cofilin-2 - Bos taurus (Bovine) 
Histone H1.1 - Bos taurus (Bovine) 
Pro-epidermal growth factor precursor - Canis familiaris (Dog) 
Glial fibrillary acidic protein - Bos taurus (Bovine) 
Probable phospholipid-transporting ATPase IF - Oryctolagus cuniculus (Rabbit) 
Histone H3.2 - Bos taurus (Bovine) 
Heat shock protein HSP 90-alpha - Bos taurus (Bovine) 
5-hydroxytryptamine 1A receptor - Equus caballus (Horse) 
Tripartite motif-containing protein 9 - Bos taurus (Bovine) 
Cystic fibrosis transmembrane conductance regulator - Sus scrofa (Pig) 
 
An additional piece of data related to protein interactions was uncovered when 
searching for AS phosphorylation sites via mass spec. When AS was overexpressed and 
then treated with okadaic acid, T131 was identified as a phosphorylation site (Chapter 
Two, Figure 19, Page 129). In addition, several other bands were cut out from the gel that 
contained purified AS and any proteins that might have come down with it. One notable 
protein identified was NOSIP (eNOS interacting protein). NOSIP is a known binding 
partner with eNOS and is important for its subcellular localization. NOSIP promotes 
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translocation of eNOS from the plasma membrane to intracellular sites, thereby 
uncoupling eNOS from caveolae and inhibiting NO synthesis. 
 
Discussion 
 
 In this Chapter, the subcellular localization of endothelial AS was defined, its co-
localization with eNOS, caveolin-1 and HSP90 was described and important AS 
interacting partners were identified. This is the second post-translational regulatory 
mechanism addressed in this dissertation. 
 
 The subcellular localization of AS has been defined in several tissues. For 
instance, in untransfected or AS-transfected VSMC, AS is detected in both cytosolic and 
membrane fractions via western blot [1]. AS expression is increased in membrane 
fractions upon stimulation with LPC/IFNγ, suggesting that AS is transported to 
membrane regions for functionally relevant purposes [1, 2]. In addition, 
immunohistochemical studies of AS-transfected cells indicates a punctuate pattern of 
expression that suggests mitochondrial localization [1], much like what is seen in liver 
[2].  This study supported the concept of substrate channeling [1], which would 
necessitate co-localization and assembly into a functional complex. Our identification of 
AS localization to the perinuclear/Golgi region and plasma membrane supports those 
previous findings since NO is produced in these two subcellular compartments [3-5]. 
Thus, much like urea cycle enzymes, the citrulline-NO cycle enzymes form functional 
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complexes in specific cellular compartments that allow efficient channeling of substrates 
so that the arginine required for NO production is distinct from bulk cellular arginine.   
 
The distinct localization pattern for AS in endothelial cells also led to an 
important observation. It is possible that AS has localization-specific or organelle-
specific functions. These functions might be related to post-translational modifications. 
Therefore, some of the difficulties in obtaining definitive mass spectrometry data may be 
related to the fact that we utilized whole cell lysates to look for AS phosphorylation sites. 
This may in fact have led to a dilution of the data since perhaps certain regions of the 
cells have a high population of phosphorylated AS while others, perhaps most, don’t. It 
will be important to determine the phosphorylation pattern in different cellular 
compartments to gain a better understanding of the impact and regulation of these 
modifications.  
 
eNOS is also known to localize to the Golgi and plasma membrane [5] and we did 
find that AS and eNOS co-localize. Although it is unclear how AS functions within 
specific cellular compartments, there are two distinct pools of active eNOS, one in the 
Golgi and one in the plasma membrane. The relative importance of these two pools of 
eNOS is still under investigation, but one study demonstrated that although NO is 
produced each of these regions, the plasma membrane produces significantly more NO 
[3]. In that study, they generated endothelial cells that expressed wild type eNOS, Golgi-
only eNOS or plasma membrane-only eNOS without altering any other components of 
the citrulline-NO cycle. This suggested that either the other enzymes of the cycle are also 
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present in Golgi and plasma membrane or that there is another source of substrate for 
eNOS. Our studies and those of others suggest that endothelial cells are dependent on 
recycling of citrulline to arginine as a source of eNOS substrate [6, 7]. The fact that AS 
localized to those regions supports those studies. It would be interesting to design a 
similar study where both AS and eNOS localization could be manipulated. Then, the 
dependence of co-localization could be definitively proven. However, the studies with 
Golgi versus plasma membrane eNOS were done by first knocking out endogenous 
eNOS and then re-constituting the endothelial cells with the different eNOS constructs 
[3]. We have shown that moderate AS knockdown leads to significant endothelial 
apoptosis [8], so the same approach might not be successful for AS. This suggests that 
while the function of eNOS may be exclusively to produce NO, AS might have several 
different functions, including as anti-apoptotic signaling [8], that make it even more 
important for overall vascular biology.  
 
In addition, we demonstrated that AS localized in distinct plasma membrane 
regions in conjunction with caveolin-1 [7, 9]. This expands our previous work by 
demonstrating that the regions where AS localizes in the plasma membrane are also 
regions where caveolin-1 is present. In other words, our previous work showing that AS 
and caveolin localized to similar crude caveolar fractions did not prove that the 
localization was to the same specific caveolar regions [9].  The co-localization of AS and 
caveolin suggests a role for caveolin-1 in assembling AS into a functional signaling 
microdomain, much like its role in regulating eNOS transport and function. For example, 
caveolar domains assemble at the Golgi and traffic to the plasma membrane as stable 
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transport platforms [10, 11].  These platforms constitute signaling microdomains where 
multiple kinases, phosphatases and regulatory enzymes assemble into functional 
complexes [12, 13]. The transport mechanisms regulating the formation of the NO 
metabolome at caveolae enhance NO production at the plasma membrane and involve 
vesicular transport elements and cytoskeletal components [10, 11, 14-17].  
 
In addition, interaction with other proteins plays a role in eNOS targeting. For 
example, there are two eNOS-interacting proteins named NOSIP (for eNOS-interacting 
protein) [18] and NOSTRIN (for eNOS-trafficking inducer) [19], which both influence 
the subcellular localization of eNOS.  NOSIP, targets eNOS to the cytoskeleton and 
inactivates it [20].  NOSTRIN, when overexpressed, leads to translocation of eNOS from 
the plasma membrane to intracellular vesicular structures [19], possibly involving an 
endocytic process [21]. Utilizing AS overexpression, purification and mass-spectrometry 
of associated proteins we did identify NOSIP as a putative binding partner of AS. This 
leads to the intriguing possibility that there are some shared mechanisms in AS and eNOS 
transport. Although these findings could not be confirmed utilizing IP/western, the 
antibodies for NOSIP that we utilized were not very good, our IP techniques needed 
optimization and the AS antibody available on the market at that time did not work well 
for IP. With the new methods and tools we now have available, it is certainly worthwhile 
to pursue this mechanism. 
 
Another mechanism that regulates the subcellular translocation of eNOS is dual 
acylation, an irreversible N-myristoylation at Gly2 and reversible thiopalmitoylation at 
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C15 and C26 [16]. These lipid functional groups are responsible for targeting eNOS to 
the Golgi and plasma membrane, particularly to caveolae [16, 22, 23]. Acylation deficient 
eNOS variants cannot translocate to the plasma membrane and this leads to alterations in 
eNOS activity [14].  It was intriguing to hypothesize that AS might be modified by 
acylation. A bioinformatic search for motifs for myristoylation and palmitoylation did not 
identify any such motifs in the AS sequence. It is still possible that AS is acylated via 
motifs that have yet to be described. In fact, the palmitoylation motif uncovered for 
eNOS is distinct from the motif found on other signaling proteins [22]. For example, the 
motif identified for the Src family of proteins is MGCXXC/S while eNOS the motif for 
eNOS is MGXXXS…C15(GL)5C26. The human AS sequence does have a glycine at 
position 5 and a cysteine at position 19, making is possible that lipidation does indeed 
occur. Although we did not examine the transport of AS in this work, the findings we 
describe below do support a dynamic translocation of AS in endothelial involving several 
key interacting partners.  
 
We believe that our evidence supports a model whereby protein interactions 
regulate the subcellular localization of AS. Caveolin-1 may indeed be a key factor in this 
level of regulation. The fact that the AS protein sequence has a caveolin binding motif 
suggests that the interaction we found via immunoprecipitation may in fact be a direct 
interaction. In addition, previous unpublished data from our laboratory supports this 
hypothesis since both GST and His-tag pull down experiments demonstrated that AS can 
pull down caveolin-1 (Brenda Flam, unpublished results). Since this motif has been 
identified, it can be utilized for the design of experiments aimed directly at disrupting the 
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motif and determining not only whether the interaction is direct, but also the specific 
region that is involved in the interaction. Since we have identified an AS phosphorylation 
site very close to that motif, it is quite possible that phosphorylation regulates this 
interaction. The eNOS caveolin binding motif is located in the peptide 348-
FPAAPFSGW-356 [24, 25]. To date, there have not been any eNOS phosphorylation 
sites in the vicinity of the caveolin binding motif with respect to the secondary structure. 
Since the entire eNOS protein has not been crystallized, it is difficult to know if perhaps 
one of the eNOS phosphorylation sites is near the caveolin binding motif in the 3-
dimensional structure. However, it is known that phosphorylation regulates the 
interaction between eNOS and caveolin-1, thus it is certainly possible that the mechanism 
involves spatial proximity of phosphorylation sites. We speculate that there is an inter-
related mechanism that controls the binding of caveolin to AS and eNOS.  
 
Along with the possible regulation of AS localization and function by caveolin-1, 
the finding the HSP90 also co-localizes with and interacts with AS strengthens our 
hypothesis due to the reciprocal regulation of NO production by these two proteins. 
HSP90 is involved in the activation of eNOS by allowing the interaction of eNOS with 
calmodulin, the phosphorylation of eNOS by Akt and the dissociation of eNOS from 
caveolin-1 [26-29]. It is possible that the AS-HSP90 interaction regulates AS through 
similar mechanisms. Interestingly, we were able to confirm this interaction with IP/mass 
spec analyses.  
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Several more interactions were uncovered via IP analyses, including the 
interactions of AS with AL, eNOS, calmodulin, PKA and PKCα, but the results have not 
been reproduced. Previous work in our lab did indicate a direct interaction between AS, 
AL and eNOS (Brenda Flam, unpublished results) and our preliminary results do support 
this. In addition, the interaction of AS with PKA and PKCα supports previous studies that 
demonstrate the presence of both of these kinases in caveolae [30, 31]. Considering that 
our results show that AS is an in vitro substrate for these kinases, these interactions are 
certainly worth pursuing. The possible interaction of AS with calmodulin suggests 
regulation via calcium signaling, and our link between AS and VEGF supports this since 
VEGF stimulates NO production, in part, by increasing intracellular calcium [26]. 
Overall, the above findings strengthen our hypothesis of a dynamic and complex set of 
interacting proteins in the NO metabolome. 
 
Up to this point, our results were obtained by rational investigation of AS 
interacting partners based on preliminary data or the known role of certain proteins in 
regulating NO production. Our ultimate goal, was to put together the pieces of the nitric 
oxide metabolome. In order to accomplish this, we needed a more global approach to 
characterize the dynamic nature of both hypothesized interactions and novel or 
understudied interactions. We developed a proteomic approach to identify all proteins 
that are pulled down when an AS or an eNOS antibody was used for IP analyses. We 
identified 85 proteins that co-immunoprecipitated with AS and/or eNOS. From those, 
there were 6 that stood out as having a possible functional role.  
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First, cGMP-dependent protein kinase or protein kinase G (PKG) was found to 
interact with both AS and eNOS. PKG is an important kinase in regulating the function of 
nitric oxide in vascular smooth muscle. When endothelial NO is released, it acts in 
smooth muscle to activate soluble guanylyl cyclase (sGC), increase cGMP and activate 
PKG. This leads to vasodilation [32]. PKG has been also been found to have direct 
functions in the endothelium. For example, PKG colocalizes to caveolae in both smooth 
muscle and endothelium [30]. In addition, PKG is involved in the regulation of 
angiogenesis in endothelial cells [33]. Considering the link between VEGF and AS that 
we established in Chapters One and Two and the well established link between VEGF 
and eNOS [26, 33-41], it is quite possible that this is a true functional interaction. This 
interaction was not verified by IP/western, but optimization of the IP methodology or a 
different methodology altogether might reveal a different result.  
 
A second interaction revealed by IP/mass spectrometry was dynamin. Dynamin is 
a large GTP-binding protein that co-localizes with and interacts with eNOS, thereby 
increasing its activity [42]. It targets to Golgi membranes and also co-localizes with 
caveolin in caveolae [43, 44]. In addition, NOSTRIN (eNOS trafficking inducer) interacts 
with dynamin and mediates eNOS subcellular translocation [21]. In our experiments, 
dynamin was not found to interact with eNOS. It is possible that the conditions and/or 
methods used did not favor this interaction. The interaction between AS and dynamin fits 
well with previous, unpublished data from our lab where tandem affinity purification was 
utilized to pull down AS and associated proteins. These results identified a GTP-binding 
protein as an AS interacting partner.  
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Another AS and eNOS interacting partner identified via IP/mass spectrometry 
was the Golgi SNAP receptor complex. This protein is one of several involved in 
transport from the endoplasmic reticulum to the Golgi and in intra-Golgi transport [45]. It 
has been demonstrated that in vascular disorders, there are disruptions of intracellular 
trafficking. Specifically, hypoxia and other conditions cause disruptions in ER/Golgi 
trafficking that lead to sequestration of eNOS and a reduction in plasma membrane 
associated eNOS. This leads to diminished NO production [46]. The possibility of AS 
interacting with this protein suggests that AS trafficking in the ER and Golgi may be an 
important regulatory mechanism. 
 
We also identified HSP90 as an AS interacting partner via IP/mass spec, which 
confirms the IP/western data described earlier. The fact that we did not find the well 
documented eNOS-HSP90 interaction highlights the fact that each methodology utilized 
to probe for protein interactions, and the variations within individual methodologies, can 
lead to false positive or false negative results. 
 
Kininogen-1 precursor was another AS and eNOS interacting partner identified 
via IP/mass spectrometry. This precursor is cleaved into several products including 
bradykinin [47]. Bradykinin is a vasodilator that regulates eNOS function via several 
mechanisms [48-51] and the coordinate interaction with both AS and eNOS suggests that 
bradykinin also plays an important role in regulating AS function. 
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The final protein in the IP/mass spectrometry analyses that has an important 
functional link in the endothelium was prohibitin-1. It interacted with both AS and eNOS. 
This protein was originally identified in yeast and is localized to the inner mitochondrial 
membrane. It is now apparent that prohibitins have diverse roles in several disease states 
such as obesity and inflammation [52]. Recently, it was determined that prohbitin-1 is 
highly expressed in the vascular system [53]. Knock-down of prohhibitin-1 in endothelial 
cells leads to dysfunction characterized by increased production of reactive oxygen 
species in mitochondria. This suggests that prohibitin-1 is important for protecting 
endothelial cells from oxidative damage [53]. Interestingly, prohibitin was recently found 
to regulate the function of OPA-1, a dynamin-like protein involved in cristae 
morphogenesis [54]. This regulation led to the control of cell proliferation and apoptosis 
and the authors speculated a role for prohibitin in lipid rafts. Since AS has been 
hypothesized to localize in mitochondria in vascular smooth muscle [1] and does localize 
to mitochondria in other tissues [2], it is possible that AS is also localizes in endothelial 
cell mitochondria. There is some evidence that eNOS localizes to mitochondria [55] but 
the function of the citrulline-NO cycle in endothelial mitochondria has not been studied. 
Furthermore, NO itself has important roles in regulating mitochondrial function and 
biogenesis [56, 57]. Collectively, the identification of dynamin and prohibitin and AS 
interacting partners implies important functional significance. Thus, a functional 
citrulline-NO cycle in mitochondria might regulate functions that are specific to that 
organelle.  
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Finally, another set of prominent interactions seen via IP, IP/mass spec and 
tandem affinity purification/mass spec were several cytoskeletal components including 
actin, vimentin and tubulin. Although the high expression of these proteins in most cell 
types leads to the initial assessment that these results are false positives, it is quite 
possible that there is an intricate cytoskeletal network responsible for the trafficking of 
AS within endothelial cells. Indeed, such mechanisms have been extensively 
characterized for eNOS. There is a prominent role of actin polymerization that regulates 
eNOS activity and transport [58]. More recently, it was uncovered that the protein α-
actinin-4, an actin binding protein responsible for actin cross-linking, interacts with and 
inactivates eNOS by competitively inhibiting calcium-dependent activation [59]. 
Furthermore, the mechanisms of eNOS regulation by NOSIP and NOSTRIN involve the 
actin cytoskeleton [18, 19]. Shear stress regulates dilation and remodeling of resistance 
arteries via several cytoskeletal components such as vimentin, desmin and intermediate 
filaments [60]. Thus, further investigation into the role of the actin cytoskeleton and other 
cytoskeletal components in AS-eNOS co-translocation and function is an important area 
for further exploration.    
 
 It is clear from our studies that obtaining an accurate picture of true interacting 
partners is a complex process. Each technique employed can lead to false positive or false 
negative results. In addition, many techniques cannot confirm whether an interaction is 
direct or indirect. Despite these limitations, our studies indicate that there is a vast and 
dynamic network of associating proteins that regulate the function of the nitric oxide 
metabolome.  
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PERSPECTIVES 
 
Summary 
 
The work conducted in this dissertation has uncovered significant advances in our 
understanding of AS regulation as it relates to nitric oxide production and vascular health. 
In Chapter One, the regulation of AS function and expression was explored.  The data 
revealed the important role of AS in the production of nitric oxide since overexpressing 
AS led to a significant increase in endothelial NO production above the levels of the 
endogenous enzymes of the citrulline-NO cycle. We were also able to show that insulin 
and VEGF up-regulated AS expression and increased NO production while ceramide 
diminished AS expression.  In Chapter Two, we identified and characterized the first 
post-translational modifications of AS in the endothelium: phosphorylation at serine, 
threonine and tyrosine residues. After utilizing bioinformatics to determine that AS 
phosphorylation was a possible AS regulation mechanism, we focused on biological 
relevance. First, we identified PKA and PKCα as kinases that regulate AS 
phosphorylation. We also showed that phosphorylation of AS by PKA and PKCα is 
required for maximal VEGF-mediated NO production. We then identified 7 different 
sites of phosphorylation utilizing a proteomics approach and demonstrated the potential 
biological roles of T131/S134, S180, S189 and S328. In Chapter Three, the subcellular 
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localization of AS was defined in endothelial cells for the first time. In addition, our 
results demonstrated an overlap in localization of AS with eNOS, caveolin-1 and HSP90. 
We were then able to characterize important AS interacting partners utilizing 
immunoprecipitation including caveolin-1 and HSP90. We also provided the first 
example of the possible relationship between AS phosphorylation and protein interactions 
utilizing the proximity of S328 to the newly identified caveolin-binding motif. Finally, 
utilizing proteomics, we were also able to identify 85 proteins that interact with eNOS 
and/or AS in BAEC’s under basal conditions. From that list of proteins, 6 were 
highlighted as having known or potential roles in regulating NO production: PKG, 
dynamin, prohibitin, HSP90, the Golgi SNAP receptor complex and kininogen-1. 
 
Significance 
 
The work presented in this dissertation demonstrated that AS is a central player in 
the regulation of NO production as evidenced by the multiple and intricate mechanisms 
that regulate its function. Often times, the studies that focus strictly on eNOS function to 
address the regulation of NO production only tell part of the story. Considering that most 
phenotypic properties of the endothelium are mediated by NO [1], it is essential that the 
scientific community focus more attention on looking at the bigger picture. 
 
The key observation that in the endothelium, AS transient overexpression 
enhances nitric oxide production further supports the fact that AS is the rate limiting step 
in the process [2-5]. Such an important distinction supports our initial hypothesis that 
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multiple-levels of AS regulation need to be in place in order to maintain NO levels at the 
appropriate levels. The finding that AS overexpression led to a loss of endothelial cell 
viability confirms the importance of AS as an anti-apoptotic signaling molecule [6] and 
implies that the specific mechanisms by which AS regulates this process warrant further 
investigation. 
 
The transcriptional regulation of AS is important in many of its key target tissues 
such as liver, immune cells and macrophages [7-11]. Our work demonstrating the 
coordinate regulation of AS and eNOS expression by both positive and negative stimuli 
extends our understanding of the importance of this mechanism in regulating the health 
of the endothelium. This also opens avenues for investigation of these observations in 
animal models of vascular disease. In addition, this work continues to add to the 
mounting evidence that the arginine paradox can be explained by the tightly coupled 
arginine regeneration system exemplified by the citrulline-NO cycle [12-14].  
 
The link between AS and VEGF is the first demonstration of a potential role of 
AS in mediating angiogenesis. The possible direct effects of AS on the angiogenic 
process could have dramatic importance in understanding the global effects of AS on 
vascular health. Furthermore, this link may explain some of the possible roles for AS in 
cancer [15]. Additionally, our work links AS to calcium signaling thus opening up 
another possible regulatory avenue. 
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Post-translational regulation of AS, whether by phosphorylation or protein 
interactions, is an essentially uncharacterized field of NO biology. Considering the fact 
that NO is such a potent mediator of whole body metabolism [16, 17], it is certainly a 
rational principle that multiple mechanisms are needed to maintain the function of the 
system. Post-translational modifications allow for acute regulation of protein function. It 
is absolutely essential for AS to be able to respond quickly to the ever changing cellular 
need for NO, and we have shown that AS phosphorylation is one such mechanism. This 
type of regulation also opens up a multitude of therapeutic avenues aimed at the kinases 
and phosphatases that control the ever-changing barcode of post-translational 
modifications. Considering that eNOS is so intricately regulated by dynamic association 
with a number of other proteins [17], it makes sense that AS is part of this regulatory 
scheme. In addition, the continuation of our work to characterize the NO metabolome 
will be essential in identifying additional, novel binding partners that have not previously 
been considered.  
 
The multiple possible functions of AS in the vasculature and the complex and 
numerous mechanisms that regulate its function, some presented in this dissertation and 
many yet to be uncovered, lead to the prospect that many possible interventions to 
regulate AS function could impact a number of disease processes. For example, there is 
controversy related to the usefulness of arginine supplementation in the treatment of 
vascular disorders [18]. Our work suggests that this is because of the multiple functions 
of AS in vascular and non-vascular roles. Although citrulline supplementation may 
indeed be a better option due to the unique metabolic fate of this amino acid as compared 
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to arginine [19], it remains to be determined whether whole body supplementation will be 
effective since increasing the substrate for AS might have additional, unwanted effects 
such as enhanced NO production in tissues that do not require it or perhaps even 
pathogenic angiogenic consequences related to tumorigenesis. Perhaps the delivery of 
citrulline to the specific tissues with a deficiency in NO production is a better option. 
 
In addition, our finding that AS is phosphorylated by kinases that are also 
important for eNOS regulation improves our understanding of how drugs that target some 
of those kinases might have a greater cardiovascular impact than originally intended. In 
addition, targeting kinases that directly phosphorylate AS for therapeutic purposes might 
have greater efficacy and fewer side effects since the target is further downstream in the 
NO signaling cascade. Another therapeutic avenue involves protein interactions. If a 
defect in the HSP90 interaction with AS and eNOS can be corrected therapeutically with 
a drugs such as insulin sensitizers that have been shown to correct this defect [20], the 
benefit to the vascular system could be prominent. The use of such specific therapies will 
depend on genomic and proteomic approaches that will allow us to understand the 
specific defect that is causing an individual’s disease. Whether the therapy is 
pharmacological or nutritional, this type of information will allow for the implementation 
of individualized patient therapies that will dramatically improve our success in the 
prevention and treatment of the prominent and devastating diseases that plague global 
health. 
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Limitations 
 
 One of the main limitations of our work is the fact that it has almost entirely been 
carried out in tissue culture. There are definite advantages to tissue culture systems since 
they allow for the study of single variables without the influence of some compensatory 
mechanisms and of other tissues. These studies also allow for tissue specific mechanisms 
to be defined. Although tissue culture does not completely mimic an in vivo approach, it 
does allow for initial hypotheses and mechanisms to be developed that can then be used 
as starting points for translational work. We have begun projects to translate our work 
into relevant animal models with an ultimate goal of determining the applicability of our 
work in humans. However, our work and that of others fits well with the known functions 
of eNOS in the vasculature which has been extensively characterized in animals and 
humans. Therefore, we feel strongly that our tissue culture work will have relevance for 
human health.  
 
 Another limitation of our work relates to the groundbreaking nature of our 
projects. For several of the experimental avenues that were undertaken, adequate tools 
were not readily available. Thus, methodologies had to be designed to make judicious use 
of available tools. In addition, for the continuation of this work, new tools will have to be 
generated such as site-specific AS antibodies and ultimately even tissue-specific AS 
knockout mouse models so that a thorough understanding of the role of AS in human 
diseases can be delineated. These tools, in conjunction with similar tools already 
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available for eNOS, will allow for a thorough understanding of the importance of AS 
within the citrulline-NO cycle.  
 
Future Directions 
 
 There are several areas of work that will be important in expanding the findings of 
this dissertation. In Chapter One, each pathway studied requires two main areas of 
investigation to clearly delineate the role of AS expression in NO production. First, the 
role of insulin, VEGF and ceramide on AS specific activity needs to be determined. That 
will allow the direct connection between these biological molecules and AS function. 
Although this was addressed partially with the AS inhibitor studies with VEGF, enzyme 
assays are critical to make stronger conclusions. Second, the regulation of AS expression 
needs to be mechanistically defined by carrying out experiments that will determine 
whether message stability or specific promoter regulation accounts for the up or 
downregulation of AS. It is also possible that the mechanisms involving AS regulation by 
ARP (Argininosuccinate Synthase Regulatory Protein) might be tied into the 
transcriptional regulation uncovered in Chapter One. 
 
 The findings Chapter Two related to AS post-translational regulation by 
phosphorylation are indeed novel and could drive the field of nitric oxide biology into 
multiple new and relevant areas of investigation. Ultimately, progress in this field will 
depend on definitively identifying specific sites of AS phosphorylation that are necessary 
for NO production and importantly, for AS specific activity. This will require continued 
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optimization of proteomic approaches, the development of AS enzyme assays and the 
generation of site-specific AS antibodies. Currently, experiments are underway to 
identify the specific sites phosphorylated by PKCα and PKA and also to assess AS 
phosphorylation in the endogenous AS enzyme via immunoprecipitation. In addition, the 
possibility of other types of PTM needs to be explored such as nitrosylation, 
glycosylation and acylation. It has taken many, many years to get a decent understanding 
of these regulatory mechanisms for eNOS function. Even with all the progress, there are 
still many areas that require further research and understanding. Certainly, it will take a 
comparable amount of time and concerted effort to get a strong understanding of how 
similar mechanisms regulate AS. 
 
 The regulation of AS by protein interactions is also of great significance. A more 
thorough understanding will require both basic molecular and proteomic approaches. 
Each individual protein interaction will have to be characterized extensively. First, the 
utilization of several types of methods such as pull down approaches will be necessary to 
confirm the interactions and to determine if the validated interactions are direct or 
indirect. Second, to further prove whether interactions are direct or indirect, studies will 
need to be designed to determine the specific regions of each protein involved in the 
interaction. We already have a good start with the caveolin-AS interaction due to the 
identification of a caveolin-binding motif in the AS protein sequence.  The biological 
significance of these interactions will need to be assessed by determining the role of each 
interaction on AS specific activity. Finally, the optimization and continuation of 
proteomic approaches to find additional members of the nitric oxide metabolome will be 
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essential to truly understand nitric oxide metabolism from a global systems perspective. 
Furthermore, these approaches will also allow us to define the role of PTM in regulating 
protein interactions via the utilization of methods that can simultaneously identify protein 
interactions and PTM. We have already designed these methodologies in conjunction 
with the Moffitt Proteomics Core and preliminary experiments have been initiated.  
 
 Finally, the significance of our work will be strengthened by projects designed to 
characterize our tissue culture findings in animal models and ultimately in humans. We 
have such a project underway currently. We plan on beginning our translational work by 
utilizing streptozotocin (STZ) to induce diabetes in rats. This type 1 diabetes model will 
allow us to examine the impact of total insulin deficiency on the expression of AS, AL 
and eNOS. This type of work will mimic our tissue culture experiments with insulin. In 
addition, we will have 4 treatment groups: sham treated, STZ only, STZ plus suboptimal 
insulin treatment and STZ plus optimal insulin treatment. This will allow us to study 
expression patterns in conditions of normal glycemia, moderate hyperglycemia and 
extreme hyperglycemia. We will also be able to measure serum NO levels, the expression 
of other proteins that we have identified as essential for AS regulation (VEGF, PKA, 
HSP90, etc.), and the subcellular localization of these proteins.  Therefore, we can build 
an in vivo model of specific dysfunction of the citrulline-NO cycle in diabetes as it relates 
to AS that can eventually be utilized to carry out human studies.  
 
 
 
 203
References 
 
[1] S. Moncada, and E. A. Higgs, The discovery of nitric oxide and its role in vascular 
biology, Br J Pharmacol 147 Suppl 1 (2006) S193-201. 
 
[2] L. Xie, and S. S. Gross, Argininosuccinate synthetase overexpression in vascular 
smooth muscle cells potentiates immunostimulant-induced NO production, J Biol Chem 
272 (1997) 16624-16630. 
 
[3] L. Xie, Y. Hattori, N. Tume, and S. S. Gross, The preferred source of arginine for 
high-output nitric oxide synthesis in blood vessels, Semin Perinatol 24 (2000) 42-45. 
 
[4] W. C. Sessa, M. Hecker, J. A. Mitchell, and J. R. Vane, The metabolism of L-arginine 
and its significance for the biosynthesis of endothelium-derived relaxing factor: L-
glutamine inhibits the generation of L-arginine by cultured endothelial cells, Proc Natl 
Acad Sci USA 87 (1990) 8607-8611. 
 
[5] A. Husson, C. Brasse-Lagnel, A. Fairand, S. Renouf, and A. Lavoinne, 
Argininosuccinate synthetase from the urea cycle to the citrulline-NO cycle, Eur J 
Biochem 270 (2003) 1887-1899. 
 
[6] B. L. Goodwin, L. P. Solomonson, and D. C. Eichler, Argininosuccinate synthase 
expression is required to maintain nitric oxide production and cell viability in aortic 
endothelial cells, J Biol Chem 279 (2004) 18353-18360. 
 
[7] Y. Hattori, E. B. Campbell, and S. S. Gross, Argininosuccinate synthetase mRNA and 
activity are induced by immunostimulants in vascular smooth muscle. Role in the 
regeneration or arginine for nitric oxide synthesis, J Biol Chem 269 (1994) 9405-9408. 
 
[8] M. Flodstrom, A. Niemann, F. J. Bedoya, S. M. Morris, Jr., and D. L. Eizirik, 
Expression of the citrulline-nitric oxide cycle in rodent and human pancreatic beta-cells: 
induction of argininosuccinate synthetase by cytokines, Endocrinology 136 (1995) 3200-
3206. 
 
[9] E. Bizzoco, M. G. Vannucchi, and M. S. Faussone-Pellegrini, Transient ischemia 
increases neuronal nitric oxide synthase, argininosuccinate synthetase and 
argininosuccinate lyase co-expression in rat striatal neurons, Exp Neurol 204 (2007) 252-
259. 
 
[10] T. Koga, W. Y. Zhang, T. Gotoh, S. Oyadomari, H. Tanihara, and M. Mori, 
Induction of citrulline-nitric oxide (NO) cycle enzymes and NO production in 
immunostimulated rat RPE-J cells, Exp Eye Res 76 (2003) 15-21. 
 
 204
[11] Y. Su, and E. R. Block, Hypoxia inhibits the induction of argininosuccinate 
synthetase by endotoxin in lung endothelial cells, Am J Physiol 272 (1997) L934-938. 
 
[12] B. R. Flam, D. C. Eichler, and L. P. Solomonson, Endothelial nitric oxide production 
is tightly coupled to the citrulline-NO cycle, Nitric Oxide 17 (2007) 115-121. 
 
[13] C. W. Shuttleworth, A. J. Burns, S. M. Ward, W. E. O'Brien, and K. M. Sanders, 
Recycling of L-citrulline to sustain nitric oxide-dependent enteric neurotransmission, 
Neuroscience 68 (1995) 1295-1304. 
 
[14] L. J. Shen, K. Beloussow, and W. C. Shen, Accessibility of endothelial and inducible 
nitric oxide synthase to the intracellular citrulline-arginine regeneration pathway, 
Biochem Pharmacol 69 (2005) 97-104. 
 
[15] B. J. Dillon, V. G. Prieto, S. A. Curley, C. M. Ensor, F. W. Holtsberg, J. S. 
Bomalaski, and M. A. Clark, Incidence and distribution of argininosuccinate synthetase 
deficiency in human cancers: a method for identifying cancers sensitive to arginine 
deprivation, Cancer 100 (2004) 826-833. 
 
[16] E. Culotta, and D. E. Koshland, Jr., NO news is good news, Science 258 (1992) 
1862-1865. 
 
[17] D. M. Dudzinski, and T. Michel, Life history of eNOS: partners and pathways, 
Cardiovasc Res 75 (2007) 247-260. 
 
[18] R. B. Preli, K. P. Klein, and D. M. Herrington, Vascular effects of dietary L-arginine 
supplementation, Atherosclerosis 162 (2002) 1-15. 
 
[19] G. Wu, J. K. Collins, P. Perkins-Veazie, M. Siddiq, K. D. Dolan, K. A. Kelly, C. L. 
Heaps, and C. J. Meininger, Dietary supplementation with watermelon pomace juice 
enhances arginine availability and ameliorates the metabolic syndrome in Zucker diabetic 
fatty rats, J Nutr 137 (2007) 2680-2685. 
 
[20] B. J. Davis, Z. Xie, B. Viollet, and M. H. Zou, Activation of the AMP-activated 
kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by 
promoting the association of heat shock protein 90 and endothelial nitric oxide synthase, 
Diabetes 55 (2006) 496-505. 
 
 
 205
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDICES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX A: Related Publications 
206 
 
 
 
TROGLITAZONE UP-REGULATES VASCULAR ENDOTHELIAL 
ARGININOSUCCINATE SYNTHASE 
 
Bonnie L. Goodwin1,2, Karen D. Corbin1, Laura C. Pendleton1, Monique M. Levy1,2, 
Larry P. Solomonson1 and Duane C. Eichler1 
 
Affiliations: 1Department of Molecular Medicine, College of Medicine and the 2Johnnie 
B. Byrd, Sr. Alzheimer’s Center and Research Institute, University of South Florida, 
Tampa, FL 33612 
 
Corresponding author: Duane C. Eichler 
Tel: 1 813-974-9716; Fax: 1 813 974-7357  
E-mail: deichler@health.usf.edu
 
 
 
 
APPENDIX A: (Continued) 
 207
Abstract 
 
Vascular endothelial nitric oxide (NO) production via the citrulline-NO cycle not 
only involves the regulation of endothelial nitric oxide synthase (eNOS), but also 
regulation of caveolar-localized endothelial argininosuccinate synthase (AS), which 
catalyzes the rate-limiting step of the cycle. In the present study, we demonstrated that 
exposure of endothelial cells to troglitazone coordinately induced AS expression and NO 
production. Western blot analysis demonstrated an increase in AS protein expression. 
This increased expression was due to transcriptional upregulation of AS mRNA, as 
determined by quantitative real time RT-PCR and inhibition by 1-D-
ribofuranosylbenzimidazole (DRB), a transcriptional inhibitor. Reporter gene assays and 
EMSA analyses identified a distal PPARγ response element (PPRE) (–2471 to –2458) 
that mediated the troglitazone increase in AS expression.  Overall, this study defines a 
novel molecular mechanism through which a thiazolidinedione (TZD) like troglitazone 
supports endothelial function via the transcriptional up-regulation of AS expression.  
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Introduction 
Almost all normal functions of vascular endothelial cells are dependent on or 
affected by the bioactivity of nitric oxide (NO). Thus, impairment of endothelial NO 
production is often a common pathogenic mechanism by which cardiovascular risk 
factors such as hypercholesterolemia, hypertension, smoking, homocystinemia, vascular 
inflammation, and diabetes mellitus promote their deleterious effects on the vascular wall 
[1]. Endothelial NO production is supported by reactions catalyzed by endothelial nitric 
oxide synthase (eNOS), argininosuccinate synthase (AS) and argininosuccinate lyase 
(AL) which are core components of the citrulline-NO cycle [2-4]. The principal role of 
AS and AL catalysis is in the conversion of citrulline to arginine, the substrate utilized by 
eNOS to produce NO and citrulline. AS is rate-limiting to the citrulline-NO cycle [3, 4], 
and as such is required to sustain endothelial function and viability [5].  
PPARγ is a member of the nuclear receptor superfamily of ligand-activated 
transcription factors that has been shown to regulate the transcription of genes involved 
in lipid metabolism  differentiation and cell growth [6]. Both naturally derived PPARγ 
ligands, including a number of fatty acid metabolites such as eicosanoid derivatives [7] 
and 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) [8, 9], as well as synthetic ligands such 
as the thiazolidinediones (TZDs) have been described. The TZDs have insulin-sensitizing 
properties [10-12] which provide cardiovascular benefits [13-17] and promote flow-
mediated vasodilatation, in part, by stimulating endothelial NO production via the 
activation of eNOS [17, 18].  Because of these findings, we examined whether the TZD, 
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troglitazone, known to promote NO production [19] and vasodilatation in diabetic 
patients [20], may affect the efficiency of the citrulline-NO cycle via AS expression in 
vascular endothelial cells.    
Materials and Methods 
 
Cell Culture: Bovine aortic endothelial cells (BAEC) were cultured in complete 
Dulbecco’s modified Eagle’s medium (1 g/L glucose, Mediatech) containing 10% fetal 
bovine serum (Hyclone Laboratories), 100 units/ml penicillin and 100 μg/ml 
streptomycin (Mediatech) at 37°C in an atmosphere of 5% CO2.  
 
Nitric Oxide Assay: BAEC were treated with troglitazone as indicated in DMEM 
(minus phenol red) plus 5% fetal bovine serum.  Aliquots (100 µl) of media were 
removed at the indicated times and nitrite was measured as an indicator of cellular NO 
produced using a fluorometric method [21]. Samples were read on a BMG Fluostar 
Galaxy spectrofluorometer in a 96-well plate. Data is presented as quantity of nitrite 
produced in pmols per mg protein.  
 
Western Blot Analysis:  Following treatment with troglitazone, BAEC were 
harvested in 500 µl PBS, centrifuged briefly and lysed in RIPA buffer. The lysate was 
incubated on ice for 30 minutes and protein concentration determined by BCA reagent 
(Pierce). Ten μg of protein was electrophoresed on 4-15% polyacrylamide gels (Bio-Rad) 
and transferred onto membrane (Immobilon-P). Membranes were incubated with 
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antibody 1:2500 anti-AS and 1:1000 anti-GAPDH (BD Transduction Labs) in 5% 
blocking solution in TBS-T (20 mM Tris-HCl, 137 mM NaCl, 0.1% Tween-20) and then 
washed in TBS-T.  Membranes were subsequently incubated with horseradish 
peroxidase-conjugated anti-mouse antibody for 1 hour, immersed in ECL reagent (GE 
Healthcare) for 1 minute and then exposed to film. Band intensities were quantitated 
using ImageQuant software (Molecular Dynamics). 
 
RNA Isolation and Quantitative RT-PCR:  Total RNA was isolated using Tri 
Reagent following the manufacturer’s instructions (Sigma). RNA was treated with DNase 
(Ambion DNA-free). Five hundred ng of RNA was reverse transcribed using Superscript 
II (Invitrogen) as described previously [22]. Real time quantitative PCR was performed 
using AS specific primers ASL228 and ASR278 [22]. Results were normalized to 18S 
rRNA.  
 
Vector Construction: Luciferase reporter constructs were designed to include the 
AS promoter and 5´-UTR up to the AUG start codon cloned upstream of the luciferase 
gene. Luciferase reporter construct p3ASP189 was described previously [23]. Left 
primers ASL-3075 (5´-GTACCTCCACTGAAATTGAA) and ASL-2616 (5´-
GCACTCGAGGAAAGTCAAAGGCCATGGTG) were combined with ASRluc, (5´-
ATAGAATGGCGCCGGGCGTTTCTTTATGTTTTTGGCGTCTTCCATCGTGACGG
GTGACCAGCGGC) to amplify a deletion series of the AS promoter with an Xho I site 
on the 5´ end and an Nco I site on the 3´ end which were used to clone into the vector 
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pGL3Basic (Promega) and create the vectors p3ASP3075 and p3ASP2616, respectively. 
Mutations were made in the PPRE sites in p3ASP2616 using a three-way PCR method 
[23]. Primer PPREmut (5´-GCTGGTCTTGATCTCCTGATCTCAGGTGA) was 
combined with primer ASRluc to amplify a fragment that contained the mutations. This 
PCR product was then used as a right primer and paired with ASL-2616 to produce a 
second product. A third round of PCR was used with the second product as a template 
with primers ASL-2616 and ASRluc to enrich for the target. Amplified products were 
purified and ligated into pGL3Basic to create p3ASP2616PPREmut. All constructs were 
verified by sequencing. 
 
Luciferase Assay Analysis: BAEC were cultured as described above and plated in 
a 24 well plate prior to transfection. Experimental plasmids (200 ng each) and renilla 
control plasmid pRL-TK (50 ng) were transiently transfected into BAEC using Transit-
LT1 (Mirus) in serum free media. Transfected cells were cultured for 24 hours in media 
containing troglitazone and lysed in passive lysis buffer (Promega). Ten l lysate was 
assayed for luciferase and renilla activity using a Dual-Luciferase Reporter Assay System 
(Promega) according to the manufacturer’s instructions.  
 
Electrophoretic Mobility Shift Assay: Nuclear extracts, prepared from BAEC as 
described previously [23, 24], were combined with or without cold oligonucleotide 
competitors and incubated for 20 minutes at room temperature. Probes were labeled by 
combining equimolar amounts of complementary oligonucleotides (2x10-10 moles), 
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which were heated to 70°C, and allowed to cool to room temperature slowly. The oligos 
were labeled using 10 μl [α-32P]dCTP (3000 Ci/mmol) and Klenow enzyme. 
Unincorporated label was removed using Nuc Away spin columns (Ambion). The 
reaction mixture contained binding buffer (10 mM HEPES, pH 7.9, 10% glycerol, 1 mM 
DTT, 0.1 μg/μl poly(dI:dC), 0.5 μg/μl BSA and 4000 dpm/μl radiolabeled probe) and 
nuclear extract (5 μg) in a total volume of 10 μl which was incubated at 30°C for 30 
minutes. Samples were loaded onto a 5% non-denaturing polyacrylamide gel and run at 
180 V. Gels were dried under vacuum and exposed to film. Double-stranded 
oligonucleotides composed of the following sequences were used for EMSA analysis: 
PPRE (5´-ACCTGAGGTCAGGAGTTCAAGACC-3´), PPREmut (5´-
ACCTGAGAACAGGAGAACAAGACC-3´), Sp1 site 1 (5´-
GCTCCAGGCGGGGGCCGGGCCCGGGGGCG-3´), Sp1 site 2 (5´-
GGCCGGGCCCGGGGGCGGGGTCTGTGGCGC-3´) and Sp1 site 3 (5´-
CCGGTCACCGGCCCTGCCCCCGGGCCCTG-3´).  
 
Statistical Analyses: Experimental data is expressed as the mean of experiments 
plus or minus the standard error of the mean. Each experiment was performed 
independently at least three times. 
Results  
 
The PPARγ Ligand, Troglitazone, Increases Endothelial NO Production: To 
confirm that troglitazone stimulates NO production in cultured endothelial cells, 
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confluent bovine aortic endothelial cells (BAECs) were incubated for 24 hours with 
increasing concentrations of this synthetic PPARγ agonist. As shown in Figure 1A, a 
dose-dependent increase in NO production following treatment was observed up to 20 
µM troglitazone. The dose dependent effect was consistent with previous findings 
relative to the extent of NO produced [18].  
  
Troglitazone Treatment Increases AS Expression: Since the expression of AS is 
necessary to support endothelial NO production [3-5, 25], we investigated whether 
troglitazone affected the increase in vascular endothelial NO production, at least in part, 
through the up-regulation of AS expression, or whether the increase in NO production 
was simply due to established effects on eNOS activation [17-19]. Confluent BAECs 
were treated with increasing concentrations of troglitazone for 24 hours and AS protein 
levels were determined by western blotting. As shown in Figure 1B & 1C, treatment with 
troglitazone resulted in an increase in AS protein that closely correlated with the 
troglitazone dependent increase in NO production, demonstrating that this PPARγ agonist 
does indeed support an increase in NO production through up-regulation of AS 
expression.  
To determine whether the increase in AS expression resulted from transcriptional 
upregulation, BAECs were grown to confluence and stimulated with troglitazone for 24 
hours. RNA was prepared and quantitative real time RT-PCR showed that treated 
endothelial cells had a 3.5-fold increase with 20 µM troglitazone (Figure 2).  This 
increase in AS mRNA could be inhibited by treatment with the transcriptional inhibitor 
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1-D-ribofuranosyl-benzimidazole (DRB) suggesting that the increase in steady-state AS 
mRNA levels was due to an increase in transcription rather than decreased AS mRNA 
turnover. These results also suggested that the increase in AS protein could be accounted 
for at the level of transcriptional regulation. 
 
Identification of a Putative PPRE in the Promoter of the AS Gene: In order to 
account for the transcriptional regulation of AS expression by troglitazone, the AS 
promoter was examined using luciferase reporter gene constructs to identify regions 
regulated by this PPARγ agonist. Previous work by others [26] and by us [27] has shown 
that three Sp1/3 elements in the proximal AS promoter are required for AS expression. 
Since PPARγ agonists are known to mediate transcriptional effects through Sp1 elements 
[28, 29], we initially examined the involvement of the proximal promoter using a 
construct, p3ASP189, containing these three Sp1/3 elements in the first 189 bp of the AS 
promoter. However, transfection of the p3ASP189 construct into BAEC followed by 
treatment with troglitazone did not result in an increase in promoter activity (Figure 3A). 
Thus, the up-regulation of AS expression by troglitazone was not mediated by these Sp1 
elements or other sequence elements located in the proximal promoter.  
Based on these findings, the search to identify the element(s) involved in PPARγ 
regulation was extended using a series of constructs containing increasing lengths of the 
AS promoter. Cells transfected with AS promoter constructs containing up to 2088 bp 
again showed no change in reporter gene activity in response to troglitazone treatment 
(data not shown). However, when a construct containing 2616 bp of the AS promoter was 
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transfected into BAEC, a significant increase in reporter gene expression was observed in 
response to treatment with troglitazone. The construct containing 2616 bp of the 
promoter was activated 2.7-fold by 20 μM troglitazone (Figure 3A). This comparative 
analysis of luciferase activity between treated and untreated transfections of the construct 
p3ASP2616 mapped the PPARγ responsive region from -2616 to -2088 bp upstream of 
the transcriptional start. 
 
DNA sequence analysis identified a near consensus PPARγ response element 
(PPRE) from –2471 to –2458 bp (AGGTCAGGAGTTCA) in the p3ASP2616 construct. 
To verify the involvement of this element, comparative transient transfection assays were 
performed using a construct mutated (non-functional) in the putative PPRE and the wild-
type construct.  As shown in Figure 3B, mutation of the putative PPRE site in 
p3ASP2616 completely abolished the activating effects of troglitazone supporting the 
involvement of this PPRE (-2471 to -2458 bp) in the distal region of the AS promoter.  
 
PPARγ Binds to the AS PPRE: To further confirm the involvement of the PPRE in 
AS promoter function, we investigated whether PPARγ binds to the putative AS PPRE. 
Electrophoretic mobility shift assays (EMSAs) were performed with oligonucleotides 
containing the putative sequence. Nuclear extracts from troglitazone and untreated BAEC 
were mixed with [32P]-labeled AS PPRE oligonucleotides. As shown in Figure 4, 
troglitazone enhanced binding to the PPRE.  
APPENDIX A: (Continued) 
 216
To demonstrate specificity, excess unlabeled PPREwt oligonucleotides were 
shown to compete, diminishing the signal of the shifted band. In contrast, addition of 
excess, unlabeled PPREmut oligonucleotide, with a mutation that should not allow 
binding and therefore should not compete with [32P]-labeled AS PPRE oligonucleotides, 
did not diminish the specific signal.  These results were taken to further support the 
involvement of this distal PPRE in the AS promoter as the element that mediates the 
transcriptional upregulation by troglitazone. 
Discussion 
One mechanism by which PPARγ agonists provide cardiovascular benefits is by 
enhancing endothelial NO production [17]. Endothelium-derived NO is a potent chemical 
mediator with antiatherogenic properties, such as stimulation of vasorelaxation and 
repression of endothelial leukocyte adhesion molecules, platelet aggregation and smooth 
muscle cell proliferation [30-32]. Although troglitazone demonstrates vasodilator 
activities to lower blood pressure in diabetic patients, its precise mechanism is not well 
defined [20, 33, 34]. However, these studies suggest that troglitazone mediated direct 
effects on the vascular wall.  
Until now, troglitazone was thought to promote endothelial NO production 
through up-regulation of eNOS protein expression [19] or activity [18], although the 
mechanism was not established. This report is the first demonstration that the PPARγ 
agonist, troglitazone, facilitates the production of vascular endothelial NO through the 
up-regulation of AS expression, the rate-limiting enzyme of the citrulline-NO cycle. The 
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increase in AS protein levels paralleled AS mRNA levels and the increased NO 
production. Since DRB, a transcriptional inhibitor, blocked the induction of AS 
expression by troglitazone, our results indicated that the increase in AS expression 
resulted from transcriptional regulation by this PPARγ agonist. Therefore, we identified a 
distal PPRE in the AS promoter that mediated the transcriptional effects of troglitazone 
on AS expression. To our knowledge, this is the first identification of a functional PPRE 
in the AS promoter.  
These results further support our view that the coordinate regulation of endothelial AS 
expression and NO production is essential [5], and that physiologic or pharmacologic 
stimuli that promote or diminish endothelial function do so not only by affecting eNOS 
activity or expression, but also by affecting AS expression [5]. Moreover, the results in 
this report contribute new and additional insight as to how PPARγ agonists promote 
endothelial NO production through diverse mechanisms [18, 19, 35]. For example, 15d-
PGJ2, a naturally occurring PPARγ ligand, increases hsp90 expression which promotes 
eNOS activation, while ciglitazone and rosiglitazone do not, yet still increase NO 
production  [35]. In addition, 15d-PGJ2 and rosiglitazone increase binding of hsp90 to 
eNOS to promote NO production, while ciglitazone does not. Finally, both 15d-PGJ2 and 
rosiglitazone, but not ciglitazone, increase phosphorylation of eNOS at ser1177, which is 
linked to enhanced enzyme activity [35] and increased NO production. In this report, 
troglitazone was found to promote NO production through the up-regulation of AS 
expression. This would be in addition to its reported effect on eNOS where troglitazone 
was shown to up-regulate eNOS expression through a mechanism independent of PPARγ 
APPENDIX A: (Continued) 
 218
activation [19], or where changes in eNOS phosphorylation correlated with an increase in 
eNOS activity rather than expression [18].  
Overall, the findings of this report demonstrate that argininosuccinate synthase 
represents an additional and physiologically important step in the citrulline-NO cycle by 
which the TZD, troglitazone, promotes vascular endothelial function. Although 
troglitazone was withdrawn from the market because of its hepatic toxicity, the multiple 
mechanisms through which TZDs can improve insulin sensitivity, as well as NO-
dependent vasodilatation, suggests that further studies with new TZD drugs may be 
warranted.   
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Figure Legends 
 
Figure 1: The PPARγ agonist, troglitazone, stimulates endothelial NO production 
and AS protein expression. BAEC were treated with increasing concentrations of 
troglitazone as indicated for 24 hours.  (A) NO was measured as nitrite produced/mg 
protein. (Nitrite is a stable reaction product of NO and molecular oxygen.) Results are 
expressed as relative levels of NO produced in control (no treatment) versus treated cells, 
and error bars represent the standard error of the mean. (B-C) Ten μg of whole cell lysate 
was loaded onto an SDS polyacrylamide gel and standard western blotting performed. 
Anti-AS (1:2500) was used to detect the amount of AS protein present. A representative 
western blot is shown in B, and relative spot density for AS protein, normalized against 
GAPDH and quantitated, is represented in C. These results are representative of three 
independent experiments and error bars represent the standard error of the mean.  
 
Figure 2: Troglitazone induces transcription of AS mRNA. BAEC were untreated 
(U) or treated with 20 µM troglitazone plus or minus the transcriptional inhibitor DRB 
(50 µM) (T and T+D, respectively) for 24 hours. Total RNA was isolated, and AS mRNA 
was detected using real time quantitative RT-PCR. Results were normalized to 18S rRNA 
and represent the average ± the standard error of the mean.  
 
Figure 3: Troglitazone induces a distal element in the AS promoter. (A) BAEC 
were transiently transfected with the proximal AS promoter construct, p3ASP189, or an 
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extended AS promoter construct, p3ASP2616, and treated with 20 µM troglitazone 
(Trog) for 24 hours. (B) BAEC were transiently transfected with the AS promoter 
constructs with wild type p3ASP2616 (W) or p3ASP2616PPREmut (M, represents 
mutated PPRE) and treated with 20 µM troglitazone (Trog) for 24 hours. All results are 
presented as relative luciferase activity units and represent the average ± the standard 
error of the mean of at least four experiments conducted in triplicate. 
 
Figure 4: Troglitazone increases binding to the AS PPRE. (A) Electrophoretic mobility 
shift assays were performed using BAEC nuclear extracts prepared from untreated and 
troglitazone treated cells for 6 hours. Extracts were combined with an oligonucleotide 
probe containing the putative PPRE sequence of the AS promoter, and competed with 
either a 100-fold excess of cold wild-type or mutated oligonucleotide probe where 
indicated. Labeled arrow indicates position of PPARγ specific bands. (B) Relative 
density of PPARγ specific bands. 
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Figure A-1 
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Figure A-2 
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Figure A-3  
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Figure A-4 
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